
[https://theses.gla.ac.uk/8701/](https://theses.gla.ac.uk/8701/)

Copyright and moral rights for this work are retained by the author

A copy can be downloaded for personal non-commercial research or study, without prior permission or charge

This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author

The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author

When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given

Enlighten: Theses
[https://theses.gla.ac.uk/](https://theses.gla.ac.uk/)
research-enlighten@glasgow.ac.uk
Investigating the function and regulation of NUAK1 and its role in Non-small cell lung cancer

Tiziana Monteverde
MSc

Submitted in fulfilment of the requirements for the Degree of Doctor of Philosophy

Institute of Cancer Sciences
College of Medical, Veterinary and Life Sciences
University of Glasgow
September 2017
Abstract

The AMPK-related kinase NUAK1 has been implicated in the regulation of a spectrum of biological processes such as cell proliferation, metabolism, cell adhesion and migration. As deregulation of such processes plays an important role in cancer, NUAK1 targeting has been suggested as a promising therapeutic strategy. In addition, higher NUAK1 expression has been correlated with more advanced tumour stages and poor prognosis in multiple cancer types, indicating that its targeting could be clinically relevant. However, manipulation of NUAK1 for therapeutic purposes is still restricted by our limited knowledge of its regulation and function.

Therefore, the work presented in this thesis aimed to further explore the NUAK1 signalling network, with particular focus on a more comprehensive understanding of the previously described synthetic lethal interaction between NUAK1 and MYC.

The tumour suppressor LKB1 is considered as the master upstream regulator of the AMPK-related kinases, including NUAK1. Our analysis performed in HeLa cells, which are characterized by LKB1 deficiency and high levels of MYC, revealed that NUAK1 activity was maintained by an alternative pathway involving Ca²⁺-dependent activation of PKCα. Ca²⁺/PKCα-dependent activation of NUAK1 supported the engagement of the Raptor-mTORC1 metabolic checkpoint to protect cells from MYC-driven cell death. Indeed, we have revealed that MYC selects for this pathway via amplification of Ca²⁺ signalling, which involves increased activation of PKC.

MYC upregulation in Non-small cell lung cancer (NSCLC) is frequently observed due to oncogenic activation of upstream signalling pathways that promote MYC stability, e.g. by RAS activation. Therefore, in light of the synthetic lethal interaction between NUAK1 and MYC but also aware of the emblematic tumour suppressor role of LKB1 in lung tumorigenesis, we sought to investigated the role of NUAK1 in a pre-clinical model of NSCLC driven by mutant KRas. Interestingly, NUAK1 did not replicate the tumour suppressive function of LKB1, while Nuak1 deletion decreased tumour angiogenesis and delayed tumour progression, which was reflected by an increased overall survival.
Finally, as we investigated the molecular mechanisms of progression of KRas mutant-driven NSCLC, we uncovered the upregulation of the ERBB network in association with the tumorigenic process. Inhibition of ERBB receptors cooperated with MEK inhibition in enhancing overall survival, proposing a novel therapeutic relevance for multi-ERBB inhibitors.

Taken together our data have provided a more comprehensive understanding of NUAK1 signalling network and have proposed new targets that could be exploited for therapeutic purposes in lung cancer and potentially in many other tumour types.
# Table of Contents

ABSTRACT .................................................................................................................. 2

TABLE OF CONTENTS .............................................................................................. 4

LIST OF TABLES ......................................................................................................... 9

LIST OF FIGURES ...................................................................................................... 10

ABBREVIATIONS ........................................................................................................ 13

ACKNOWLEDGMENTS ................................................................................................. 17

AUTHOR’S DECLARATION .......................................................................................... 18

CHAPTER 1 - INTRODUCTION ................................................................................. 19

1.1 AMPK, THE MASTER ENERGY SENSOR............................................................ 19

1.1.1 Structure and expression of AMPK ................................................................. 19

1.1.2 Nucleotide-dependent activation of AMPK .................................................... 22

1.1.3 Pharmacological activation of AMPK ............................................................. 23

1.1.4 Upstream kinases of AMPK ............................................................................ 24

1.1.5 Metabolic implications of AMPK activity ....................................................... 25

1.1.5.1 Regulation of protein synthesis .................................................................. 26

1.1.5.2 Regulation of glucose and lipid metabolism ............................................... 29

1.1.5.3 Regulation of mitochondria biogenesis and autophagy ............................... 30

1.1.6 Role of AMPK in the regulation of proliferation ............................................ 31

1.1.7 Role of AMPK in cancer .................................................................................. 31

1.2 AMPK RELATED KINASES ............................................................................. 33

1.2.1 Activation modalities of ARKs ....................................................................... 35

1.2.2 Regulation of ARKs by upstream kinases ....................................................... 36

1.3 NUAK1 ................................................................................................................. 38

1.3.1 Structure and expression profile of NUAK1 .................................................. 38

1.3.2 Upstream kinases regulating NUAK1 ......................................................... 38

1.3.3 Lesson on NUAK1’s physiological role from in vivo studies .......................... 39

1.3.4 Additional biological roles of NUAK1 ......................................................... 41

1.3.4.1 Migration and Invasion ............................................................................ 41

1.3.4.2 Cell adhesion ............................................................................................ 42

1.3.4.3 Cell proliferation and senescence .............................................................. 43
1.3.4.4 Metabolic homeostasis .......................................................... 44
1.3.5 Clinical relevance for NUAK1 .................................................. 45
1.3.6 Exploiting the synthetic lethal interaction between NUAK1 and MYC in cancer therapy .......................................................... 47
1.4 LUNG CANCER .............................................................................. 48
1.4.1 Heterogeneity of lung cancer .................................................... 48
1.4.2 Molecular profiling of NSCLC ................................................... 52
1.4.2.1 EGFR and the ERBB signalling network ............................... 53
1.4.2.2 RAS signalling ................................................................. 54
1.4.3 Targeted therapies for NSCLC .................................................. 58
1.5 PhD OBJECTIVES ....................................................................... 60

CHAPTER 2 - MATERIALS AND METHODS ........................................ 62
2.1 MATERIALS .................................................................................. 62
2.1.1 Chemicals .................................................................................. 62
2.1.2 Kits .............................................................................................. 63
2.1.3 Solutions ...................................................................................... 64
2.1.4 Primary Antibodies ..................................................................... 64
2.1.5 Secondary Antibodies ................................................................. 66
2.1.6 siRNA .......................................................................................... 66
2.1.7 shRNA .......................................................................................... 67
2.1.8 Primers .......................................................................................... 67
2.1.9 Acrylamide gels .......................................................................... 68
2.1.10 Drugs ........................................................................................... 68
2.2 METHODS ..................................................................................... 69
2.2.1 Cell Culture ................................................................................ 69
2.2.1.1 Tumour Cells ........................................................................ 69
2.2.1.2 Primary mouse embryonic fibroblasts ..................................... 69
2.2.1.3 Cryopreservation and resuscitation of cells ............................. 70
2.2.2 Plasmid transfection ................................................................. 71
2.2.3 siRNA transfection ................................................................. 71
2.2.4 RNA extraction and Quantitative Real-Time PCR ................. 72
2.2.4.1 RNA extraction ...................................................................... 72
2.2.4.2 cDNA synthesis ................................................................. 72
2.2.4.3 qPCR primers design and analysis ........................................ 73
2.2.4.4 Quantitative Real-Time PCR ................................................ 73
2.2.5 Immunoprecipitation and immunoblotting .............................. 74
2.2.5.1 Immunoprecipitation ........................................................... 74
2.2.5.2 Preparation of whole cell proteins extracts ........................................ 74
2.2.5.3 SDS-PAGE .................................................................................. 74
2.2.5.4 Western Blotting ........................................................................... 75
2.2.6 Cell death analysis ........................................................................... 75
2.2.7 Determination of protein synthesis rates .......................................... 76
2.2.8 Animals .......................................................................................... 76
   2.2.8.1 Mouse Models ............................................................................. 76
   2.2.8.2 Breeding and Maintenance .......................................................... 76
   2.2.8.3 Intranasal instillation of Adenovirus .............................................. 77
   2.2.8.4 Administration of drugs ............................................................... 78
   2.2.8.5 In vivo imaging ............................................................................ 78
   2.2.8.6 Tissue collection ......................................................................... 78
   2.2.8.7 Protein isolations from lung tumours ............................................. 79
2.2.9 Histology ......................................................................................... 79
   2.2.9.1 Immunohistochemistry ................................................................. 79
   2.2.9.2 TUNEL staining .......................................................................... 81
2.2.10 Tumour burden quantification and Immunohistochemistry scoring .. 82
2.2.11 Laser-Capture Microdissection and RNA-SEQ analysis ................. 83
2.2.12 Statistical analysis ......................................................................... 84

CHAPTER 3 - INVESTIGATING THE ROLE OF NUAK1 IN CELL SURVIVAL UNDER METABOLIC STRESS ................................................................. 85

3.1 INTRODUCTION ................................................................................... 85
3.2 RESULTS ............................................................................................ 88
  3.2.1 NUAK1 does not regulate AMPK subunits nor basal activity .......... 88
  3.2.2 NUAK1 is specifically required for Ca\textsuperscript{2+}-mediated activation of AMPK 89
  3.2.3 NUAK1 is activated by Ca\textsuperscript{2+} signalling by an LKB1-independent pathway .......... 91
  3.2.4 CaMKK\textbeta does not mediate Ca\textsuperscript{2+}-induced activation of NUAK1 .... 92
  3.2.5 Both NUAK1 and NUAK2 phosphorylate MYPT1\textsuperscript{S445} in response to increased intracellular Ca\textsuperscript{2+} ................................................................. 94
  3.2.6 MYC modulates activation of PKC .................................................... 96
  3.2.7 PKC\textalpha mediates NUAK1 activation by Ca\textsuperscript{2+} signalling .......... 97
  3.2.8 PKC\textalpha regulates NUAK1 protein levels .................................... 100
  3.2.9 NUAK1 and NUAK2 reside in two distinct pathways for the regulation of MYPT1\textsuperscript{S445} phosphorylation in response to Ca\textsuperscript{2+} signalling .......... 102
3.2.10 The PKCα-NUAK1 pathway supports viability of MYC overexpressing cells ................................................................. 103
3.2.11 The PKCα-NUAK1 pathway regulates activation of mTORC1 via Raptor ............................................................................. 106
3.3 DISCUSSION .............................................................................................................. 111

CHAPTER 4 - INVESTIGATION OF NUAK1 ROLE IN LUNG TUMORIGENESIS ..... 118

4.1 INTRODUCTION ........................................................................................................ 118
4.1.1 Mouse models ........................................................................................................ 119
4.2 RESULTS .................................................................................................................... 120
4.2.1 KRas-mutant lung tumours develop as adenocarcinoma even in the absence of Nuak1 ................................................................................................................. 120
4.2.2 Deletion of Nuak1 does not affect the cell of origin of KRas-mutant lung adenocarcinoma ........................................................................................................... 123
4.2.3 Nuak1 deletion does not affect KRas-driven tumorigenic process ........ 125
4.2.4 Characterization of Nuak1 deletion in KRasG12D/MYC lung adenocarcinoma ................................................................................................................................. 126
4.2.5 MYC overexpression is not synthetically lethal with Nuak1 deletion in KRas-driven NSCLC ........................................................................................................... 129
4.2.6 Upregulation of the PI3K/AKT pathway in Nuak1 deleted lung tumours ................................................................................................................................. 130
4.2.7 Deletion of Nuak1 does not sensitize lung tumours to mTORC1 inhibition ................................................................................................................................. 132
4.2.8 Deletion of Nuak1 confers a survival advantage to KRasG12D/MYC mice ................................................................................................................................. 135
4.3 DISCUSSION ............................................................................................................. 136

CHAPTER 5 - THE ROLE OF THE ERBB NETWORK IN SUPPORTING KRAS MUTANT LUNG ADENOCARCINOMA ............................................. 141

5.1 INTRODUCTION ....................................................................................................... 141
5.1.1 Mouse models ....................................................................................................... 142
5.2 RESULTS .................................................................................................................. 143
5.2.1 Upregulation of the ERBB network during progression of KRas mutant lung adenocarcinoma .......................................................................................................... 143
5.2.2 KRasG12D/MYC lung tumours are sensitive to ERBB inhibition ................. 145
5.2.3 Inhibition of the ERBB receptors impairs KRas-driven tumorigenesis 147
5.2.4 ERBB blockade enhances therapeutic impact of MEK inhibition in KRas mutant lung adenocarcinoma .................................................. 148

5.3 DISCUSSION ........................................................................ 153

CHAPTER 6 - FINAL DISCUSSION ........................................ 158

REFERENCES ............................................................................. 164
List of Tables

Table 1. 1 - Histological types and subtypes of NSCLC ........................................... 51
Table 2. 1 - Chemicals and Suppliers ................................................................. 63
Table 2. 2 - Kits .................................................................................................. 63
Table 2. 3 - Recipes of solutions ........................................................................ 64
Table 2. 4 - Primary antibodies ......................................................................... 66
Table 2. 5 - Secondary antibodies ...................................................................... 66
Table 2. 6 - siRNA used for RNA interference experiments ......................... 66
Table 2. 7 - shRNA used for RNA interference experiments ......................... 67
Table 2. 8 - qPCR primer sequences .................................................................. 67
Table 2. 9 - Acrylamide gels composition ......................................................... 68
Table 2. 10 - Drugs and Suppliers ................................................................. 68
Table 2. 11 - Cycling conditions for qPCR reaction ....................................... 73
Table 2. 12 - Primary antibodies used for Immunohistochemistry ............... 81

Table 5. 1 - Overexpression of genes belonging to the ERBB network in phospho-ERK$^{\text{high}}$ tumour regions. ................................................................. 144
List of Figures

Figure 1. 1 - Domain structure of AMPK subunits. ................................................. 21
Figure 1. 2 - Signal pathways regulated by AMPK. .................................................. 26
Figure 1. 3 - The mTORC1 signalling pathway......................................................... 28
Figure 1. 4 - Dendrogram of the AMPK related kinases. ......................................... 34
Figure 1. 5 - ARKs sequence homology of the kinase domain. ................................ 36
Figure 1. 6 - Mechanism of regulation of cell adhesion by NUAK1. ....................... 43
Figure 1. 7 - NUAK1 gene alteration frequency in human cancer. ......................... 46
Figure 1. 8 - Histogenesis and molecular markers of Adenocarcinoma and Squamous cell carcinoma. ................................................................. 50
Figure 1. 9 - The ERBB signalling network. ......................................................... 54
Figure 1. 10 - Downstream targets of RAS. ......................................................... 56

Figure 3. 1 - NUAK1 is not required for the maintenance of AMPK subunits. .... 88
Figure 3. 2 - NUAK1 is not required for the maintenance of AMPK basal activity. ........................................................................................................ 89
Figure 3. 3 - AMPK response to increase in intracellular Ca\(^{2+}\) is impaired by NUAK1 inhibition................................................................. 90
Figure 3. 4 - NUAK1 is still required for AMPK response to increase in intracellular Ca\(^{2+}\) in the absence of LKB1........................................ 91
Figure 3. 5 - NUAK1 is active and can be modulated in LKB1-null cells. .......... 92
Figure 3. 6 - CaMKKβ is not an upstream kinase for NUAK1. ............................. 93
Figure 3. 7 - Modulation of intracellular Ca\(^{2+}\) levels impacts on NUAK1 activation. ........................................................................................................ 94
Figure 3. 8 - Simultaneous depletion of NUAK1 and NUAK2 abrogates modulation of phospho-MYPT\(^{15445}\) in response to calcium. ............ 95
Figure 3. 9 - Overexpression of MYC induces upregulation of components of the Ca\(^{2+}\) signalling pathway. ................................................................. 97
Figure 3. 10 - Inhibition of PKC impairs MYPT\(^{15445}\) phosphorylation............. 98
Figure 3. 11 - PKCa and not PKCb\(_1\) regulates downstream phosphorylation of MYPT\(^{15445}\). ..................................................................................... 99
Figure 3. 12 - Phosphorylation of NUAK1 is decreased by PKC inhibition. .... 100
Figure 3. 13 - PKCa depletion induces NUAK1 degradation. .............................. 101
Figure 3. 14 - PKCα and NUAK2 co-depletion further decreases phospho-MYPT1S445 levels. ................................................................. 102
Figure 3. 15 - NUAK1 inhibition and depletion is lethal in HeLa cells. ........... 103
Figure 3. 16 - Cell death induced by NUAK1 inhibition is rescued by MYC downregulation. ................................................................. 104
Figure 3. 17 - PKCα depletion and inhibition is lethal in HeLa cells. ............. 105
Figure 3. 18 - Dynamic Ca2+-dependent modulation of mTORC1 .................. 106
Figure 3. 19 - PKCα and NUAK1 depletion impairs Raptor inhibition at basal levels and in response to AMPK stimulation. .................................... 108
Figure 3. 20 - NUAK1 downregulation increases protein translation. ........... 109
Figure 3. 21 - mTORC1 inhibition rescues cell death induced by PKCα or NUAK1 depletion. ........................................................................ 110
Figure 3. 22 - NUAK1 regulates RaptorS792 phosphorylation in the absence of AMPK. ................................................................. 111
Figure 3. 23 - Proposed model for the MYC-PKCα-NUAK1 signalling pathway... 117
Figure 4. 1 - Schematic representation of conditional lsl-KRasG12D and lsl-
KRasG12D;Nuak1F/F mouse model. .................................................. 120
Figure 4. 2 - KRasG12D/Nuak1F/F mice develop only lung adenocarcinoma. ...... 122
Figure 4. 3 - Nuak1 deletion does not affect the histogenesis of KRasG12D lung adenocarcinoma. ................................................................. 124
Figure 4. 4 - Nuak1 deletion does not affect KRasG12D-driven lung tumorigenesis. ........................................................................ 125
Figure 4. 5 - Moderate overexpression of MYC accelerate KRasG12D-driven lung cancer. ................................................................. 126
Figure 4. 6 - Histological examintaion of KM and KMN tumours. ................. 128
Figure 4. 7 - Deletion of Nuak1 does not affect growth of KRas/MYC lung tumours. ................................................................. 129
Figure 4. 8 - Nuak1 deletion decreases signalling through ERK. ................. 131
Figure 4. 9 - Nuak1 deletion results in increased AKT phosphorylation in lung tumours. ........................................................................ 132
Figure 4. 10 - Nuak1 deletion results in increased phosphorylation of 4E-BP1. 133
Figure 4. 11 - Nuak1 deletion does not senstize tumours to mTORC1 inhibition. ........................................................................ 134
Figure 4. 12 - Nuak1 deletion affects tumour blood vessels. ................. 135
Figure 4. 13 - Nuak1 deletion enhances survival of KRas\textsuperscript{G12D}/MYC lung tumours-bearing mice……………………………………………………………………………….. 136

Figure 5. 1 - Schematic representation of the lsl-KRas\textsuperscript{G12D}/R26-lsl-MYC/Hprt-lsl-Irfp mouse model. ................................................................. 142

Figure 5. 2 - ERBB receptors are active in KRas\textsuperscript{G12D}/MYC lung adenomas. …… 145

Figure 5. 3 - ERBB inhibition induces growth arrest and cell death in KM lung tumours. ........................................................................................................ 146

Figure 5. 4 - Neratinib but not Erlotinib treatment reduces lung tumour burden of KM mice. ........................................................................................................ 148

Figure 5. 5 - Neratinib treatment does not increase the overall survival of KM mice. ........................................................................................................ 149

Figure 5. 6 - Combination of ERBB and MEK inhibition more efficiently induces cell death in KRas mutant human lung cancer cell lines. ...................... 150

Figure 5. 7 - iRFP signal detection identified impaired growth of lung tumours treated with Neratinib in combination with Trametinib. ...................... 151

Figure 5. 8 - Combination of Neratinib with Trametinib enhances survival of KM mice. ........................................................................................................ 152

Figure 5. 9 - Simultaneous inhibition of the ERBB receptors and MEK impacts on AKT activation................................................................. 153
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-OHT</td>
<td>4-Hydroxytamoxifen</td>
</tr>
<tr>
<td>4E-BP1</td>
<td>Eukaryotic translation initiation factor 4E-binding protein 1</td>
</tr>
<tr>
<td>AAH</td>
<td>Atypical adenomatous hyperplasia</td>
</tr>
<tr>
<td>ACC</td>
<td>Acetyl-CoA Carboxylase</td>
</tr>
<tr>
<td>ADAM</td>
<td>A Disintegrin and Metalloprotease</td>
</tr>
<tr>
<td>ADP</td>
<td>Adenosine diphosphate</td>
</tr>
<tr>
<td>AID</td>
<td>Auto-inhibitory domain</td>
</tr>
<tr>
<td>AMARA</td>
<td>Synthetic peptide, AMARAASAAALARRR</td>
</tr>
<tr>
<td>AMP</td>
<td>Adenosine monophosphate</td>
</tr>
<tr>
<td>AMPK</td>
<td>AMP-activated protein kinase</td>
</tr>
<tr>
<td>ARK</td>
<td>AMPK-related kinases</td>
</tr>
<tr>
<td>ATM</td>
<td>Ataxia-telangiectasia mutated</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>BCA</td>
<td>Bicinchoninic acid</td>
</tr>
<tr>
<td>BrdU</td>
<td>Bromodeoxyuridine</td>
</tr>
<tr>
<td>BRSK</td>
<td>Brain-specific kinases</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>CaMKK</td>
<td>Calcium/calmodulin-dependent protein kinase kinase</td>
</tr>
<tr>
<td>cAMP</td>
<td>Cyclic adenosine monophosphate</td>
</tr>
<tr>
<td>CBM</td>
<td>Carbohydrate binding module</td>
</tr>
<tr>
<td>CBS</td>
<td>Cystathionine B-synthase</td>
</tr>
<tr>
<td>CC10</td>
<td>Clara Cell 10</td>
</tr>
<tr>
<td>CoA</td>
<td>Coenzyme A</td>
</tr>
<tr>
<td>CTD</td>
<td>C-terminal domain</td>
</tr>
<tr>
<td>DAG</td>
<td>Diacylglycerol</td>
</tr>
<tr>
<td>DEPTOR</td>
<td>DEP Domain Containing MTOR Interacting Protein</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s Modified Eagle Medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>eEF2K</td>
<td>Eukaryotic elongation factor-2 kinase</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal growth factor receptor</td>
</tr>
<tr>
<td>EH</td>
<td>Epithelial hyperplasia of the bronchioles</td>
</tr>
<tr>
<td>EIF4E</td>
<td>Eukaryotic translation initiation factor 4E</td>
</tr>
<tr>
<td>EMT</td>
<td>Epithelial-to-mesenchymal transition</td>
</tr>
<tr>
<td>ER</td>
<td>Estrogen receptor</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular signal-regulated kinase</td>
</tr>
<tr>
<td>FACS</td>
<td>Fluorescence activated cell sorting</td>
</tr>
<tr>
<td>FBS</td>
<td>Foetal Bovine Serum</td>
</tr>
<tr>
<td>FFPE</td>
<td>Formalin-fixed paraffin-embedded</td>
</tr>
<tr>
<td>FT</td>
<td>Farnesyltransferase</td>
</tr>
<tr>
<td>g</td>
<td>Relative centrifugal force</td>
</tr>
<tr>
<td>GBD</td>
<td>Glycogen-binding domain</td>
</tr>
<tr>
<td>GDP</td>
<td>Guanosine diphosphate</td>
</tr>
<tr>
<td>GEM</td>
<td>Genetically engineered mouse</td>
</tr>
<tr>
<td>GGT</td>
<td>Geranylgeranyltransferase</td>
</tr>
<tr>
<td>GLUT</td>
<td>Glucose transporter</td>
</tr>
<tr>
<td>GS</td>
<td>Glycogen synthase</td>
</tr>
<tr>
<td>GSK-3β</td>
<td>Glycogen synthase kinase-3β</td>
</tr>
<tr>
<td>GTP</td>
<td>Guanosine triphosphate</td>
</tr>
<tr>
<td>H&amp;E</td>
<td>Haematoxylin &amp; Eosin</td>
</tr>
<tr>
<td>HCl</td>
<td>Hydrochloric acid</td>
</tr>
<tr>
<td>HRP</td>
<td>Horseradish peroxidase</td>
</tr>
<tr>
<td>IDT</td>
<td>Integrated DNA Technology</td>
</tr>
<tr>
<td>IGF</td>
<td>Insulin-like growth factor</td>
</tr>
<tr>
<td>IHC</td>
<td>Immunohistochemistry</td>
</tr>
<tr>
<td>IP2</td>
<td>Inositol bisphosphate</td>
</tr>
<tr>
<td>IP3</td>
<td>Inositol trisphosphate</td>
</tr>
<tr>
<td>KD</td>
<td>Kinase domain</td>
</tr>
<tr>
<td>KRT</td>
<td>Keratin</td>
</tr>
<tr>
<td>LATS</td>
<td>Large tumour suppressor</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen-activated protein kinase</td>
</tr>
<tr>
<td>Acronym</td>
<td>Definition</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
</tr>
<tr>
<td>MAPKK</td>
<td>Mitogen-activated protein kinase kinase</td>
</tr>
<tr>
<td>MAPKKK</td>
<td>Mitogen-activated protein kinase kinase kinase</td>
</tr>
<tr>
<td>MARCKS</td>
<td>Myristoylated alanine-rich C-kinase substrate</td>
</tr>
<tr>
<td>MARK</td>
<td>Microtubule affinity-regulating kinase</td>
</tr>
<tr>
<td>MEF</td>
<td>Mouse Embryonic Fibroblast</td>
</tr>
<tr>
<td>MELK</td>
<td>Maternal embryonic leucine zipper kinase</td>
</tr>
<tr>
<td>MEM</td>
<td>Minimum Essential Media</td>
</tr>
<tr>
<td>MFF</td>
<td>Mitochondrial fission factor</td>
</tr>
<tr>
<td>MLC</td>
<td>Myosin regulatory light chain</td>
</tr>
<tr>
<td>MMP</td>
<td>Matrix metalloproteinases</td>
</tr>
<tr>
<td>MO25</td>
<td>Mouse protein 25</td>
</tr>
<tr>
<td>MOI</td>
<td>Multiplicity of infection</td>
</tr>
<tr>
<td>mTOR</td>
<td>Mechanistic Target of rapamycin</td>
</tr>
<tr>
<td>mTORC</td>
<td>mTOR complex</td>
</tr>
<tr>
<td>MYPT1</td>
<td>Myosin phosphatase targeting 1</td>
</tr>
<tr>
<td>NDR</td>
<td>Nuclear Dbf2-Related Kinase</td>
</tr>
<tr>
<td>NGS</td>
<td>Normal goat serum</td>
</tr>
<tr>
<td>NSCLC</td>
<td>Non-small cell lung cancer</td>
</tr>
<tr>
<td>NT</td>
<td>Non-targeting control</td>
</tr>
<tr>
<td>NUAK</td>
<td>Nua (novel) kinase</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate-buffered saline</td>
</tr>
<tr>
<td>PBS/T</td>
<td>Phosphate-buffered saline with Tween</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PFK-2</td>
<td>6-phosphofructo-2-kinase</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphoinositide 3-kinase</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein kinase C</td>
</tr>
<tr>
<td>PLK1</td>
<td>Polo like kinase 1</td>
</tr>
<tr>
<td>PP1</td>
<td>Protein Phosphatase 1</td>
</tr>
<tr>
<td>PRAS40</td>
<td>Proline-rich Akt substrate of 40 kDa</td>
</tr>
<tr>
<td>Raptor</td>
<td>Regulatory-associated protein of mTOR</td>
</tr>
<tr>
<td>Rheb</td>
<td>RAS homologue enriched in brain</td>
</tr>
<tr>
<td>RIM</td>
<td>Regulatory subunit-interacting motif</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>rpm</td>
<td>Revolutions per minute</td>
</tr>
<tr>
<td>SCC</td>
<td>Squamous cell carcinoma</td>
</tr>
<tr>
<td>SCLC</td>
<td>Small cell lung cancer</td>
</tr>
<tr>
<td>SD</td>
<td>Standard Deviation</td>
</tr>
<tr>
<td>SDS</td>
<td>Sodium dodecyl sulfate</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SIK</td>
<td>Salt-inducible kinases</td>
</tr>
<tr>
<td>SNF1</td>
<td>Sucrose non-fermenting protein 1</td>
</tr>
<tr>
<td>SPC</td>
<td>Surfactant protein C</td>
</tr>
<tr>
<td>STRAD</td>
<td>STE20-related adaptor protein</td>
</tr>
<tr>
<td>TAK1</td>
<td>Transforming growth factor-β activated kinase-1</td>
</tr>
<tr>
<td>TBC1D1</td>
<td>TBC1 domain family member 1</td>
</tr>
<tr>
<td>TBS</td>
<td>Tris-buffered saline</td>
</tr>
<tr>
<td>TBS/T</td>
<td>Tris-buffered saline with Tween</td>
</tr>
<tr>
<td>TdT</td>
<td>Terminal deoxynucleotidyl transferase</td>
</tr>
<tr>
<td>TK</td>
<td>Tyrosine Kinase</td>
</tr>
<tr>
<td>TKI</td>
<td>Tyrosine kinase inhibitor</td>
</tr>
<tr>
<td>TSC</td>
<td>Tuberous sclerosis complex</td>
</tr>
<tr>
<td>TXNIP</td>
<td>Thioredoxin-interacting protein</td>
</tr>
</tbody>
</table>
Acknowledgments

I would like to express my gratitude to my supervisor Daniel Murphy for giving me the opportunity to work in his group and for his precious guidance over the years. I am also thankful to all the members of M10, past and present, for their support, advice and for creating a great working environment. Thanks also to Björn, Allan and Nat for their feedbacks during the writing process, and to Jacqueline for her support and encouragement over the years. Nat has been a great mentor and friend from the very first day, always available for constructive discussions but also for a laugh together that helped during tough times.

Words cannot describe the important role that my work-wife, Jennifer, has played throughout my adventure in Scotland; with her sparklingly personality and kind heart she has always been there for me. Thanks to Alessandra, Dominika and Christin for the great time we had together, our therapeutic chats over coffee and drinks and for sharing with me the pain and the joy of this PhD. My wish is that our friendship will last in time and space.

I am grateful to my family for always believing in me and supporting my decisions; despite the distance, my heart will always be next to theirs. Thanks to Nicolas, without him by my side I would have not made it this far. His love gave me the strength during this journey and I will always be grateful for his willingness to follow me to Scotland and make everything possible.
Author’s Declaration

I declare that, except where explicit reference is made to the contribution of others, this dissertation is the result of my own work and has not been submitted for any other degree at the University of Glasgow or any other institution.

Tiziana Monteverde
Chapter 1 – Introduction

The Novel (Nua) kinase family 1 (NUAK1, also known as ARK5), is a serine/threonine kinase identified as the fifth AMPK-related kinase (ARK) (Suzuki et al., 2003a). The biological function of NUAK1 has not been extensively studied but multiple experimental evidence has suggested a role for NUAK1 in a broad variety of processes ranging from metabolism to cell adhesion, migration and neuronal axon branching. Although the information obtained so far places NUAK1 as a potential target in cancer therapy, additional studies are required to fully explore and understand its roles. On the other hand, a large number of investigations have been carried out on the function and activity of AMPK, which provided the molecular basis for the understanding of the roles of other AMPK-related kinases, such as NUAK1. Therefore, in this chapter an overview of AMPK and the AMPK-related kinases is given before discussing in more detail the function and regulation of NUAK1. Lung cancer is also discussed, as the mechanisms of progression and the involvement of NUAK1 in lung tumorigenesis have been investigated as part of this thesis.

1.1 AMPK, the master energy sensor

1.1.1 Structure and expression of AMPK

The AMP-activated protein kinase (AMPK) is a threonine-serine kinase with a fundamental role in the maintenance of energy homeostasis. The key function exerted by AMPK is to act as a sensor of cellular energetic levels and to rebalance them when energetic stress occurs. It is conserved across most eukaryotes, with one of the exception represented by the intracellular parasite Encephalitozoon cuniculi, and exists as a heterotrimeric complex composed by an α catalytic subunit and two regulatory subunits, β and γ. The existence of multiple isoforms for each subunit further increases the level of complexity of AMPK. Specifically, the genes PRKAA1 and PRKAA2 encode for two isoforms of the catalytic subunit, α1 and α2, respectively; two and three isoforms for the β and γ regulatory subunits are encoded by PRKAB1, PRKAB2 and PRKAG1, PRKAG2 and PRKAG3, respectively.
Several studies have been carried out in the recent years to characterize the structure of AMPK. Starting from the identification of the crystal structure of isolated domains and fragments of the heterotrimeric complex (Chen et al., 2009; Townley and Shapiro, 2007), more recent studies have obtained data on full-length complexes (Li et al., 2015b; Xiao et al., 2013), contributing with precious information to the function of the kinase. The α subunit is formed by an N-terminal kinase domain (KD), which possesses catalytic activity and that contains a conserved threonine in the activation loop (Thr172) that can be phosphorylated resulting in full activation of the kinase. The kinase domain is then followed by an auto-inhibitory domain (AID) and by the α regulatory subunit-interacting motifs (RIMs), which has been shown to be important for allosteric activation (Chen et al., 2009). Located at the C-terminus of the α subunit, the subunit-interacting domain mediates the interaction with the β regulatory subunit (Fig. 1.1).

The β subunits are characterized by a glycogen-binding domain (GBD) that allows binding of the complex to glycogen and β-cyclodextrin (Polekhina et al., 2005) and by a C-terminal domain (CTD) for interaction with α-CTD. Finally, the structure of three γ subunits slightly differ from each other because the γ2 and γ3 subunits contain an N-terminal extension that is missing in γ1. The γ isoforms, which form complexes with the β subunits through β-strands interactions (Xiao et al., 2007), comprise four tandem repeats of a cystathionine β synthase motifs (CBS1-4). A pair of CBS motifs forms the Bateman domain, which can bind two adenine nucleotides (Fig. 1.1). In particular, AMP is permanently bound to site-4 and appears not exchangeable as soaking of ATP into AMPK crystals did not displace AMP from site 4 (Xiao et al., 2007). Site-2 remains constantly unoccupied whereas site-1 and site-3 are the two exchangeable sites in which ATP, ADP and AMP bind in a competitive manner. Binding of adenine nucleotides at site-1 is at least 30-fold stronger than at the site-3 (Xiao et al., 2011).
Figure 1.1 – Domain structure of AMPK subunits.
Schematic representation of the domain organization of the catalytic (α1, α2) and regulatory (β1, β2, γ1, γ2, γ3) subunits of AMPK. AID, autoinhibitory domain; RIMs, regulatory subunit-interacting motifs; CTD, C-terminal domain; GBD, glycogen binding domain; NTD, N-terminal domain; CBS, cystathionine β synthase motifs. Adapted from (Salt and Hardie, 2017).

Different combinations of the multiple isoforms can give rise to twelve distinctive holo-AMPK complexes and their expression levels differ across tissue types. Specifically, AMPKα1, AMPKβ1, AMPKγ1 and AMPKγ2 are widely expressed whereas expression of AMPKα2 and AMPKβ2 is dominant in the skeletal and cardiac muscle, but lower levels can be found in many other tissue; expression of AMPKγ3 appears to be limited to skeletal and cardiac muscle.

A further level of complexity is given by the dynamic localization of AMPK in various cell compartments. It has been previously described that AMPK can shuttle between the cytoplasm and the nucleus (Kodiha et al., 2007), but Miyamoto and colleagues, by using a FRET-based biosensor for detection of AMPK activity, were additionally able to show a differential modulation of AMPK
activation and subcellular localization in response to stimuli like 2-Deoxyglucose or glucose starvation (Miyamoto et al., 2015).

### 1.1.2 Nucleotide-dependent activation of AMPK

As the key regulator of the cellular energetic status, AMPK can sense changes in ATP, ADP and AMP levels. During energetic stress, induced i.e. by nutrient or oxygen deprivation, an increased use of ATP, which represents the “energy currency molecule” of the cell, would lead to energetic imbalance characterized by increased ADP:ATP and AMP:ATP ratios. Binding of adenine nucleotide to the γ subunit of AMPK, commonly referred to as canonical activation, can regulate the activity of the AMPK complex by three mechanisms. Firstly, binding of AMP, but not ADP, can induce allosteric activation of various folds depending on the type of the γ isoform comprised in the complex (Cheung et al., 2000). Secondly, binding of AMP or ADP can promote phosphorylation at Thr172 by upstream kinases, such as LKB1 or CaMKKβ, which represents the most important event for full activation. However, the mechanism still remains controversial, with some experimental evidence supporting a role of CaMKKβ in phosphorylation of AMPK in response to ADP and AMP (Oakhill et al., 2011), whereas other studies have highlighted that AMP can induce phosphorylation through LKB1 and not CaMKKβ (Gowans et al., 2013). In addition, myristoylation of the β subunit was reported to be necessary for phosphorylation at Thr172 in response to AMP binding, as loss of the post-translational modification resulted in a reduction of the phosphorylation levels (Oakhill et al., 2010). Finally, binding of either AMP or ADP can induce a conformational change that protects the Thr172 site in the α catalytic subunit from dephosphorylation by phosphatases (Gowans et al., 2013; Xiao et al., 2011), with a more potent effect exerted by binding of AMP in comparison to ADP (Ross et al., 2016). Binding of ATP instead of ADP or AMP can inhibit all the three mechanisms of activation.
1.1.3 Pharmacological activation of AMPK

As a consequence of energetic stress, changes in adenine nucleotide ratios can finely tune the activation of AMPK. However, many other xenobiotics and natural compounds have been found to induce AMPK activity. Natural products such as Resveratrol (polyphenol compound found in grapes), or other plant extracts such as Berberin and Curcumin can activate AMPK and were utilised since ancient times as part of herbal remedies (Kim et al., 2009; Lee et al., 2006; Park et al., 2007). In addition, synthetic compounds such as Metformin, extensively used for the treatment of type II diabetes, and phenformin have also been described for their ability to induce AMPK. Although some of those compounds, like Resveratrol, phenformin and Berberine are mitochondrial poisons that interfere with ATP generation (Owen et al., 2000; Turner et al., 2008; Zheng and Ramirez, 2000), thereby activating AMPK by increasing the ADP or AMP levels, other drugs have revealed novel and AMP/ADP-independent mechanisms of activation. For example, Salicylate, which is the active metabolite of aspirin and a natural molecule found in many flowering plants, has been shown to directly induce AMPK activation. Similarly to AMP Salicylate is inducing allosteric activation and inhibits dephosphorylation of Thr172, but without affecting the AMP and ADP levels and interacting with a different site compared to the adenine nucleotides (Hawley et al., 2012). Furthermore, a synthetic compound member of the thienopyridone family and named A-769962 was identified during a screening of over 700,000 compounds for its ability to directly activate AMPK (Cool et al., 2006). Particularly, A-769662 was found to activate AMPK with a similar mechanism to Salicylate, without affecting the levels and the binding of AMP to the γ subunit of AMPK (Goransson et al., 2007; Sanders et al., 2007). Interestingly, both the synthetic and natural activators were found to require a wild-type AMPKβ1 subunit for their function. Mutation of the Ser108 residue to Alanine in the β1 subunit was shown to abolish the activation by both agents, suggesting an overlap of their site of action (Hawley et al., 2012).
1.1.4 Upstream kinases of AMPK

The Thr172 was identified as the major site for phosphorylation in AMPK (Hawley et al., 1996), which results in more than 100-fold activation (Suter et al., 2006). In the long search for the upstream kinase of AMPK, the yeast enzymes Tos3p, Pak1p and Elm1p were initially identified as being required for the in vivo function but also in vitro phosphorylation of Snf1, the yeast homologue of AMPK (Hong et al., 2003). In addition, Tos3p was found in the same study to phosphorylate AMPK in vitro. The similarity of Tos3p, Pak1p and Elm1p to the mammalian Liver Kinase B1 (LKB1) led to the important identification of the latter as the major upstream kinase for AMPK (Hong et al., 2003; Woods et al., 2003). Following studies have revealed that the activity of LKB1 was enhanced when in complex with two other proteins, STRAD and MO25 (Boudeau et al., 2003), and that the same complex could activate AMPK (Hawley et al., 2003).

The yeast activators of Snf1 displayed a similarity to the mammalian family of Ca\(^{2+}\)/Calmodulin-dependent kinases CAMKK, suggesting that alternative upstream kinases to LKB1 could take part in AMPK activation. Indeed, despite the initial underestimation of CaMKK as a potential alternative upstream kinase for AMPK, further studies have compellingly established the role of CaMKK in the activation of AMPK through phosphorylation at Thr172. Particularly, Carling’s group demonstrated that AMPK can be activated in cells lacking LKB1, such as HeLa cells, corroborating the theory of the existence of additional upstream kinases. Moreover, treatment of HeLa cells with STO-609, a pharmacological inhibitor of CaMKK, strikingly reduced the basal levels of AMPK activity as well as its response to multiple activators. Further experiments in the same study proved that agents that cause an increase in intracellular Ca\(^{2+}\) levels, such as ionomycin, could induce activation of AMPK and established that the CaMKK\(\beta\) isoform, rather than the \(\alpha\) isoform, is the main regulator of AMPK in cells lacking LKB1 (Woods et al., 2005). Corroborating the findings of Woods and colleagues, additional studies published in the same year also highlighted the Calcium/CaMKK\(\beta\) dependent activation of AMPK (Hawley et al., 2005; Hurley et al., 2005). Overall, the studies provided compelling evidence on CaMKK\(\beta\) being an alternative upstream kinase for AMPK and revealed a novel and Calcium-dependent mechanism of regulation.
A third kinase has been suggested to play a role in the activation of AMPK. Some reports have suggested that the Transforming growth factor-β-activated kinase (TAK1) can phosphorylate and activate AMPK (Momcilovic et al., 2006; Xie et al., 2006). In addition, further investigations have suggested a reciprocal regulation between TAK1 and AMPK, as AMPKα1 was shown to induce TAK1 with a role in inflammatory processes (Kim et al., 2012b). However, the physiological implications of AMPK activation by TAK1 are not clear yet.

1.1.5 Metabolic implications of AMPK activity

As the pivotal regulator of energy homeostasis, a fundamental function of AMPK in restoring the energetic levels is to activate intracellular catabolic pathways intent to produce energy while inhibiting energy consuming processes (Fig. 1.2). Over time, several downstream targets of AMPK have been identified, ranging from enzymes and kinases to transcription factors. AMPK, through the modulation of many targets, can regulate major cellular metabolic processes, such as protein synthesis, glucose and lipid metabolism, mitochondrial biogenesis and autophagy to orchestrate the energy production and consumption of cells, specifically under stress conditions.
Figure 1.2 – Signal pathways regulated by AMPK.

AMPK can regulate several downstream targets to inhibit anabolic pathways in favour of catabolic processes. Phosphorylation of TBC1D1 (TBC1 domain family member 1) promotes membrane translocation of the glucose transporter GLUT4 and glucose uptake; phosphorylation and inhibition of Glycogen synthase (GS) inhibits glycogen synthesis; Phosphorylation and inhibition of ACC1 and ACC2 (Acetyl CoA carboxylase) impairs fatty acids biosynthesis and promotes fatty oxidation, respectively; Phosphorylation of ULK1 (Unc-51 Like Autophagy Activating Kinase 1) contributes to autophagy induction; inhibition of protein synthesis is achieved by AMPK-mediated inhibition of Raptor and induction of Tuberin (TSC2, Tuberous Sclerosis 2). Only some of the targets and pathways are represented in this image generated using items from Servier Medical Art.

1.1.5.1 Regulation of protein synthesis

AMPK has been established as an important negative regulator of the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) (Fig. 1.3). mTOR acts as a coordinator of signals from nutrients and growth factors to regulate cell growth and proliferation. mTOR is the catalytic subunit of two distinct complexes that differ in their components but also for their substrates and regulation: mTORC1 and mTORC2. mTORC1 is a multi-protein complex formed by mTOR, Raptor (regulatory protein associated with mTOR), mLST8 (mammalian lethal with Sec13 protein 8, also known as GßL) and two inhibitory subunits, namely PRAS40 and DEPTOR. mTORC1 regulates multiple processes, such as...
protein synthesis, lipid and glucose metabolism and autophagy. mTORC1 is activated by Rheb on the surface of the lysosomes but active mTOR has also been detected in other cellular compartments, such as nucleus and cytoplasm (Betz and Hall, 2013; Manifava et al., 2016).

Regarding the regulation of protein synthesis, two important effectors are located downstream of mTORC1: p70S6 Kinase 1 (S6K1) and eIF4E Binding Protein (4E-BP1) (Fig. 1.3). Phosphorylation and consequent activation of S6K promotes mRNA translation. 4E-BP1 negatively regulates 5’-cap-dependent mRNA translation by binding the eukaryotic translation initiation factor 4E (eIF4E). Hyperphosphorylation of 4E-BP1 by mTORC1 induces the release of the eIF4E factor and stimulation of 5’-cap-dependent mRNA translation.

Interestingly, AMPK was shown to target multiple components of the mTORC1 pathway. In particular, AMPK activation by nutrient starvation resulted in the induction of TSC2, a negative regulator of mTORC1, through phosphorylation of Thr1227 and Ser1345 (Inoki et al., 2003). Active TSC2 can then inhibit Rheb, which is a GTPase of the RAS superfamily. Rheb has been proposed to control mTOR catalytic activity through multiple mechanisms: 1) Interaction with the mTOR kinase domain resulting in an increase in mTOR kinase activity (Long et al., 2005); 2) Rheb-GTP binds to the mTOR inhibitor FKBP (FK506-binding protein) 38, displacing it from mTOR (Bai et al., 2007); 3) Rheb-GTP interacts with phospholipase D1 (PLD1), causing the generation of phosphatidic acid, which positively regulates mTOR (Sun et al., 2008).

Additionally, AMPK has been involved in the regulation of mTORC1 through Raptor. Raptor, as previously mentioned, is part of mTORC1 complex and it was shown to be necessary for mTOR signalling in vivo as well as in vitro (Hara et al., 2002; Kim et al., 2002). Specifically, Shaw and colleagues identified Raptor as a direct target of AMPK and revealed that phosphorylation of Raptor at Ser722 and Ser792 caused its binding to the 14-3-3 protein and reduction of mTOR activity. Moreover, in cells stimulated with the AMPK activators phenformin and AICAR, inhibition of mTORC1 was not efficient when a mutant form of Raptor, in which Ser722 and Ser792 were replaced with Alanine, was expressed, suggesting that AMPK phosphorylation of Raptor is required for inhibition of mTORC1 (Gwinn et al., 2008).

Further checkpoints activated by AMPK for the regulation of translation have been described over time. For example, AMPK can directly activate eEF2K
(Eukaryotic elongation factor-2 kinase) to block translation elongation (Leprivier et al., 2013). Overall, the modulation of multiple components of the TOR pathway makes AMPK a key regulator of translation during energetic stress.

Figure 1.3 – The mTORC1 signalling pathway.
The mTORC1 complex is formed by a catalytic subunit (mTOR) and regulatory components (Raptor, PRAS40, DEPTOR, GβL). Active mTOR transmits the signal to the downstream effectors 4E-BP1 and S6K1 to modulate mRNA translation. AMPK can inhibit protein synthesis by phosphorylation and inhibition of Raptor; alternatively, phosphorylation and induction of TSC2 results in inhibition of Rheb, which is a positive regulator of mTORC1 activity. Image made using items from Servier Medical Art.
1.1.5.2 Regulation of glucose and lipid metabolism

Glucose and lipids are an important source of energy for cells and AMPK can modulate pathways involved in their metabolism to maintain energetic homeostasis. AMPK can stimulate glucose uptake in the skeletal muscle by transcriptional regulation of the glucose transporter GLUT4 through phosphorylation and inactivation of the transcriptional repressor Histone Deacetylase 5 (HDAC5) (McGee et al., 2008) and by promoting GLUT4 translocation to the plasma membrane through phosphorylation and inhibition of TBC1D1 (Chavez et al., 2008; Chen et al., 2008). Furthermore, AMPK-mediated phosphorylation and inhibition of Thioredoxin-interacting protein (TXNIP), a negative regulator of GLUT1, was shown to contribute to enhanced glucose uptake (Wu et al., 2013).

To increase energy production, AMPK has been described to promote the oxidation of glucose via stimulation of the glycolytic enzyme 6-phosphofructo-2-kinase (PFK-2) in cardiac cells and activated monocytes (Marsin et al., 2000; Marsin et al., 2002). In addition, glucose storage has been reported to be modulated by AMPK in the liver and muscle through the inactivation of glycogen synthase (GS) (Bultot et al., 2012; Jorgensen et al., 2004).

Lipids are an alternative source of energy when glucose levels are low. Among the various substrates of the lipid metabolism modulated by AMPK, inhibition of Acetyl-CoA Carboxylase (ACC) represents a key event in the regulation of lipid biosynthesis and oxidation (Ha et al., 1994; Munday et al., 1988). ACC is expressed in two isoforms, ACC1 and ACC2, which differ in their cellular localization and tissue distribution. In eukaryotes, ACC1 is expressed in all tissues but it is particularly enriched in lipogenic tissues such as liver, mammary glands and adipose tissue; ACC2 is the predominant isoform in oxidative tissues such as skeletal and cardiac muscle. ACC1 regulates lipid biosynthesis by generation of malonyl-CoA in the cytoplasm. Conversely, the malonyl-CoA generated by ACC2 acts as inhibitor of the carnitine/palmitoyltransferase 1 (CPT1), a mitochondrial enzyme involved in the movement of Acyl-CoA from the cytoplasm to the mitochondria for β-oxidation. Therefore, by inhibiting the two isoforms of ACC, AMPK can on one hand downregulate lipid biosynthesis and on the other hand it can stimulate lipid oxidation for energy production.
1.1.5.3 Regulation of mitochondria biogenesis and autophagy

Mitochondria are organelles with the important role of producing energy to support life. Indeed, as the key regulator of energy homeostasis, it is not surprising for AMPK to have been involved in the regulation of mitochondria biogenesis in response to energetic stress.

AMPKβ1/β2 deleted mice showed reduced activity and expression of mitochondrial enzymes such as citrate synthase and cytochrome c oxidase, as well as reduction in mitochondrial DNA copy number and alteration of mitochondria morphology (O’Neill et al., 2011). Moreover, AMPK was described to phosphorylate the proliferator-activated receptor γ coactivator 1α (PGC-1α), which is considered the master regulator of mitochondria biogenesis, causing the binding of PGC-1α to its own promoter to increase its expression levels (Jager et al., 2007). More recently, Shaw’s group revealed that following mitochondrial stress AMPK is activated to promote mitochondrial fission by phosphorylation of the mitochondrial fission factor (MFF), which is the receptor for the fission promoter dynamin-related protein 1 (DRP1) (Toyama et al., 2016). Mitochondrial fission is important for the generation of new mitochondria but also for their clearance when damaged and induction of this process by AMPK was suggested to prime cells for subsequent mitophagy. The term mitophagy refers to the mechanism of autophagy related to mitochondria, and represents an additional mechanism through which damaged mitochondria are removed.

In addition to a role in the degradation of dysfunctional proteins and organelles, mitophagy and more broadly autophagy are important cellular processes that allow the recycle of macromolecules in response to energetic needs. In agreement with its role as energy sensor, it was noted that AMPK activation under nutrient starvation could induce autophagy by phosphorylation of the autophagy-initiating kinase ULK1 (Egan et al., 2011; Kim et al., 2011).

Overall, by regulating both mitochondria biogenesis and clearance, as well as modulating autophagy in response to nutrient limitation, AMPK has established itself has a crucial coordinator of the cellular energetic engine.
1.1.6 Role of AMPK in the regulation of proliferation

Cell proliferation is a high energy-demanding process that not only requires new nucleotides for DNA and RNA synthesis, but also building blocks necessary to produce two daughter cells. Indeed, back in 1974 it was noticed that cells cultured in a shortage of amino acids, glucose and phosphate ions were entering in a quiescent status that was reverted by the addition of the limiting nutrient (Holley and Kiernan, 1974). In agreement with its role in maintaining the energetic balance, activation of AMPK was described to inhibit proliferation under glucose deprivation. In particular, AMPK was found to activate p53 through phosphorylation at Ser15, which induced cell cycle arrest at the G1 phase (Jones et al., 2005). Although the finding of AMPK-mediated induction of p53 was confirmed by other studies (Imamura et al., 2001), Ser15 does not appear to conform to the consensus motif of AMPK and evidence of a direct interaction between p53 and AMPK has not been provided, suggesting the possibility of an indirect effect. However, other investigations have revealed a potential role of AMPK in mitosis. In particular, during a study aimed to identify novel substrates of AMPKα2, Banko and colleagues revealed 28 new targets, many of them involved in mitosis and cytokinesis. AMPK was found to contribute to proper completion of mitosis and cytokinesis through phosphorylation of protein phosphatase 1 regulatory subunit 12C (PPP1R12C) (Banko et al., 2011). The function of AMPK in promoting mitosis might not be in line with its role of cell cycle inhibitor. However, the authors claimed that the regulation of mitosis could not be related to the energy regulating role of AMPK, as the mechanism was not affected by glucose deprivation.

1.1.7 Role of AMPK in cancer

The established function of AMPK in the regulation of metabolism has led to an increased interest in its role in metabolic diseases and to exploit AMPK as a potential therapeutic target. For example, the increase in glucose uptake and utilization as a result of AMPK activation is beneficial in metabolic conditions such as type II diabetes that is characterized by elevate blood sugar levels, insulin resistance and reduced insulin production. Indeed, the well-known AMPK
activator Metformin has been successfully employed in clinic for the treatment of type II diabetes. Interestingly, a pilot case-study conducted on patients affected by type II diabetes that received treatment with Metformin revealed a decrease in the incidence of cancer (Evans et al., 2005). Similarly, aspirin, which is metabolized to Salicylate, a direct activator of AMPK, was shown to improve insulin sensitivity in diabetic patients and reduce the risk of cancer (Cuzick et al., 2009; Hundal et al., 2002). The metabolic and cancer preventive effects observed might be the overall result of additional effects on other tissues and beyond AMPK activation. Indeed, metformin has been reported to reduce insulin levels in non-diabetic patients affected by breast cancer (Goodwin et al., 2008), and patients affected by type II diabetes and hyperinsulinaeemic have a higher risk of cancer development, thus suggesting that the reduction of insulin levels might contribute to the cancer preventive effect. Nevertheless, the role of AMPK in cancer remains of great interest. The features of uncontrolled proliferation and high metabolic demands of cancerous cells, often in a scenario of low availability of nutrients and oxygen, imply the intervention of AMPK to support energy homeostasis. However, there is still controversy on the role of AMPK as a friend or foe in cancer. Some studies have pointed towards a tumour suppressor role of AMPK. For example, it was reported that loss of AMPKα1 cooperated with Eμ-Myc in the acceleration of lymphomagenesis and caused a significant reduction in overall survival (Faubert et al., 2013). To note that the study made use of a full body knockout of AMPKα1, giving rise to the possibility that deletion of AMPK in other compartments, such as stromal cells, could contribute to the observed phenotype.

Several suggestions of a tumour suppressor role for AMPK come from studies related to LKB1 loss. In fact, given that the tumour suppressor LKB1 is the master upstream kinase for AMPK, it has been assumed that the effect observed upon LKB1 loss are mediated by the consequent loss of AMPK function. For example, BRAF mutation in melanoma cells was described to cause LKB1 inactivation and consequent loss of function of AMPK, claiming a role of the LKB1/AMPK axis in mediating the oncogenic role of BRAF (Zheng et al., 2009). However, AMPK is not the only kinase downstream of LKB1 since, as elucidated in the next paragraph, several other AMPK-related kinases have been identified and they can mediate some of the functions of LKB1. In addition, genetic alterations of the AMPK subunits are not common events in cancer. Contrariwise,
we have highlighted a selective amplification of specific AMPK subunits in human cancer, which would suggest a tumour promoter role (Monteverde et al., 2015). Indeed, on one hand AMPK activity can counteract the growth of cancer cells by inhibiting proliferation and mTORC1 activity, but on the other hand the same functions can also help cancer cells to survive in stressful conditions and environments. In support of a tumour promoting role, increased AMPK activity was observed in the early phases of glioma development and was maintained throughout later stages (Jang et al., 2011). Moreover, an additional study revealed how the ability of AMPK to maintain NADPH levels by inhibition of ACC1 and ACC2 contributed to the survival of tumour cells (Jeon et al., 2012). An intriguing aspect that has emerged in the recent years is to exploit the sensitivity to metabolic stress in case of impairments in the LKB1/AMPK axis. In particular, Shaw’s group revealed an increased sensitivity to the metabolic drug phenformin of LKB1-deficient non-small cell lung cancer (Shackelford et al., 2013). In addition, a recent study demonstrated how the maintenance of Leukaemia-Initiating cells requires the activity of AMPK, as deletion of AMPKα1/α2 from the hematopoietic cells enhanced the survival of mice affected by Acute Myeloid Leukaemia and sensitized tumour cells to metabolic stress induced by dietary restriction (Saito et al., 2015).

Further investigations are required to elucidate not only the context-dependent role of AMPK but also how different complexes might act as tumour promoters and suppressors before we can confidently manipulate AMPK for therapeutic purposes.

1.2 AMPK related kinases

AMPK was first named in 1988 by Hardie’s group (Munday et al., 1988), although previous reports had described an ATP-dependent kinase that could regulate Acetyl coenzyme A carboxylase by phosphorylation (Carlson and Kim, 1974). The function of AMPK has been extensively studied over time and, based on sequence similarity, several other kinases related to AMPK, called AMPK related kinases (ARKs), have emerged (Manning et al., 2002) (Fig. 1.4). Twelve other members have been included in the AMPK family: BRSK1 (SAD-B), BRSK2 (SAD-A), NUAK1
(ARK5), NUAK2 (SNARK), SIK1 (SIK), SIK2 (QIK), SIK3 (QSK), MARK1, MARK2, MARK3 (PAR1A or C-TAK1), MARK4 and MELK.

Figure 1.4 – Dendrogram of the AMPK related kinases.
Dendrogram obtained by the analysis of the full-length amino acid sequence of the 12 AMPK related kinases (ARKs) and AMPK using a freely available online tool from www.phylogeny.fr.

These ARKs exert multiple biological functions, some of them shared with AMPK. In particular, the Microtubule affinity-regulating kinases (MARKs) and the Brain-specific kinases (BRSK) are important regulator of cell polarity. The three isoforms of the salt-inducible kinases (SIK) exerts a variety of functions. Specifically, SIK1, first identified from the adrenal glands of rats that were fed on a high-salt diet (Wang et al., 1999), has been involved in cell cycle regulation, gluconeogenesis and lipogenesis regulation, muscle growth and differentiation; SIK2 is highly expressed in the adipose tissue but it has also been implicated in neuronal survival (Sasaki et al., 2011); SIK3 is thought to be important for cell proliferation as its downregulation resulted in chromosome abnormalities. The Maternal embryonic leucine zipper kinase (MELK) has been involved in the regulation of cell cycle and pre-mRNA splicing. NUAK2 activation
was described to play a role in the induction of cell-cell detachment (Suzuki et al., 2003b) and in the protection of tumour cells from CD95-mediated apoptosis (Legembre et al., 2004). In addition, NUAK2 was also described to promote cell migration (Namiki et al., 2011) and to share some functions and substrates with NUAK1, its closest AMPK related kinase, as further elucidated in the following paragraphs.

1.2.1 Activation modalities of ARKs

ARKs are characterized by a similar structure of the catalytic domain. However, the regulation of ARKs appears to be different from AMPK. Indeed, they do not contain regulatory subunits (Al-Hakim et al., 2005) and do not seem to be modulated by adenine nucleotides binding, although NUAK1 was reported to be activated by AMP and, similarly to NUAK2, by AICAR (an analogue of AMP) (Fisher et al., 2005; Lefebvre et al., 2001; Suzuki et al., 2003a). However, the evidence provided by the studies is not biochemically compelling as the response of the kinases to stimulation with AICAR or AMP was evaluated either exclusively by a cross-reacting antibody or employing a kinase assay that cannot completely preclude that the observed effect is mediated by other ARKs. In addition, an alternative study provided opposite evidence, as stimulation of MEFs with AICAR did not affect NUAK2 kinase activity (Lizcano et al., 2004a), questioning that other ARKs might be activated by AMP.

Additionally, initial evidence suggested that AMPK was the only member to be responsive to increased intracellular Ca$^{2+}$ levels. By using the AMARA peptide (a minimal phosphorylation substrate for the members of the AMPK family) multiple ARKs were tested for their ability to be activated in response to treatment with the calcium ionophore A23187. The assay revealed that none of the ARKs tested (SIK1/2/3, NUAK2, MARK1/2/3/4) was responsive to A23187, claiming that AMPK was the only member modulated by Ca$^{2+}$ levels (Fogarty et al., 2010). However, the AMARA peptide may not be the optimal substrate for all the ARKs as it has been shown that they can phosphorylate peptide substrates at dissimilar rates, suggesting a different substrate specificity (Lizcano et al., 2004a). Additionally, and a more recent study has disputed the theory of AMPK being the only member to be responsive to Ca$^{2+}$, as SIK2 was shown to be activated by an increase in
intracellular Ca\textsuperscript{2+} levels (Miranda et al., 2016). Therefore, further investigations and the development of more specific assays to test ARKs activity might reveal additional and surprising mechanisms of regulation.

### 1.2.2 Regulation of ARKs by upstream kinases

The finding that the Threonine 172 in the activation loop of AMPK\(\alpha_1/\alpha_2\) was conserved across the other ARKs (Fig. 1.5) led to the hypothesis that the family members could share the upstream kinases. In this regard, Lizcano and colleagues identified the LKB1/MO25/STRAD complex to be a common upstream kinase of the AMPK family members, responsible for phosphorylation of the conserved threonine residue in the T-loop leading to over 50-fold increase in activity of the ARKs. The only exception was MELK, which was shown to autophosphorylate the T-loop without the requirement of LKB1 (Lizcano et al., 2004a).

![Figure 1.5](image)

**Figure 1.5 – ARKs sequence homology of the kinase domain.**
Alignment of the T-loop amino acid sequence of the AMPK related kinases. Highlighted in red are the conserved amino acids across the kinases; the star denotes the conserved threonine in the activation loop.
CaMKKβ has been recognised as an alternative upstream kinase for AMPK and modulates its response to increased intracellular Ca²⁺ levels (Hurley et al., 2005; Woods et al., 2005). However, CaMKKβ has been disclaimed from being an upstream kinase for other ARKs. In particular, whereas expression of CaMKKβ was shown to enhance AMPK activation, the other ARKs tested did not respond similarly (Fogarty et al., 2010). In addition, in the same study BRSK1 activity appeared to be modulated by increased expression of CaMKKα, which was also reported to interact with BRSK1 (Fujimoto et al., 2008), although Fogarty and colleagues suggested it to be a poor substrate for CaMKKα.

TAK1, the third suggested alternative kinase for AMPK, is not known to modulate any other ARKs. However, alternative upstream kinases have been shown to modulate some ARKs. For example, using a proteomic approach, the atypical protein kinase PKCλ was found to interact with MARK4 (Brajenovic et al., 2004). A later study identified an additional atypical PKC, PKCζ, to phosphorylate MARK2 at Thr595 and negatively affect its association to the plasma membrane as well as activity (Hurov et al., 2004). In addition, GSK3β was documented to inhibit MARK2 activity through phosphorylation at Ser212 (Timm et al., 2008).

The three isoforms of SIK have been shown to be modulated by cAMP/Protein kinase A (PKA). In particular, phosphorylation at Ser577 by PKA was described to be required for nuclear translocation of SIK1 (Takemori et al., 2002), whereas phosphorylation of SIK2 on multiple serine and threonine residues by PKA was reported to affect cellular localization (Henriksson et al., 2012; Henriksson et al., 2015) and inhibit SIK3 activity in adipocytes (Berggreen et al., 2012). Additionally, AKT2 was shown to induce SIK2 activity by phosphorylation at Ser358 (Dentin et al., 2007). Finally, as already mentioned, SIK2 was found to be activated in response to increased Ca²⁺ signalling, although the responsible kinase was not identified in the study (Miranda et al., 2016).
1.3 NUAK1

1.3.1 Structure and expression profile of NUAK1

NUAK1 was identified during the analysis of its close member SNARK (NUAK2) performed by Suzuki and colleagues. By using an antibody developed against the SNARK peptide, they observed a cross-reacting protein by Western blot, which further analysis based on sequence homology revealed to be an additional member of the AMPK family (Suzuki et al., 2003a).

The human NUAK1 gene is located on chromosome 12 and encodes a protein of 661 amino acids, with a molecular weight of 78 kDa, whereas the mouse orthologous gene, Omphk1, is located on chromosome 10 and encodes for a 658 amino acids protein. Expression of NUAK1 is conserved across species: from mammals to Zebrafish and Drosophila, with two homologous (NUAK1 and NUAK2) in vertebrates and only one in *Drosophila melanogaster* and *Caenorhabditis elegans*. Currently, there is no crystal structure available for NUAK1, but protein sequence analysis indicates a 55, 47 and 45.8% identity to NUAK2, AMPKα1 and AMPKα2, respectively, with a conserved threonine residue at position 211 in the activation loop (Fig. 1.5).

The tissue distribution of mouse NUAK1 was analysed at mRNA levels and revealed high expression in oxidative tissues such as the cerebellum, heart and soleus muscle. In addition, analysis of protein levels confirmed high expression in the skeletal muscles (Inazuka et al., 2012).

1.3.2 Upstream kinases regulating NUAK1

LKB1 has been described as the master kinase for the members of the AMPK family. However, alternative upstream regulators have been identified for AMPK and other ARKs, as elucidated in the previous paragraphs. Regarding NUAK1, its activation was reported to be predominantly regulated by LKB1, as its deletion in mouse embryonic fibroblasts abolished NUAK1 basal activity (Zagorska et al., 2010). However, a residual basal activity of NUAK1 was detected in HeLa cells, which are functionally null for LKB1. Furthermore, NUAK1 levels and activity
could still be increased by treatment with EDTA, described in the same study to induce NUAK1 activation, although to a lesser extent in comparisons to HeLa cells stably expressing LKB1 (Zagorska et al., 2010). Therefore, there are experimental suggestions for the presence of alternative kinases upstream of NUAK1. Indeed, the analysis of NUAK1 sequence revealed the presence of a putative site for AKT phosphorylation and in vitro analysis indicated that AKT could phosphorylate NUAK1 at Ser600. Activation of NUAK1 by AKT was described to promote ATM induction, which resulted in the phosphorylation of its target p53 to support cell survival under glucose starvation (Suzuki et al., 2003a). However, additional analysis reported that the S600A mutation of NUAK1 did not affect the kinase activity (Humbert et al., 2010), suggesting that the AKT signalling may not play a direct role in NUAK1 activity or that this mechanism of regulation might not be conserved in various contexts.

The nuclear dbf2-related kinase 2 (NDR2) has been suggested in an isolated study as an additional alternative kinase for NUAK1. NDR1 and NDR2 were identified with a BLAST search for proteins with homology to the catalytic domain of LKB1 and CAMKKβ. Moreover, NDR2 was found to phosphorylate NUAK1 at Thr211 in response to IGF-1 stimulation. Interestingly, in the study the deletion of LKB1 did not affect IGF-1-mediated phosphorylation of NUAK1 at Thr211, implicating that LKB1 does not mediate NUAK1 activation under these specific conditions (Suzuki et al., 2006). Although additional kinases other than LKB1 have been suggested to modulate NUAK1 activity, more work will be required to confirm those findings and clarify their functional relevance.

1.3.3 Lesson on NUAK1’s physiological role from in vivo studies

The physiological role of NUAK1 has been highlighted by some in vivo studies carried out in mouse models. In particular, during the search of genes involved in brain development, the mouse homologous of NUAK1, Omphalocele kinase (Omphk1), was found to be enriched in the brain and a mutant form of the gene was shown to induce defects in the abdominal wall closure during embryogenesis, even though it did not cause brain morphological abnormalities (Hirano et al., 2006). A following study reported that a mouse double knockout mutant for NUAK1 and NUAK2 displayed facial clefting, spina bifida and
exencephaly, which is a malformation of the cranium that results in the external protrusion of brain tissue (Ohmura et al., 2012). Additionally, together with LKB1, NUAK1 was found to be involved in neuronal axon branching and growth by regulating the mitochondrial immobilization at the presynaptic site (Courchet et al., 2013).

To obtain more insights on the function of NUAK1 in adult tissues, Esumi’s group developed the first conditional knockout mouse model for Nuak1. Furthermore, in light of the tissue expression analysis of NUAK1, they specifically focused on its role in the skeletal muscle by controlling the deletion of the gene using a muscle Creatin kinase (Mck)-Cre (MNUAK1KO) (Inazuka et al., 2012). Whereas constitutive deletion of Nuak1 is embryonically lethal, the conditional knockout mice did not display any abnormality. In addition, the analysis of the muscle fibres composition and size revealed no significant difference between MNUAK1KO and wild type animals. However, when the authors investigated the effect of Nuak1 deletion on glucose metabolism it was revealed that MNUAK1KO mice were characterized by lower body weight, fasting blood glucose and free fatty acids levels in comparison to wild type animals when fed on a high-fat diet. A further analysis of the mechanism of the observed regulation of glucose metabolism revealed that, in response to acute administration of glucose, Nuak1 deletion resulted in enhanced membrane translocation of the glucose transporter GLUT4, through the increased phosphorylation of TBC1D4 at Thr649, which is known to regulate insulin-dependent trafficking of GLUT4. Phosphoproteomic analysis of isolated soleus muscle from MNUAK1KO and wild type mice exposed a decrease of the inhibitory phosphorylation of multiple proteins involved in glucose metabolism, such as the Insulin receptor substrate 1 (IRS1), Glycogen synthase and Protein kinase θ, indicative of a higher insulin sensitivity and glycogen synthesis. Overall, data obtained from the muscle-specific knockout of Nuak1 revealed a role of this AMPK-related kinase in the negative regulation of insulin signalling in soleus muscle (Inazuka et al., 2012).
1.3.4 Additional biological roles of NUAK1

Investigations carried out in cancer cell lines contributed to the improvement of our knowledge of NUAK1 function and provided key indications on its potential use as target for cancer therapy. As a matter of fact, NUAK1 has been involved in a plethora of biological processes that can be exploited by cancer cells to support their survival and help them to disseminate to distant sites.

1.3.4.1 Migration and Invasion

Multiple independent studies have established over time a crucial role of NUAK1 in cell migration and invasion to such an extent that initial reports were using those processes as a readout for NUAK1 activity. An initial study that highlighted NUAK1’s involvement in cell migration was carried out in a human pancreatic cancer cell line (PANC-1). Overexpression of NUAK1 in PANC-1 cells significantly increased their invasive capacity, which was further enhanced by IGF-1 stimulation and attenuated by AKT inhibition, suggesting an IGF/AKT regulatory mode. The mechanism through which NUAK1 contributed to cell invasion was suggested to involve increased activity of metalloproteinase 2 and 9 (MMP-2 and MMP-9), as a higher activity of those two enzymes was detected in NUAK1 overexpressing PANC-1 cells. In addition, the increased invasion upon NUAK1 overexpression was also confirmed in vivo. Subcutaneous tumours derived from transplantation of PANC-1 cells stably overexpressing NUAK1 displayed an extensive degree of invasion of the muscle layer and metastasis at multiple organs were also detected at earlier stages in comparison to PANC-1 cells expressing endogenous levels of NUAK1 (Suzuki et al., 2004). Additional investigations have further establishing the pivotal role of NUAK1 in cell migration and invasion in multiple cancer settings (Chang et al., 2012; Lu et al., 2013; Shi et al., 2014).
1.3.4.2 Cell adhesion

A proteomic study carried out on immunoprecipitated NUAK1 identified interactors belonging to the myosin phosphatase complex, which is responsible for dephosphorylation of proteins such as Myosin light chain 2 (MLC2) and Polo-like kinase-1 (PLK1) (Zagorska et al., 2010). The myosin phosphatase complex is formed by a catalytic subunit represented by the Protein Phosphatase 1 (PP1), and two regulatory subunits termed Myosin phosphatase target subunit (MYPT), which is expressed in three isoforms, and M20, of unknown function. NUAK1 was reported to interact with the complex formed by PP1β and MYPT1 and phosphorylate the latter at three different sites, Ser445, Ser472, Ser910 to promote binding of 14-3-3 protein to MYPT1, resulting in the inhibition of the myosin phosphatase complex (Zagorska et al., 2010). The described function of NUAK1 was shown to depend on the upstream kinase LKB1, since phosphorylation of MYPT1 was reduced in cells with LKB1 deletion. Moreover, inhibition of the myosin phosphatase complex following activation of the LKB1/NUAK1 axis was shown to result in higher phosphorylation levels of MLC2, which promotes cell detachment (Fig. 1.6). In addition, the study also identified the presence of a Gly-Ile-Leu-Lys (GILK) motif in NUAK1 sequence that mediates the interaction with the MYPT1-PP1β complex. Interestingly, NUAK2 was also shown to contain the GILK motif and to interact with the MYPT1-PP1β complex, sharing with NUAK1 the same phosphorylation sites on MYPT1, confirming previous reports that indicated MYPT1 phosphorylation by NUAK2 (Yamamoto et al., 2008; Zagorska et al., 2010). NUAK1 and NUAK2 are the only AMPK related kinases containing a GILK motif and evidence provided by Zagorska’s study also indicated that they are the only kinases of the family able to interact with MYPT1-PP1β.
Following phosphorylation and activation by LKB1, NUAK1 forms a complex with the Protein Phosphatase 1 β (PP1β) and with its regulatory subunit Myosin phosphatase target subunit (MYPT1). NUAK1 then phosphorylates MYPT1 at Ser445, Ser472, Ser910 to promote binding of 14-3-3 protein to MYPT1 and inhibition of the phosphatase activity of PP1β. The overall outcome represented in the diagram is the increased phosphorylation of the myosin light chain 2 (MLC2) which promotes Myosin II activation and cell detachment. Image adapted from (Zagorska et al., 2010) using items from Servier Medical Art.

1.3.4.3 Cell proliferation and senescence

Experimental evidence has suggested that NUAK1 takes part in the regulation of cell proliferation, although with contradictive findings on its role as promoter or inhibitor of cell cycle progression. Specifically, NUAK1 was found to interact and phosphorylate p53 at Ser15 and Ser392, causing induction of p21 and cell cycle arrest at the G1/S checkpoint (Hou et al., 2011). In contrast, a function as positive regulator of cell cycle was suggested by Alessi’s group. In their study inhibition of NUAK1 activity using the selective inhibitor HTH-01-015 reduced the percentage of cells in the S-phase of the cell cycle and restricted the progression to the mitotic phase. A more detailed analysis of the mechanism
revealed an interplay between NUAK1 and Polo like kinase 1 (PLK1). The inhibition of the phosphatase activity of the PP1βMYPT1 complex upon NUAK1 induction was suggested to increase PLK1 phosphorylation and activity to promote G2/M transition. In addition, active PLK1 was shown to phosphorylate NUAK1 at Ser476 and Ser480, inducing the interaction of SCFβTrCP E3 ubiquitin ligase complex with NUAK1 for its ubiquitylation and degradation. Thus, reciprocal modulation of PLK1 and NUAK1 levels during the different phases of cell cycle was suggested to orchestrate cell cycle progression (Banerjee et al., 2014b). Further studies have supported a positive role of NUAK1 in cell cycle regulation as its downregulation resulted in cell cycle arrest (Perumal et al., 2016) and its overexpression was described to enhance proliferation (Huang et al., 2014).

NUAK1 has also been involved regulation of ploidy and senescence (Humbert et al., 2010). During a screening to identify genes involved in senescence, downregulation of NUAK1 was found to increase the replicative potential of senescent cells. Additional analysis revealed that NUAK1-induced senescence was related to its role in the regulation of cell ploidy. In particular, NUAK1 was reported to induce aneuploidy via the negative regulation of the protein levels of the Large Tumour Suppressor kinase 1 (LATS1) (Humbert et al., 2010), known to promote cytokinesis (Yang et al., 2004).

### 1.3.4.4 Metabolic homeostasis

In addition to a biological role in adhesion, invasion and cell proliferation, NUAK1 was reported to regulate metabolic homeostasis and promote the survival of MYC-overexpressing cells. In particular, NUAK1 was identified in a synthetic lethality screening carried out to search for genes for which the loss of function was lethal only in the presence of MYC overexpression (Liu et al., 2012). In addition to the intriguing discovery that NUAK1 depletion led to cell death of MYC-overexpressing cells, the study confirmed some of the previous findings, such as a cell cycle arrest in the S-phase upon NUAK1 depletion, but most importantly it revealed new functions in the regulation of metabolic homeostasis. Indeed, NUAK1 was found to contribute to the maintenance of ATP levels by two major mechanisms: inhibition of the mTOR pathway and promotion
of the expression of components of the mitochondrial respiratory chain. Activation of MYC resulted in an increased induction of AMPK and in a decrease of mTORC1 activity. However, NUAK1 depletion ablated the increase in AMPK activity, resulting in an overall enhancement of protein synthesis, probably due to the inability of AMPK to restrain mTORC1. Treatment with Rapamycin, an mTORC1 inhibitor, could protect cells from death by relieving the metabolic stress induced by NUAK1 depletion, supporting NUAK1 contribution to cell survival through restraining mTORC1 activity. Furthermore, NUAK1 was shown to sustain metabolic homeostasis through the maintenance of the mitochondrial respiratory chain, as NUAK1 depletion caused a significant decrease in the expression of multiple subunits of the electron transport chain. Finally, analysis of a tumour model obtained by the transplantation of hepatoma cells expressing MYC revealed that downregulation of NUAK1 reduced the incidence of tumour formation but also increased survival of mice in comparison to the NUAK1 wild type counterpart (Liu et al., 2012). Therefore, overall the study suggested important implications of NUAK1 in metabolism and proposed targeting of NUAK1 as therapeutic approach in cancer.

1.3.5 Clinical relevance for NUAK1

Some of the investigations on NUAK1 function have been carried out in tumour cell lines, elucidating not only its roles but also a relevance for tumour biology and cancer therapy. Although NUAK1 gene alterations do not frequently occur in the four most common human cancers, with the exception of neuroendocrine prostate cancer (Fig. 1.7), studies done in human samples have strengthen the idea of a tumour promoter role.
Figure 1.7 – NUAK1 gene alteration frequency in human cancer.
The histogram represents the alteration frequency in NUAK1 gene across the four most lethal human cancers: pancreatic, breast, lung and colorectal cancer. NEPC, neuroendocrine prostate cancer; PAAC, Acinar cell carcinoma of the pancreas; MBL, Mutational profiles of metastatic breast cancer. Graphic obtained from cBioportal and truncated from the right to omit non-relevant data.

Multiple investigations have underlined a negative correlation between NUAK1 expression levels and survival of patients affected by a number of cancer types. For example, analysis of samples derived from patients affected by colorectal cancer revealed higher levels of NUAK1 expression in the tumours compared to the normal adjacent tissue. Additionally, in agreement with a described role in invasion, NUAK1 was highly expressed in liver metastasis (Kusakai et al., 2004). Similarly, investigation of NUAK1 expression in tumour samples from patients affected by hepatocellular carcinoma and glioma indicated higher levels in the tumour tissue compared to normal adjacent tissue. Moreover, high expression levels of NUAK1 correlated with a poor prognosis for both glioma and hepatocellular carcinoma (Cui et al., 2013; Lu et al., 2013). The analysis of NUAK1 expression in human gastric and non-small cell lung cancer samples
similarly revealed high levels in the tumour samples, a negative correlation with prognosis and a positive correlation with the depth of invasion and lymph node metastasis (Chen et al., 2013; Ye et al., 2014).

Most studies have highlighted a role of NUAK1 in invasion and metastasis. However, to date no genetically engineered mouse (GEM) models have been employed to characterize NUAK1 role in the early and late phases of tumour progression. In fact, given the variety of biological functions described, its role in cancer might not be limited to the metastatic process. In addition, the master upstream kinase LKB1 has been established as an important tumour suppressor in lung tumorigenesis, therefore we cannot exclude that NUAK1 might mediate some of tumour suppressive function in specific cancer types, such as lung cancer. Therefore, the use of GEM models could improve our understanding of NUAK1 role in cancer and suggest new therapeutic approaches.

1.3.6 Exploiting the synthetic lethal interaction between NUAK1 and MYC in cancer therapy

The important finding of a synthetic lethal interaction between NUAK1 and MYC opened the door to a new therapeutic strategy for cancer.

The proto-oncogene c-MYC, together with the family members N-MYC and L-MYC, is a basic helix-loop-helix-leucine zipper (bHLH-LZ) transcription factor that controls the expression of a large number of genes. Upon dimerization with the protein partner MAX, MYC binds to the E-box element CACGTG to induce gene expression, whereas upon interaction with the transcriptional activator Miz-1, MYC causes repression of Miz-1 target genes. Extensive studies carried out in the last decades have revealed that 15% of all genes belong to the network of targets regulated by MYC. These genes are involved in several biological processes, such as cell cycle regulation, anabolic metabolism (biosynthesis of amino acids, nucleotides and lipids), ribosome biogenesis, mitochondrial biogenesis and metabolic pathways (glycolysis, glutaminolysis) (Dang, 2012). Therefore, given its crucial role in cell metabolism and proliferation, it is not surprising that MYC is frequently dysregulated in human cancer. For example, MYC translocation to one of the immunoglobulin loci gives rise to Burkitt lymphoma (Dalla-Favera et al., 1982). In other cases, dysregulation of MYC
occurs via overexpression, while somatic mutations are not frequent events in cancer. In particular, MYC gene amplification has been frequently detected in many cancer types such as breast cancer, in which a correlation with disease progression has been suggested (Deming et al., 2000). Furthermore, upregulation of MYC can also be due to oncogenic activation of upstream signalling pathways that can promote MYC stability, i.e. RAS activation. Therefore, given its incontrovertible role in cancer, MYC targeting has been the focus of many therapeutic strategies. However, its inhibition has proved difficult to achieve because the lack of enzymatic activity limits the use pharmacological inhibitors and its localization in the nucleus prevents access to antibody-based therapies. Thus, the identification of synthetic lethal interactors, such as NUAK1, might represent a more successful strategy to challenge cancer addiction to MYC.

1.4 Lung cancer

1.4.1 Heterogeneity of lung cancer

Lung cancer is the second most common cancer in both males and females, secondary for incidence to prostate and breast cancer, respectively. Although the incidence and mortality has experienced a reduction over the last 30 years, it still represents the leading cause of cancer-related death worldwide.

Lung cancer can be classified in two major groups: Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC). The former accounts for the majority of cases (80%), and can be further classified in three groups based on histological characteristics: squamous cell carcinoma (SCC), adenocarcinoma (ADC) and large-cell carcinoma. Half of all cases of NSCLC are categorized as adenocarcinomas, which are malignant tumours with glandular histology and derive from the distal airways, particularly from bronchiolar and alveolar epithelial cells. Squamous cell carcinomas, which occurs in 40% of cases, typically derive from bronchial epithelial cells and are characterized by squamous differentiation, whereas large-cell carcinomas have a lower incidence and are diagnosed based on the lack of squamous or glandular differentiation.

The specific cell or cells of origin is a contributor to the histological diversity of NSCLC. Although over the recent years the cell of origin for ADC has been
debated, the use of genetically engineered mouse models has facilitated the investigation of the topic. To date, three types of cells have been considered for their potential to give rise to ADC: Clara cells (or Club cells), alveolar epithelial type 2 (AT2) cells and bronchioalveolar stem cells (BASCs). Conversely, the limited availability of GEM models for the study of SCC has restricted the investigation of the histogenesis of this specific subtype, however basal cells are thought to be the at the origin of SCC (Chen et al., 2014) (Fig. 1.8).

The classification of the multiple subtypes of NSCLC has been recently revisited by the World Health Organization, with the inclusion of several histological subtypes (Tab 1.1), and the recommendation for the use of immunohistochemistry along with morphological criteria for classification (Travis et al., 2015). In particular, in agreement with the protein expressed by the cell of origin, ADC displays positivity for markers like surfactant protein C (SPC), Keratin 7 (KRT7) and thyroid transcription factor 1 (TTF1), whereas SCC is characterized by expression of basal cells markers such as p63 and Keratin 5 (KRT5) (Fig. 1.8).
Figure 1. 8 – Histogenesis and molecular markers of Adenocarcinoma and Squamous cell carcinoma.

The distinct cell populations that give rise to Squamous cell carcinoma and Adenocarcinoma are depicted in the diagram. Squamous cell carcinoma typically originate from basal cells in the proximal lung whereas Adenocarcinoma is thought to arise from distal airways. TTF1, Thyroid transcription factor 1; KRT7, Keratin 7; SPC, surfactant protein C; KRT5, Keratin 5. Image adapted from (Chen et al., 2014) and generated using items from Servier Medical Art.
# 2015 WHO CLASSIFICATION OF LUNG TUMOURS

## Histological types and subtypes

<table>
<thead>
<tr>
<th>Adenocarcinoma</th>
<th>Squamous cell carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lepidic adenocarcinoma</td>
<td>Keratinizing squamous cell carcinoma</td>
</tr>
<tr>
<td>Acinar adenocarcinoma</td>
<td>Nonkeratinizing squamous cell carcinoma</td>
</tr>
<tr>
<td>Papillary adenocarcinoma</td>
<td>Basaloid squamous cell carcinoma</td>
</tr>
<tr>
<td>Micropapillary adenocarcinoma</td>
<td>Preinvasive lesion</td>
</tr>
<tr>
<td>Solid adenocarcinoma</td>
<td>Squamous cell carcinoma in situ</td>
</tr>
<tr>
<td>Invasive mucinous adenocarcinoma</td>
<td>Large cell carcinoma</td>
</tr>
<tr>
<td>Mixed invasive mucinous and nonmucinous adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Colloid adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Fetal adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Enteric adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Minimally invasive adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Nonmucinous</td>
<td></td>
</tr>
<tr>
<td>Mucinous</td>
<td></td>
</tr>
<tr>
<td>Preinvasive lesions</td>
<td></td>
</tr>
<tr>
<td>Atypical adenomatous hyperplasia</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma in situ</td>
<td></td>
</tr>
<tr>
<td>Nonmucinous</td>
<td></td>
</tr>
<tr>
<td>Mucinous</td>
<td></td>
</tr>
</tbody>
</table>

**Table 1.1 - Histological types and subtypes of NSCLC.**

A summary of the histological types and subtypes of Non-small cell lung cancer (NSCLC) as for classification by the World Health Organization (Travis et al., 2015).
1.4.2 Molecular profiling of NSCLC

The accumulation of genetic alterations leads ultimately to the dysregulation of the normal physiology of the cells and their transformation into cancerous cells. The development of new technologies such as Next Generation Sequencing has allowed the dissection of the genetic abnormalities in human cancer, providing us with a greater knowledge of the disease but simultaneously revealing its impressive complexity. The genetic investigation of SCC and ADC has added another level of separation between the two subtypes. Somatic mutations in PIK3CA, PTEN, are frequently detected in SCC, whereas mutations in EGFR, KRAS and ROS1 are more common in ADC. In addition, recent molecular profiling carried out on hundreds of tumour samples derived from patients with lung adenocarcinoma has uncovered several genetic aberrations and chromosomal rearrangements, placing lung ADC as one of the cancers with the highest mutation rate (The Cancer Genome Atlas Research, 2014). Interestingly, the mutation rates of some genes differ according to ethnicity and they also strongly correlate with tobacco smoke. For example, mutation in EGFR and ERBB2 are more frequent in never-smokers and Asian patients (Shigematsu et al., 2005), and tobacco smokers showed a higher number of mutations in comparison to never-smokers (Govindan et al., 2012).

The study of genetically engineered mouse models for NSCLC has enormously contributed to our current knowledge of the molecular mechanisms that drive the disease. However, pre-clinical studies of lung adenocarcinoma have been primarily conducted at the expense of squamous cell carcinoma, due to the limited availability of mouse models for the latter. Although numerous genes are being investigated for their potential tumorigenic role in lung adenocarcinoma, activating mutations of EGFR and KRAS have been established as important drivers of the disease and targeting of their aberrant activity has been a major clinical goal in the recent years.
1.4.2.1 EGFR and the ERBB signalling network

The dysregulation of the epidermal growth factor receptor (EGFR) in lung cancer was described already three decades ago (Veale et al., 1987), when immunostaining of tumour sections indicated higher levels of EGFR relative to normal lung tissue. Since then remarkable progresses have been made in the understanding of its role in lung cancer and overexpression of EGFR, detected in 62% of cases, is now considered a common event in NSCLC, with activating mutations present in approximately 15% of lung adenocarcinoma.

EGFR (also known as ERBB1 or HER1) belongs to the ERBB family of receptor tyrosine kinases together with ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4). These receptors are ubiquitously expressed as transmembrane proteins, characterized by an extracellular ligand-binding domain and an intracellular tyrosine kinase domain (Fig. 1.9). Although ERBB3 lacks a kinase domain and no ligand has been shown to bind to ERBB2, these two members can still function upon dimerization with EGFR and ERBB4. In addition, ERBB2-containing heterodimers have been shown to occur preferentially due to its peculiar conformation that resemble an active state that facilitates interaction with other ERBB receptors (Garrett et al., 2003).

ERBB receptors are activated by several ligands that belong to the family of EGF-related peptide growth factors (Fig. 1.9). These ligands are usually produced as transmembrane precursors that can be cleaved and released in the extracellular space by the enzymatic activity of the sheddases ADAMs (ADAM9, ADAM10, ADAM15 and ADAM17). Upon ligand binding, ERBB monomers form homo- and heterodimers, which triggers trans-phosphorylation of tyrosine residues of the intracellular kinase domain and stimulate the recruitment of effector proteins.
Multiple downstream signalling pathways are modulated by activation of the ERBB receptors and experimental evidence suggests that the type of ligand and heterodimer formed controls the selection of the effector proteins (Dankort et al., 2001; Sordella et al., 2004). Overall, the ERBB network modulates a number of biological processes: from cell proliferation and survival to cell migration and differentiation, with PI3K/AKT, RAS, PKC, JAK/STAT representing some of the several downstream effectors of the ERBB receptors.

### 1.4.2.2 RAS signalling

The story of the oncogene RAS goes back to 1960s, when Jennifer Harvey and Werner Kirsten discovered that a virus preparation from leukemic rat could induce sarcomas when injected in new-born rats (Ras= rat sarcoma). The homologous of the viral Ras sequence was identified in rat, mouse and humans in the following decades, and despite the extensive time and efforts spent in studying its function and, most importantly, its targeting, we are still in search of its Achilles’ heel.
The RAS family is frequently mutated in human cancer and consists of three
genes: H-RAS, K-RAS and N-RAS. KRAS is the isoform more frequently mutated in
lung cancer (30% of lung adenocarcinoma), with activating mutation first
described in 1984 by Mariano Barbacid (Santos et al., 1984).

RAS is a small GTPase that cycle between an off-state when bound to GDP to an
on-state when bound to GTP. However, because of its poor intrinsic GTPase
activity, it relies on two classes of proteins to switch between the on and off
states: GTPase activating proteins (RASGAPs) and guanine nucleotide exchange
factors (RASGEFs). In particular, RASGAPs stimulate the hydrolysis of GTP to
GDP, promoting inactivation of RAS, whereas the RASGEFs induce the exchange
of GDP for GTP, leading to RAS activation. Binding of GTP to RAS induces a
conformational change in two regions, named Switch I and Switch II, resulting in
an increased affinity and interaction of RAS with effector proteins (Vetter and
Wittinghofer, 2001). Activating mutations impair RAS sensitivity to the activity of
RASGAPs, which leads to a persistently active GTP-bound RAS (Malumbres and
Barbacid, 2003).

Mutations in KRAS frequently occur at codon 12, but the frequency of the type of
substitution changes according to the type of cancer. In lung cancer, the
mutation G12C is the most recurrent, followed by G12V and G12D (Cox et al.,
2014). Interestingly, the different substitutions have been shown to have a
different correlation with cigarette smoke, with G12C and G12V being associated
more with tobacco exposure than G12D (Riely et al., 2008), but also to engage
different downstream effectors of RAS (Ihle et al., 2012).

Regarding the downstream effectors, over 11 families have been identified as
mediators of RAS function, but the Raf/MEK/ERK cascade and AKT pathway are
among the major downstream effectors (Fig. 1.10).
Figure 1.10 - Downstream targets of RAS.

Active RAS in the GTP-bound state can stimulate multiple downstream pathways, among which the PI3K/AKT and the Raf/MEK/ERK cascade are the most important effectors. The PI3K/AKT axis support cell survival and proliferation through induction of mTORC1, the downregulation of the pro-apoptotic protein BAD and activation of MDM2, negative regulator of p53. On the other hand, RAS mediates activation of Raf, which culminates with the phosphorylation and activation of ERK, responsible for the regulation of several substrates located in the cytoplasm and in the nucleus, such as transcription factors, to support cell survival and proliferation. Only some of the targets are represented in the image. PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate. Image generated using items from Servier Medical Art.

The Raf/MEK/ERK signalling is one of the Mitogen-activated protein kinase (MAPK) cascade and transduces signals to regulate cell growth, differentiation and migration. The first step that triggers the pathway is the interaction and
phosphorylation of the Raf (MAPKKK) kinase by RAS. There are three isoforms of Raf (Raf-1, A-Raf, B-Raf), which differ not only in tissue distribution but also in their capability to activate the downstream effector MEK (Mitogen-activated protein kinase kinase or MAPKK). B-Raf is the isoform that most effectively activates the two isoforms of MEK (MEK1/2), followed by Raf-1, as opposed to the weak activation by A-Raf (Pritchard et al., 1995). This cascade of phosphorylation and activation events culminates with MEK catalysing a dual phosphorylation of a regulatory threonine and tyrosine on ERK. The serine/threonine kinase ERK (extracellular signal-regulated kinases or MAPK) is the only physiological substrate known of MEK and is encoded in two isoforms, ERK1 and ERK2, although several splicing forms are also produced. Once activated, ERK can regulate multiple targets located in the cytoplasm but also modulate nuclear transcription factors (Fig. 1.10).

An additional and crucial downstream effector of RAS is the PI3K/AKT axis (Fig. 1.10). This pathway is an important regulator of cell proliferation and survival and thus often dysregulated in cancer. Mechanisms of dysregulation include aberrant upstream signalling, i.e. EGFR or RAS mutation, as well as somatic mutations of its components (Vivanco and Sawyers, 2002). The first element of the signalling pathway is the Phosphoinositide 3-kinase (PI3K), a family of lipid kinases that consists of three classes: class I (further divided into subclasses IA and IB), class II and class III. Class IA of the PI3K family is the best characterized and plays a prominent role in cancer (Thorpe et al., 2015). It is formed by a p85 regulatory subunit and a p110 catalytic subunit, both of them being expressed as multiple isoforms. Active PI3K can phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to form phosphatidylinositol-3,4,5-trisphosphate (PIP3), which functions as second messenger and activator of AKT and additional numerous effector proteins. There are three genes encoding as many forms of AKT: AKT1, AKT2 and AKT3. Upon activation of PI3K, AKT is recruited to the plasma membrane where the binding of PIP3 to the PH domain of AKT causes a change to an active conformation that facilitates the access of upstream kinases for phosphorylation. Phosphorylation of AKT1 at Thr308 and Ser473 by PDK1 and mTORC2, respectively, is required for the full activation of the kinase. Phosphorylation also occurs on the corresponding sites in AKT2 (Thr309 and Ser474) and AKT3 (Thr305 and Ser472). As phosphorylation and PIP3 are
important factors in triggering AKT activity, its inactivation is mediated by phosphatases and by the tumour suppressor PTEN, which is responsible for dephosphorylation of PIP$_3$ (Manning and Toker, 2017). Although over 100 substrates for AKT have been suggested, not all of them have been validated. Nonetheless, multiple effectors proteins belonging to a variety of signalling pathways have been established as key mediators of AKT function. For example, in its role to promote cell survival, AKT can phosphorylate and inhibit the pro-apoptotic protein BAD and regulate the tumour suppressor p53 (Datta et al., 1997; Ogawara et al., 2002); furthermore, AKT can stimulate cell growth by promoting mTORC1 activity through inhibition of the repressors TSC2 and PRAS40 (Inoki et al., 2002; Sancak et al., 2007).

1.4.3 Targeted therapies for NSCLC

Despite the tremendous efforts made in the last decades to improve current treatments and introduce new therapies, patients affected by advanced lung cancer still have a 5-year survival rate of only 15%. However, the identification of genetic drivers of the disease has allowed the clinical use of targeted therapies that, in some instances, offer a better therapeutic outcome in comparisons to standard chemotherapy. For example, patients with activating mutations in EGFR can benefit from EGFR tyrosine kinase (TK) inhibitors. Responsiveness of patients with EGFR mutation to treatment with Gefitinib, an EGFR inhibitor, was firstly described in 2004 (Santos et al., 1984), almost twenty years after the discovery of EGFR dysregulation in lung cancer. Subsequent clinical studies have described the benefit of EGFR TK inhibitors, accountable for a longer median progression-free survival and also a higher response rate over standard chemotherapy in lung cancer patients selected based on EGFR mutations (Maemondo et al., 2010). However, the emergence of resistance to long-term treatments represents a major clinical problem, to which the response has involved the use of second and third generation TK inhibitors, mutant-specific inhibitors or targeting additional upregulated kinases. A wide range of resistance mechanisms to EGFR inhibition has been identified over time, such as activation of collateral pathways (MET amplification or activation of ERBB2
signalling), but also secondary mutations in EGFR, such as the T790M substitution, which affects the binding of the small molecule inhibitors (Kobayashi et al., 2005; Turke et al., 2010; Yonesaka et al., 2011). Overall, introduction of TK inhibitors in combination with patients’ stratification based on mutation status has revolutionized the therapeutic strategy for non-small cell lung cancer and many other cancer types. Nevertheless, limited targeted therapies are available for patients bearing mutations in the alternative oncogenic driver KRAS, as its inhibition has been extremely challenging to achieve. In particular, the development of GTP-competitive inhibitors that could impair RAS activity has proved to be unsuccessful due to the picomolar affinity of GTP for RAS (Spiegel et al., 2014). In addition, a broad inhibition of RAS, without distinction between the mutant and wild type form, might exhibit significant toxicity given its fundamental role in the biology of normal tissues. Therefore, in the recent years researchers have been trying to develop inhibitors that specifically target the mutant forms of RAS, with some promising results that need to be evaluated in clinical trials (Ostrem et al., 2013).

Alternatively, researchers have tried to impair RAS function by targeting those mechanisms that are required for its activity and its ability to engage with effector proteins. For example, localization of RAS to the plasma membrane is a key prerequisite for its function and requires the attachment of a farnesyl group to the CAXX motif that is present in all RAS isoforms. However, upon inhibition of the farnesyltransferase (FT) enzyme, which catalyses the farnesylation, RAS can be post-translationally modified by geranylgeranyltransferase (GGT). Simultaneous inhibition of both FT and GGT has proved to be highly toxic in preclinical models, limiting its clinical application (Lobell et al., 2001). Additionally, inhibition of the downstream effectors of RAS represents an alternative therapeutic strategy. A major effector of RAS is the MAPK pathway, which is hyper activated in 30% of cancers. Several pharmacological inhibitors of the components of the MAPK cascade have been developed and reached clinical evaluation over time. For example, MEK inhibitors have been approved for clinical use in B-RAF mutant metastatic melanoma and combination of Selumetinib (MEK inhibitor) with standard chemotherapy (docetaxel) resulted in an increase of the median progression-free survival in comparison to chemotherapy alone in a phase II trial in advanced KRAS-mutant NSCLC (Janne et al., 2013). However, a phase II trial suggested that inhibition of MEK using
Trametinib was not beneficial over chemotherapy with docetaxel in lung cancer patients selected for KRas mutation (Blumenschein et al., 2015). Further studies suggested the potential mechanism responsible for the lack of therapeutic efficacy of MEK inhibition alone. Specifically, Bernards group revealed that MEK inhibition resulted in upregulation of ERBB2 and ERBB3, which can sustain tumour cell growth through upregulation of the PI3K/AKT pathway. Therefore, a combinatorial therapy with ERBB receptors and MEK inhibitors was shown to be more effective and overcome resistance to MEK inhibition (Sun et al., 2014). Overall, preclinical and clinical data suggest that the success of a single-agent therapy is highly unlikely given the ability of tumour cells to rewire their signalling to support viability in the presence of inhibitory drugs.

1.5 PhD objectives

The great magnitude of studies in the cancer research field has contributed to make an impressive progress in the understanding and treatment of cancer. However, they have also highlighted the high complexity of cancer and how it cannot be defined as a single disease but as an extremely heterogeneous set of diseases. Although key oncogenes have been identified decades ago for their crucial role in the onset and maintenance of tumour cells viability, many of them still remain ‘undruggable’ and their targeting represents a major clinical goal.

The recent finding of the requirement of NUAK1 in cells overexpressing the oncogene MYC gave rise to a new therapeutic potential of this AMPK related kinase. Although other studies have revealed a clinical relevance for NUAK1 targeting in cancer, our knowledge about its regulation and biological function remains limited. In addition, experimental evidence has suggested a tumour promoter role for NUAK1, albeit its location downstream of the tumour suppressor LKB1. Therefore, the objective of this work are:

- Improve our knowledge of the mechanisms of NUAK1 regulation;
- Understand NUAK1’s role in metabolic homeostasis and specifically explore its involvement in lung tumorigenesis;
• Enhance our understanding of the molecular mechanisms of Non-small cell lung cancer to develop new therapeutic approaches.
Chapter 2 - Materials and Methods

2.1 Materials

2.1.1 Chemicals

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Supply</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-mercaptoethanol</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>2-propanol</td>
<td>Fisher Scientific</td>
</tr>
<tr>
<td>30% Acrylamide</td>
<td>VWR</td>
</tr>
<tr>
<td>96-Well PCR plates</td>
<td>Biorad</td>
</tr>
<tr>
<td>Ammonium persulfate (APS)</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Anti-FLAG M2 affinity gel</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>APC Annexin V</td>
<td>Biolegend</td>
</tr>
<tr>
<td>BSA</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>CaCl$_2$ solution</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Captisol</td>
<td>Selleckchem</td>
</tr>
<tr>
<td>Chloroform</td>
<td>Fisher Scientific</td>
</tr>
<tr>
<td>DMSO</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>DNAse/RNase free water</td>
<td>Qiagen</td>
</tr>
<tr>
<td>Dulbecco’s Modified Eagle Medium (DMEM)</td>
<td>Life Technologies</td>
</tr>
<tr>
<td>ECL Western blotting substrate</td>
<td>Pierce</td>
</tr>
<tr>
<td>Fetal Bovine Serum (FBS)</td>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>L-Glutamine</td>
<td>Life Technologies</td>
</tr>
<tr>
<td>Lipofectamine 3000</td>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>Lipofectamine RNAiMAX</td>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>Milk powder</td>
<td>Marvel</td>
</tr>
<tr>
<td>Minimum Essential Media (MEM), powder</td>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>N,N,N’,N’-Tetramethylethylenediamine (TEMED)</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Nitrocellulose membrane (0.2 µm pore size)</td>
<td>GE Healthcare Life Sciences</td>
</tr>
<tr>
<td>Normal Goat Serum (NGS)</td>
<td>Vector labs</td>
</tr>
<tr>
<td>NP-40</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Kit</td>
<td>Supplier</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Opti-MEM</td>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>PageRuler Prestained Protein Ladder</td>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>Peanut oil</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>PEG 400</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Penicillin/Streptomycin</td>
<td>Life Technologies</td>
</tr>
<tr>
<td>Phosphatase inhibitor cocktail 2</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Phosphatase inhibitor cocktail 3</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Polybrene</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Ponceau S</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Propidium Iodide</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Protease inhibitor cocktail</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Puromycin</td>
<td></td>
</tr>
<tr>
<td>Spectra multicolour high range protein ladder</td>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>SuperSignal West Dura</td>
<td>Pierce</td>
</tr>
<tr>
<td>Tris HCl</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Trizol</td>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>Trypsin</td>
<td>Life Technologies</td>
</tr>
<tr>
<td>Tween-20</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Glycerol</td>
<td>Sigma-Aldrich</td>
</tr>
</tbody>
</table>

Table 2.1 – Chemicals and Suppliers

### 2.1.2 Kits

<table>
<thead>
<tr>
<th>Kit</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>ApopTag Peroxidase in situ Apoptosis Detection kit</td>
<td>Millipore</td>
</tr>
<tr>
<td>Pierce BCA Protein Assay kit</td>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>Quantitect-Rev. transcription kit</td>
<td>Qiagen</td>
</tr>
<tr>
<td>Vectastain ABC HRP Kit</td>
<td>Vector Laboratories</td>
</tr>
<tr>
<td>SYBR green Fast Mix</td>
<td>VWR</td>
</tr>
</tbody>
</table>

Table 2.2 – Kits
### 2.1.3 Solutions

<table>
<thead>
<tr>
<th>Solution</th>
<th>Recipe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole cell extract lysis buffer</td>
<td>150 mM NaCl, 50 mM Tris (pH 7.5), 1% NP-40 (v/v), 0.5% Sodium deoxycholic acid (w/v), 1% SDS (v/v), protease and phosphatase inhibitor cocktails</td>
</tr>
<tr>
<td>IP lysis buffer</td>
<td>50 mM Tris HCl (pH 7.5), 1% NP-40 (v/v), 0.27M sucrose, phosphatase and protease inhibitors</td>
</tr>
<tr>
<td>IP washing buffer</td>
<td>50 mM Tris HCl (pH 7.5), phosphatase inhibitors</td>
</tr>
<tr>
<td>Annexin V Binding Buffer</td>
<td>10 mM HEPES (pH 7.4), 140 mM NaCl, 2.5 mM CaCl$_2$</td>
</tr>
<tr>
<td>5X Sample Buffer</td>
<td>0.3 M Tris (pH 6.8), 50% Glycerol (v/v), 10% SDS (w/v), 0.5% Bromophenol Blue (w/v), 4% 2-mercaptoethanol</td>
</tr>
<tr>
<td>Ponceau S</td>
<td>0.1% Ponceau S (w/v), 5% acetic acid</td>
</tr>
<tr>
<td>PBS</td>
<td>137 mM NaCl, 2.7 mM KCl, 10 mM Na$_2$HPO$_4$, KH$_2$PO$_4$,</td>
</tr>
<tr>
<td>PBS/T</td>
<td>PBS, 0.1% Tween-20 (v/v)</td>
</tr>
<tr>
<td>TBS</td>
<td>10 mM Tris HCl pH7.4, 150 mM NaCl</td>
</tr>
<tr>
<td>TBS/T</td>
<td>TBS, 0.1% Tween-20 (v/v)</td>
</tr>
<tr>
<td>Sodium Citrate Buffer</td>
<td>10 mM Sodium citrate (pH 6.0)</td>
</tr>
<tr>
<td>Running Buffer</td>
<td>10% SDS, 250 mM Tris, 1.92 M Glycine</td>
</tr>
<tr>
<td>Transfer Buffer</td>
<td>0.1% SDS, 25 mM Tris, 0.192 M Glycine, 20% Methanol</td>
</tr>
</tbody>
</table>

Table 2.3 – Recipes of solutions

### 2.1.4 Primary Antibodies

<table>
<thead>
<tr>
<th>Protein</th>
<th>Species</th>
<th>Antibody</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phospho-ACC (Ser79)</td>
<td>Rabbit</td>
<td>3661</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>ACC</td>
<td>Rabbit</td>
<td>3676</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Phospho-RAPTOR (Ser792)</td>
<td>Rabbit</td>
<td>2083</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Antibody Name</td>
<td>Species</td>
<td>Catalog Number</td>
<td>Company</td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>---------------</td>
<td>---------</td>
</tr>
<tr>
<td>RAPTOR</td>
<td>Rabbit</td>
<td>2280</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Phospho-4E-BP1 (Thr37/46)</td>
<td>Rabbit</td>
<td>2855</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>4E-BP1</td>
<td>Rabbit</td>
<td>9644</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Phospho-p70 S6 Kinase (Thr389)</td>
<td>Rabbit</td>
<td>9234</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>p70 S6 Kinase</td>
<td>Rabbit</td>
<td>2708</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Phospho-AMPK (Thr172)</td>
<td>Rabbit</td>
<td>2535</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>AMPKα1/α2</td>
<td>Rabbit</td>
<td>2532</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>AMPKβ1/β2</td>
<td>Rabbit</td>
<td>4150</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>AMPKγ1</td>
<td>Rabbit</td>
<td>32508</td>
<td>Abcam</td>
</tr>
<tr>
<td>NUAK1</td>
<td>Rabbit</td>
<td>4458</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Phospho-NUAK1 (Thr211)</td>
<td>Rabbit</td>
<td>NA</td>
<td>Eurogentec</td>
</tr>
<tr>
<td>NUAK2</td>
<td>Sheep</td>
<td>S225B</td>
<td>MRC PPU</td>
</tr>
<tr>
<td>Phospho-(Ser) PKC substrate</td>
<td>Rabbit</td>
<td>2261</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Phospho-PKCα/βII (Thr638/641)</td>
<td>Rabbit</td>
<td>9375</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>PKCα</td>
<td>Rabbit</td>
<td>2056</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>phospho-MARCKS (Ser159/163)</td>
<td>Rabbit</td>
<td>11992</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>anti-MARCKS</td>
<td>Rabbit</td>
<td>72459</td>
<td>Abcam</td>
</tr>
<tr>
<td>Phospho-MYPT1 (Ser445)</td>
<td>Sheep</td>
<td>S508C</td>
<td>MRC PPU</td>
</tr>
<tr>
<td>MYPT1</td>
<td>Rabbit</td>
<td>8574</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>MYC</td>
<td>Rabbit</td>
<td>32073</td>
<td>Abcam</td>
</tr>
<tr>
<td>Phospho-EGFR (Tyr1068)</td>
<td>Rabbit</td>
<td>3777</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>EGFR</td>
<td>Rabbit</td>
<td>06-847</td>
<td>Millipore</td>
</tr>
<tr>
<td>Phospho-ERBB2 (tyr1248)</td>
<td>Rabbit</td>
<td>06-229</td>
<td>Millipore</td>
</tr>
<tr>
<td>ERBB2</td>
<td>Mouse</td>
<td>OP15L</td>
<td>Merk-Millipore</td>
</tr>
<tr>
<td>Phospho-ERBB3 (Tyr1197)</td>
<td>Rabbit</td>
<td>4561</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>ERBB3</td>
<td>Mouse</td>
<td>05-390</td>
<td>Millipore</td>
</tr>
<tr>
<td>Phospho-ERK (Tyr204)</td>
<td>Mouse</td>
<td>7383</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>ERK</td>
<td>Rabbit</td>
<td>4695</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Phospho-AKT (Ser473)</td>
<td>Rabbit</td>
<td>4060</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>AKT</td>
<td>Mouse</td>
<td>2920</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>FLAG</td>
<td>Mouse</td>
<td>F1804</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Vinculin</td>
<td>Rabbit</td>
<td>129002</td>
<td>Abcam</td>
</tr>
<tr>
<td>β-Actin</td>
<td>Mouse</td>
<td>A5441</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>γ-Tubulin</td>
<td>Mouse</td>
<td>173831</td>
<td>Abcam</td>
</tr>
</tbody>
</table>
### Table 2. 4 – Primary antibodies

<table>
<thead>
<tr>
<th>Protein</th>
<th>Species</th>
<th>Antibody</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>H2B</td>
<td>Rabbit</td>
<td>1790</td>
<td>Abcam</td>
</tr>
</tbody>
</table>

#### 2.1.5 Secondary Antibodies

<table>
<thead>
<tr>
<th>Protein</th>
<th>Species</th>
<th>Antibody</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRP anti-rabbit</td>
<td>Sheep</td>
<td>NA934</td>
<td>Ge Healthcare</td>
</tr>
<tr>
<td>HRP anti-mouse</td>
<td>Sheep</td>
<td>NA931</td>
<td>Ge Healthcare</td>
</tr>
<tr>
<td>HRP anti-sheep</td>
<td>Rabbit</td>
<td>31480</td>
<td>Pierce</td>
</tr>
</tbody>
</table>

Table 2. 5 – Secondary antibodies

#### 2.1.6 siRNA

<table>
<thead>
<tr>
<th>Target</th>
<th>SiRNA</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-targeting control</td>
<td>FlexiTube 1022076</td>
<td>Qiagen</td>
</tr>
<tr>
<td>NUAK1 #1</td>
<td>FlexiTube SI00108388</td>
<td>Qiagen</td>
</tr>
<tr>
<td>NUAK1 #2</td>
<td>FlexiTube SI00108388</td>
<td>Qiagen</td>
</tr>
<tr>
<td>NUAK2</td>
<td>FlexiTube SI02660224</td>
<td>Qiagen</td>
</tr>
<tr>
<td>PKCα #1</td>
<td>FlexiTube SI00605934</td>
<td>Qiagen</td>
</tr>
<tr>
<td>PKCα #2</td>
<td>FlexiTube SI00605927</td>
<td>Qiagen</td>
</tr>
<tr>
<td>MYC #1</td>
<td>FlexiTube SI00300902</td>
<td>Qiagen</td>
</tr>
<tr>
<td>MYC #2</td>
<td>FlexiTube SI02662611</td>
<td>Qiagen</td>
</tr>
<tr>
<td>MYC #3</td>
<td>FlexiTube SI03101847</td>
<td>Qiagen</td>
</tr>
</tbody>
</table>

Table 2. 6 – siRNA used for RNA interference experiments
2.1.7 shRNA

<table>
<thead>
<tr>
<th>Target</th>
<th>Sequence</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-targeting control</td>
<td>Renilla</td>
<td>Mirimus Inc</td>
</tr>
<tr>
<td>MYC #1</td>
<td>CTGAGTCTTGAGACTGAAAGAT</td>
<td>Mirimus Inc</td>
</tr>
<tr>
<td>MYC #2</td>
<td>CGCCTCCCTCCACTCGGAAGGA</td>
<td>Mirimus Inc</td>
</tr>
</tbody>
</table>

Table 2.7 – shRNA used for RNA interference experiments

2.1.8 Primers

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITPR1 forward</td>
<td>5'-GAAGGCATCTTTTGGAGGAAGT-3'</td>
</tr>
<tr>
<td>ITPR1 reverse</td>
<td>5'-ACCCTGAGGAAGGTTCTG-3'</td>
</tr>
<tr>
<td>PKCα forward</td>
<td>5'-CAAGGGATGAAATGTGACACC-3'</td>
</tr>
<tr>
<td>PKCα reverse</td>
<td>5'-CCTCCTTCTCTGATGCACCATTCC-3'</td>
</tr>
<tr>
<td>NUAK1 forward</td>
<td>5'-CCGCTCACTGTGATGTAATC-3'</td>
</tr>
<tr>
<td>NUAK1 reverse</td>
<td>5'-GTCATCTCTCAACCCTCCTCAT-3'</td>
</tr>
<tr>
<td>CaMKKβ forward</td>
<td>5'-GGAGGTGCGAGAACTCAGTCAA-3'</td>
</tr>
<tr>
<td>CaMKKβ reverse</td>
<td>5'-CATGTTCTTCCAGCAGTCAA-3'</td>
</tr>
<tr>
<td>β-Actin forward</td>
<td>5'-CCAACCGCGAGAAGATGA-3'</td>
</tr>
<tr>
<td>β-Actin reverse</td>
<td>5'-CCAGAGGTGACAGGAGTGATAG-3'</td>
</tr>
<tr>
<td>β2m forward</td>
<td>5'-ACCTCCATGATGTGCTCTTAC-3'</td>
</tr>
<tr>
<td>β2m reverse</td>
<td>5'-GGACTGCTTTCTATCTCTTTGAC-3'</td>
</tr>
</tbody>
</table>

Table 2.8 – qPCR primer sequences
2.1.9 Acrylamide gels

<table>
<thead>
<tr>
<th></th>
<th>Separating Gel</th>
<th>Stacking Gel</th>
</tr>
</thead>
<tbody>
<tr>
<td>30% Acrylamide</td>
<td>3.75 ml</td>
<td>5.1 ml</td>
</tr>
<tr>
<td>1M Tris pH8.9</td>
<td>5.6 ml</td>
<td>5.6 ml</td>
</tr>
<tr>
<td>1M Tris pH6.8</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>H₂O</td>
<td>5.5 ml</td>
<td>4.2 ml</td>
</tr>
<tr>
<td>10% SDS</td>
<td>150 μl</td>
<td>150 μl</td>
</tr>
<tr>
<td>20% APS</td>
<td>75 μl</td>
<td>75 μl</td>
</tr>
<tr>
<td>TEMED</td>
<td>15 μl</td>
<td>15 μl</td>
</tr>
</tbody>
</table>

Table 2. 9 – Acrylamide gels composition

2.1.10 Drugs

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>A23187</td>
<td>Abcam</td>
</tr>
<tr>
<td>A769662</td>
<td>Abcam</td>
</tr>
<tr>
<td>BAPTA-AM</td>
<td>Tocris</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>LC Labs</td>
</tr>
<tr>
<td>Gö6976</td>
<td>Tocris</td>
</tr>
<tr>
<td>HTH-01-015</td>
<td>Cambridge Bioscience</td>
</tr>
<tr>
<td>Ionomycin</td>
<td>Abcam</td>
</tr>
<tr>
<td>MG132</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Neratinib</td>
<td>Carbosynth</td>
</tr>
<tr>
<td>phenformin</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Rapamycin</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Sto-609</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Trametinib</td>
<td>Insight Biotechnology</td>
</tr>
<tr>
<td>WZ 4003</td>
<td>Tocris</td>
</tr>
</tbody>
</table>

Table 2. 10 – Drugs and Suppliers
2.2 Methods

2.2.1 Cell Culture

2.2.1.1 Tumour Cells

U2OS and HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 g/L glucose, 2 mM L-Glutamine, 100 U/ml of penicillin, 100 μg/ml of streptomycin, 10% foetal bovine serum (FBS) and incubated at 37 °C in 5% CO₂. Cells were passaged when they reached 70% confluency and kept in culture until a maximum of 20 passages.

To split cells, the medium was removed and cells were washed once with PBS. Cells were then incubated with Trypsin-EDTA at 37 °C until complete detachment of the adherent cells was observed. Trypsin was then quenched by the addition of complete culture medium and cells were counted using a hemocytometer or an automated cell counter (Innovate) and re-seeded at the desired density for further experiments or for maintaining cells in culture.

All cell lines were routinely tested for mycoplasma contamination and were validated by STR profiling using an in-house validation service (CRUK-BICR).

2.2.1.2 Primary mouse embryonic fibroblasts

Pregnant females were euthanized by CO₂ at 13.5 days after plugging was observed. The uterus was dissected using dissecting forceps and each embryo was released from the yolk sac and placed in individual petri dishes containing PBS; embryos were then decapitated and a piece of tissue was used for genotyping purposes. After the removal of the embryonic internal organs, the embryo body was transferred into a fresh petri dish containing 2 ml of PBS and finely minced using a scalpel. Minced tissue was transferred to a falcon tube containing 1 ml of Trypsin-EDTA and incubated at room temperature for 15 minutes with occasional shaking. The tissue suspension was then placed in a 10 cm diameter petri dishes containing complete Dulbecco’s modified Eagle’s medium (DMEM) and incubated at 37 °C and 3% of Oxygen. The entire procedure was carried out in sterile conditions in a laminar flow hood. Cells were passaged
every 3 days using the same protocol as described in section 2.2.1.1, and re-seeded at a density of 1.3x10^6 into a 10 cm petri dish.

To induce recombination of the loxP-flanked regions, wild type and Rosa26-lsl-MYC MEFs were infected with 300 multiplicity of infection (MOI) of Adenovirus (University of Iowa) expressing Cre recombinase. Briefly, Adenovirus Cre, stored at -80 °C, was thawed on ice and mixed with the minimum sufficient volume of DMEM complete medium to cover the plate. Polybrene (4 μg/ml) was also added to the vector-medium solution to increase the transduction efficiency and the final mixture was added to the cells. Culture medium was removed after 6-8 hours post-transduction and replaced with fresh complete medium. Nuak1^{FL/FL} MEFs were infected with retrovirus expressing tamoxifen-inducible CreER and selected on 1 μg/mL puromycin.

SV40 T antigen-immortalised Prkaa1^{FL/FL}; Prkaa2^{FL/FL} MEFs were generously provided by Russell Jones, McGill University, and infected with 300 MOI of Adenovirus-Cre or Adenovirus-LacZ.

2.2.1.3 Cryopreservation and resuscitation of cells

For long-term storage, cells were cryopreserved when in log-phase growth, i.e. when cells were below the confluent density. Culture medium was removed and cells were washed once with PBS. Trypsin-EDTA was then added to detach the cells, which were re-suspended in freezing medium (10% DMSO, 90% FBS). The cell suspension was aliquoted into cryovials, which were transferred into Mr Frosty freezing containers filled with 2-propanol and stored at -80 °C before long-term storage in liquid nitrogen.

For resuscitation of frozen cells, cryovials containing cells were quickly thawed by incubation in a 37 °C water bath for 3-5 minutes. The cell suspension was then transferred to a 15 ml falcon tube containing complete culture medium and centrifuged at 1200 rpm for 5 minutes. After centrifugation, the supernatant was removed and the cell pellet was re-suspended in complete culture medium, transferred to appropriate culture plates and incubated at 37 °C.

For resuscitation of Mouse Embryonic Fibroblasts, cryovials were quickly thawed as described above and the cell suspension was added drop-wise to culture
plates containing complete medium, avoiding the centrifugation step, and incubated at 3% Oxygen.

2.2.2 Plasmid transfection

Cells were seeded at 1.5x10^6 cells per 10 cm and incubated overnight at 37 °C. The next day, 3 µg of DNA was re-suspended in 500 µl OPTI-MEM, with the subsequent addition of 6 µl of p3000 reagent. At the same time, 5 µl of Lipofectamine 3000 was added to 500 µl of Opti-MEM. Then, the two solutions were mixed together and incubated at room temperature for 15 min, as for manufacturer’s instructions. The DNA-lipid complex was added drop-wise to the cells in Pen/Strep free DMEM medium, following incubation at 37 °C. After 12 hours, medium was replaced with complete DMEM and cells re-seeded for further experiments and analysed as per figure legends.

shRNA-encoding plasmids, containing a puromycin resistance gene, were transfected as described above. In addition, cells were selected using 1µg/mL of puromycin before subsequent experiments. Non-transfected cells treated with the same antibiotic were used as control to assess the antibiotic response. FLAG- tagged NUAK1 T211A mutant plasmid was generously provided by David Bernard, Cancer Research Center of Lyon, and was reverted to the wild type form using a mutagenesis kit (QuikChange XL Site-Directed Mutagenesis Kit, Agilent Technologies).

2.2.3 siRNA transfection

Cells were seeded at 1x10^6 cells per 10 cm and the incubated overnight at 37 °C. Next day, the desired volume of siRNA, as per figure legends, was re-suspended in 500 µl OPTI-MEM and 10 µl of Lipofectamine RNAiMAX was also diluted in a second vial containing 500 µl Opti-MEM. The diluted siRNA was then added to the diluted Lipofectamine RNAiMAX and the solution obtained was incubated at room temperature for 5 minutes before adding it drop-wise to the cells in Pen/Strep free DMEM medium. Cells were incubated at 37 °C and re-seeded for further experiments as per figure legends.
2.2.4 RNA extraction and Quantitative Real-Time PCR

2.2.4.1 RNA extraction

Cells were seeded at $1 \times 10^5$ cells per well in a 6 well plate in triplicates. To isolate RNA, they were first rinsed in PBS and then harvested by adding 1 mL of Trizol. 200 μl of Chloroform was then added and the cell suspension was centrifuged at 14,000 rpm for 15 minutes at 4 °C. The upper aqueous phase was transferred to a fresh tube and mixed with an equal volume of isopropanol. The mix was incubated on ice for 20 minutes before centrifugation at 15,000 rpm for 10 minutes at 4 °C. The supernatant was removed and the RNA pellet was washed by the addition of 500 μl of 70% ethanol followed by centrifugation at 8,000 rpm for 5 min at 4 °C. The washing step was repeated a second time before air-drying the RNA pellet to completely remove the residual ethanol. Finally, RNA was re-suspended in 30 μl of RNase and DNase free water and incubated at 56 °C for 10 min. RNA concentration was measured using NanoDrop 2000c (ThermoFisher).

2.2.4.2 cDNA synthesis

Reverse transcription of 1 μg RNA into cDNA was carried out using QuantiTect Reverse Transcription Kit, according to manufacturer’s instructions. Briefly, 1 μg of RNA was added to 2 μl of gDNA Wipeout buffer and a final volume of 14 μl was reached with the addition of RNase free water. The mixture was incubated at 42 °C for 2 minutes to remove contamination with genomic DNA and then samples were transferred on ice. For the reverse transcription of RNA into cDNA, 1 μl of Quantiscript Reverse Transcriptase, 4 μl of Quantiscript RT buffer and 1 μl of RT Primer mix were added to each RNA sample and incubated first at 42 °C for 15 minutes and then at 95 °C for 3 minutes to inactivate the reverse transcriptase enzyme.
2.2.4.3 qPCR primers design and analysis

Primers for amplification of the gene of interest were designed using the Assay Design Centre freely available from Roche website, using an intron spanning assay. They were then analysed for the formation of hairpins, self- and hetero-dimers with the OligoAnalizer 3.1 freely available from IDT (Integrated DNA Technology).

2.2.4.4 Quantitative Real-Time PCR

Real time quantification was performed using SYBR Green Fast Mix. Specifically, 1 µl of cDNA was added to a mix containing 5 µl of SYBR Green Fast Mix, 0.1 µl of each Reverse and Forward primers (10 µM stock), and 3.8 µl of DNAase/RNAse free water to reach a final volume of 10 µl. Samples not containing the cDNA template were included to test the primer formation of homo- or heterodimers. Samples were plated in triplicates in a 96-well PCR plate and the qPCR reaction was carried out using a C1000 thermal cycler (Bio-Rad). A three-step protocol was used for the qPCR reaction:

<table>
<thead>
<tr>
<th>Temperature (°C)</th>
<th>Time</th>
<th>Cycle number</th>
</tr>
</thead>
<tbody>
<tr>
<td>95</td>
<td>5 minutes</td>
<td>1</td>
</tr>
<tr>
<td>95</td>
<td>30 seconds</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>20 seconds</td>
<td>35</td>
</tr>
<tr>
<td>72</td>
<td>10 minutes</td>
<td>1</td>
</tr>
<tr>
<td>65</td>
<td>10 seconds</td>
<td>1</td>
</tr>
<tr>
<td>95</td>
<td>30 seconds</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 2. 11 – Cycling conditions for qPCR reaction

The relative quantification of gene expression was performed using the comparative ΔΔCt method, with normalization of the target gene to the control genes β2-macroglobulin or Actin.
2.2.5 Immunoprecipitation and immunoblotting

2.2.5.1 Immunoprecipitation

FLAG-NUAK1 wild type, mutant (T211A) or empty vector transiently overexpressed HeLa cells were rinsed with ice-cold PBS and then lysed in IP Lysis Buffer (Tab. 2.3). Protein content of the cell lysates was quantified using the BCA quantification kit according to manufacturer’s instructions and 1 mg of proteins were incubated overnight at 4 °C with anti-FLAG M2 Affinity gel. Immunoprecipitated were centrifuged at 2,000 rpm at 4 °C for 1 minute, the supernatant was discarded and pellet washed twice with IP Washing Buffer (Tab. 2.3). After the final washing step, the immunoprecipitated were re-suspended in 30 μl of 2X SDS Sample Buffer.

2.2.5.2 Preparation of whole cell proteins extracts

For whole cell extracts, cells were rinsed twice with ice-cold PBS and then lysed in situ with ice-cold lysis buffer (Tab. 2.3). Lysates were then sonicated to reduce viscosity and diluted in 5X SDS Sample Buffer.

2.2.5.3 SDS-PAGE

Immunoprecipitated and whole cell extract proteins were resolved by SDS-PAGE. Samples were boiled at 95 °C for 10 minutes and centrifuged at 5,000 rpm for 2 minutes before loading onto hand-cast acrylamide gels of 1.5 mm thickness and of various percentage (Tab. 2.9) according to the molecular weights intended to separate. Electrophoresis was performed using a Bio-Rad Electrophoresis chamber containing Running Buffer (Tab. 2.3) and gels were run at 90 V until samples reached the separating gel and then the run was continued at 120 V until the visualization of the protein ladder indicated the preferred separation.
2.2.5.4 Western Blotting

Proteins were transferred to nitrocellulose membrane using a Bio-Rad tank transfer system, in which gels and membranes are submerged under transfer buffer (Tab. 2.3). Transfer was performed at 250 mA for a maximum of 2.5 hours.

The membrane was quickly stained using a Ponceau S solution to observe the quality of the transfer process and then rinsed with TBS/T before adding a blocking solution of 5% milk in TBS/T for 1 hour at room temperature with gentle shaking. The membrane was then rinsed in TBS/T before the overnight incubation with primary antibodies diluted in either 5% BSA or 1% milk in TBS/T at 4 °C.

Membranes were then washed three times, for 10 minutes each, in TBS/T and incubated with gentle shaking for 1 hour at room temperature with a 1:5000 dilution of the appropriate HRP-conjugated secondary antibody in 5% milk in TBS/T. Membranes were thoroughly washed three times in TBS/T to remove the secondary antibody and then incubated with the ECL Western blotting substrate for 1 minute. For detection of low intensity signal, membranes were incubated with SuperSignal West Dura Extended Duration Substrate in place of ECL Western blotting substrate. Membranes were then placed in a plastic sheet protector and transferred in a film cassette for detection of the chemiluminescent signal by autoradiography using X-ray film and a Kodak X-Omat 488 X-ray film processor.

2.2.6 Cell death analysis

Cells were seeded in triplicates at $10 \times 10^4$ cells per well in a 6-well plate and on the day of the analysis the supernatant was collected in round-bottom polystyrene tubes kept on ice. Cells were rinsed in PBS, following by the addition of 500 µl of 1X trypsin. Trypsin was quenched with 100 µl of FBS and cells were collected and transferred in to the polystyrene tubes for centrifugation at 300 g for 5 min at 4 °C. The supernatant was discarded and the cell pellet was incubated in 200 µl Annexin V Binding Buffer (Tab. 2.3) containing 2 µl of APC Annexin V (5 µg/ml stock) for 10 min at room temperature in the dark. 100 µl of
a 1 mg/ml propidium iodide solution was added prior to the analysis with FACSCalibur (BD Biosciences).

### 2.2.7 Determination of protein synthesis rates

Cells were seeded in triplicates at 9x10⁴ cells per well in a 12-well plate after siRNA transfection and incubated with 30 μCi/ml ³⁵S-methionine label (EasyTag from Perkin Elmer) for 30 minutes. Medium was then removed and cells washed with ice cold PBS before lysis. Protein precipitation was performed using a final concentration of 12.5% trichloroacetic acid and precipitated collected by vacuum filtration onto glass filter paper (Whatmann). Filters were then washed with 70% ethanol and acetone before counting scintillation (Ecoscint) for 2 minutes. An aliquot of the lysates was used for a BCA assay (Pierce) to normalise scintillation counts per minute to total protein.

### 2.2.8 Animals

#### 2.2.8.1 Mouse Models

Multiple Genetically Engineered Mouse (GEM) models were used for research purposes and provided by different research groups. Specifically, *R26-Is1-MYC* mice were generated by Daniel Murphy (Neidler and Murphy, unpublished), *Is1-Kras⁴¹⁴D* mice (Jackson et al., 2001) were obtained from Jackson lab and *Nuak¹F/F* mice were generously provided by Hiroyasu Esumi (Inazuka et al., 2012). *Lkb¹F/F* mice (Sakamoto et al., 2005) were provided by Owen Sansom and *Hprt-Is1-Irfp* mice were generated by Hock Andreas in collaboration with the Transgenic Production facility at the Beatson Institute (Hock et al., 2017).

#### 2.2.8.2 Breeding and Maintenance

All animal work was carried out in accordance with UK Home Office guidelines in line with Animals (Scientific Procedures) Act 1986 and the European Directive
2010/63/EU. Experimental cohorts and breeding stocks were kept in a light/dark 12 hours cycle, bred and maintained at the Beatson Institute Animal Facility. All breeding stocks and experimental cohorts were regularly checked for health concerns. Ear notching and general maintenance (food, water and housing) was carried out by the Biological Services Unit at the Beatson Institute. Animals were euthanized according to Schedule 1 techniques. Genotyping was carried out using ear notch tissue by Transnetyx (Cordova, TN, US). All experimental procedures were carried out under the Project Licence No. 70-7950 and my personal licence No. ICB9550E7.

**2.2.8.3 Intranasal instillation of Adenovirus**

Administration of Adenovirus Cre was carried out according to the following protocol in animals aged between 8 and 10 weeks. Minimum Essential Medium (MEM) was prepared by dissolving MEM powder in distillate water and pH was adjusted at 7.86 using NaOH. Medium was then filter-sterilised using a 0.22 μm filter. Adenovirus expressing Cre recombinase, stored at -80 °C, was thawed on ice and diluted to obtain the desired concentration in the prepared MEM medium. To create virus particle precipitates, CaCl₂ was added to a final concentration of 4 mM to the diluted virus and incubated at room temperature for approximatively 30 minutes.

Mice were anesthetized using a combination of Medetomidine (0.25 mg/Kg) and Ketamine (50 mg/Kg) diluted in 0.9% NaCl and administered by intraperitoneal injection. The depth of the anesthesia was checked by pinching animal’s feet before proceeding with the administration of 45 μl of Adenovirus Cre precipitates through the nostrils. Animals were then kept in recovery cages placed on heated plates to help maintain their body temperature. Once mice were fully recovered from the anaesthesia, they were housed in filter-top cages and maintained in a contained room for two weeks.
2.2.8.4 Administration of drugs

Rapamycin was administrated by intraperitoneal injection (i.p.) for 3 days at a dose of 10 mg/kg. A stock solution of 50 mg/ml was prepared in 100% Ethanol and 500 µl was further diluted in 9.5 ml of vehicle (5% PEG400, 5% Tween 20, PBS).

Neratinib and Trametinib were dissolved in peanut oil and sonicated in an ultrasonic bath. Both drugs were administered daily by i.p. injection, for the duration indicated as per figure legends, at a dose of 80 mg/Kg and 1 mg/Kg, respectively.

Erlotinib was dissolved in 6% captisol (w/v) in water and administered at a dose of 100 mg/Kg for 4 weeks by daily gavage.

Animals under treatment were frequently monitored for sides effects and sacrificed in case of excessive adverse response.

2.2.8.5 In vivo imaging

In vivo iRFP imaging was carried out using the Pearl Trilogy Small Animal Imaging System (LI-COR). To minimize the signal background originating from the stomach and intestine due to standard diet, mice were fed with alfalfa-free chow (AIN-93M, DBM Scotland) for at least 7 days prior to imaging. Briefly, animals were anesthetized under 2% isoflurane-mixed oxygen and the hair of the thorax and abdominal regions was removed using Nair depilatory cream. Animals were then imaged for the acquisition of the iRFP fluorescence in the 700 channel using the Pearl imaging system. Quantification of the iRFP signal intensity was performed with Image Studio v5 (LI-COR).

2.2.8.6 Tissue collection

To isolate the lungs for histological and pathological analysis, animals were euthanized according to Schedule 1 protocol by asphyxiation with carbon dioxide (CO₂) followed by cervical dislocation. To clear the internal organs of red blood cells, a whole-body perfusion was carried out through the heart by injecting PBS solution in the left ventricle and making an incision in the right ventricle to
allow for the discharge of the blood flow. To ensure a proper fixation of the lungs, 10% neutral buffered formalin was injected through the trachea using a 18g needle until the lungs were completely inflated. Lungs were then removed and placed in a conical tube containing 10% neutral buffered formalin. Tissue was fixed for approximately 16-20 hours before further histological processing was carried out by the Histology Service at the Beatson Institute.

2.2.8.7 Protein isolations from lung tumours

To isolate proteins from lung tumours, animals were sacrificed according to Schedule 1 protocol. Whole-body perfusion with PBS was carried out as described in paragraph 2.2.8.6 and lungs were quickly removed and placed in a petri dish containing PBS. Lung tumours were then dissected and placed in pre-chilled tubes containing 10 volumes of ice-cold lysis buffer (Tab. 2.3) for 1 volume of tissue sample. The tumour samples were homogenised using polypropylene pestles attached to a motor-driven grinder and then centrifuged at 12,000 rpm for 10 minutes at 4 °C. Supernatant was transferred to a fresh tube and stored at -20 °C for further analysis. Protein concentration was determined by BCA protein assay prior to Western blot analysis.

2.2.9 Histology

2.2.9.1 Immunohistochemistry

Paraffin-embedded tissue sections of 4 μm thickness were routinely cut and stained with Hematoxylin & Eosin by the Histology Service at the Beatson Institute.

Immunohistochemical staining for specific antigens was performed by initial de-paraffinization of the tissue sections through the incubation in three washes of xylene for 5 minutes each. Sections were then rehydrated by washing in a decreasing concentration of ethanol series (100%, 70%, 50%, 30%) for 2 minutes each, followed by incubation in dH₂O for 5 minutes.
Heat-induced antigen retrieval was carried out to unmask the antigen and allow for its recognition by the primary antibody by placing the tissue sections in pre-warmed sodium citrate buffer (pH 6.0) and heated for 6 minutes at 120 °C in a pressure cooker using a microwave. Sections were left to cool down for at least 30 minutes before washing in dH₂O for 5 minutes.

To prevent non-specific signal or high background staining due to endogenous peroxidase activity, sections were incubated in 3% hydrogen peroxide (H₂O₂) for 10 minutes to block the endogenous peroxidase. Sections were then washed for 5 minutes in TBS/T before incubation in the appropriate blocking solution for 30 minutes at room temperature.

Primary antibodies were diluted as indicated in Table 2.12 and sections incubated overnight at 4 °C in a humidified chamber. To remove the excess of primary antibody, sections were washed twice in TBS/T for 5 minutes per wash. Detection of the primary antibody bound to the antigen was carried out using the Vectastain ABC HRP Kit, which allows the amplification of the signal by exploiting the Avidin/Biotin complex formation. In particular, the use of a protein with high affinity-binding to biotin (avidin), allows the formation of a molecular bridge between the biotinylated secondary antibody and the biotinylated peroxidase enzyme, resulting in an enhanced signal detection upon addition of the enzyme substrate.

Tissue sections were incubated for 30 minutes with the appropriate biotinylated secondary antibody (Vectastain ABC HRP Kit) diluted in 5% Normal goat serum (NGS) diluted in TBS/T. At the same time, the ABC (Avidin/Biotinylated enzyme Complex) reagent was prepared as for manufacturer’s instructions (Vectastain ABC HRP Kit) and incubated at room temperature for 30 minutes. Sections were washed twice in TBS/T for 5 minutes each and incubated with the ABC reagent for 30 minutes in a humidified chamber. They were rinsed twice in TBS/T for 5 minutes and then DAB (3,3'-diaminobenzidine) was applied to each section and the staining monitored closely using a bright field microscope to establish the optimal incubation time. The peroxidase enzyme, in complex with Avidin and the biotinylated secondary antibody, determines the oxidation of DAB resulting in the deposition of a brown, alcohol-insoluble precipitate at the site of enzymatic activity. As soon as the signal of the desired intensity was developed, sections were rinsed in dH₂O and then counterstained for 1-2 minutes with a solution of Hematoxylin to stain cell’s nucleus. They were then rinsed in gently
running tap water before and after dipping into a differentiation solution (Acid Alcohol) to remove excess staining and define nuclei, following by 30 seconds incubation in a blueing reagent (Scott’s tap water) to transform the initial soluble colour of the Hematoxylin within the nucleus to an insoluble blue colour. Finally, tissue sections were dehydrated by washing in an increasing concentration of ethanol series (70%, 95%, 100%) for 2 minutes each and then incubated in two washes of xylene for 5 minutes per wash. Coverslips were mounted using a drop of DPX mounting media.

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Antibody (Supplier)</th>
<th>Blocking Buffer</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ki67</td>
<td>RM-9106-SO (Fisher Scientific)</td>
<td>1% BSA in TBS/T</td>
<td>1:200</td>
</tr>
<tr>
<td>BrdU</td>
<td>4370 (Cell Signaling)</td>
<td>1% NGS in TBS/T</td>
<td>1:200</td>
</tr>
<tr>
<td>p-ERK</td>
<td>4060 (Cell Signaling)</td>
<td>5% NGS in PBS</td>
<td>1:500</td>
</tr>
<tr>
<td>p-AKT (Ser473)</td>
<td>4370 (Cell Signaling)</td>
<td>5% NGS in TBS/T</td>
<td>1:25</td>
</tr>
<tr>
<td>p-4E-BP1 (Thr37/46)</td>
<td>2855 (Cell Signaling)</td>
<td>5% NGS in TBS/T</td>
<td>1:500</td>
</tr>
<tr>
<td>p-S6 (Ser235/236)</td>
<td>4858 (Cell Signaling)</td>
<td>5% NGS in TBS/T</td>
<td>1:800</td>
</tr>
<tr>
<td>p63</td>
<td>Sc-8431 (Santa Cruz)</td>
<td>No blocking</td>
<td>1:1000</td>
</tr>
<tr>
<td>SPC</td>
<td>AB3786 (Millipore)</td>
<td>3% NGS in PBS</td>
<td>1:1000</td>
</tr>
<tr>
<td>CD31</td>
<td>28364 (Abcam)</td>
<td>No blocking</td>
<td>1:75</td>
</tr>
</tbody>
</table>

Table 2. 12 – Primary antibodies used for Immunohistochemistry

2.2.9.2 TUNEL staining

Detection of apoptosis was performed using the ApopTag Peroxidase *In Situ* Apoptosis detection kit which consists of digoxigenin-conjugated nucleotide and the terminal deoxynucleotidyl transferase (TdT) enzyme. Apoptotic cells are characterized by fragmented DNA with free 3’-OH ends. The TdT enzyme can incorporate digoxigenin-conjugated nucleotide to the free 3’-OH ends, labelling the DNA fragments localized in apoptotic bodies. The digoxigenin-nucleotide can
then be detected by an HRP conjugated anti-digoxigenin antibody. Therefore, upon the addition of DAB, the HRP enzyme will catalyse the conversion of the chromogenic substrate into a visible brown coloured product, identifying the fragmented DNA.

Briefly, tissue sections were de-paraffinised and re-hydrated as already described in section 2.2.9.1, and antigen retrieval was carried out by incubation in a Coplin jar containing a solution of proteinase K (20 µg/ml in PBS) for 15 minutes at room temperature with gentle shaking. Sections were washed twice with dH2O for 2 minutes per wash and endogenous peroxidase activity was blocked by incubation in 3% H2O2 in PBS for 5 minutes at room temperature. After rinsing twice in PBS for 5 minutes each, 75 µl of Equilibration buffer was added to each section and incubated for 10 seconds. The TdT Enzyme was diluted 1:10 in Reaction Buffer and, after aspiration of the Equilibration buffer, 60 µl of the solution was added to each section for incubation at 37 ºC for 30 minutes in a humidified chamber. Sections were incubated in a Coplin jar containing the STOP Buffer (1 ml STOP buffer+ 34 ml dH2O) for 10 minutes at room temperature and then washed three times in PBS for 1 minute per wash. The HRP-conjugate anti-digoxigenin antibody was applied to each section and incubated at room temperature for 30 minutes in a humidified chamber. Sections were rinsed three times in PBS for two minutes per wash before addition of the DAB substrate for 2-3 minutes. Optimal staining time was established by monitoring the brown colour development under the microscope. Counterstaining with hematoxylin and coverslip mounting were performed as described in section 2.2.9.1.

2.2.10 Tumour burden quantification and Immunohistochemistry scoring

Lung tissue sections were scanned using the Aperio Digital Pathology Slides Scanner (Leica) and tumour burden (n≥3 per genotype) was quantified with SlidePath Digital Image Hub. For quantification of Ki67 and TUNEL staining, images of lung tissue sections at 20X magnification were taken of at least 5 fields of view (n=3 per genotype) and
scoring was performed by counting the percentage of positively stained nuclei within tumours using ImageJ software.

Quantification of BrdU and CD31 staining was performed using SlidePath Digital Image Hub.

### 2.2.11 Laser-Capture Microdissection and RNA-SEQ analysis

Formalin-fixed paraffin-embedded (FFPE) sections of 10 μm thickness were mounted on framed membrane slides (Leica). To identify phospho-ERK positive regions, adjacent sections were mounted on standard glass slides and stained for phospho-ERK. Tissue mounted on membrane slides was stained with ice-cold 1% cresyl violet after de-paraffinization and rehydration. Selected phospho-Er^Low^ and phospho-Er^High^ tumour regions were micro-dissected using a Leica DM 6000B microscope and harvested into separate tubes before combining tissue obtained from multiple sections for each of 4 mice. RNA was then isolated using the RNEasy FFPE kit (Qiagen) according to manufacturer’s instructions and depletion of ribosomal RNA was achieved using Ribo-Zero (Epicentre). Synthesis of cDNA was performed using the SMARTER Stranded random primed RNA-SEQ kit (Takara/Clontech), resulting in cDNA libraries flanked by Illumina indexing primers. Libraries were standardized to 10 nM after quantification (Quant-IT Pico green kit, Invitrogen), denatured and diluted to 10 pM for subsequent analysis by paired-end sequencing using an Illumina GA11X deep sequencer. Statistical analysis was performed by a combination of HTSeq and the R 3.0.2 environment, utilizing packages from the Bioconductor data analysis suite and differential gene expression analysis based on the negative binomial distribution using the EdgeR package (Robinson et al., 2010). Pathway modulation analysis was performed using Metacore GeneGO (Thompson Reuters). For analysis of individual gene expression, data were normalized internally to B2M for each mouse, and fold change and false discovery rates were recalculated.
2.2.12 Statistical analysis

Statistical analysis was carried out by GraphPad 6.0 software. Comparison of two data sets was performed with unpaired or paired t-tests, as indicated per figure legend. To compare more than two data sets, ANOVA with a post-hoc Tukey’s multiple comparison test was used. Log-rank Mantel-Cox test was used for statistical analysis of survival data. Statistical significance is indicated in each figure legend, with p<0.05 considered as significant.
Chapter 3 - Investigating the role of NUAK1 in cell survival under metabolic stress

In this chapter, we elucidate the contribution of NUAK1 to AMPK activation. In addition, we examine the activity of NUAK1 in the absence of the upstream kinase LKB1 and investigate an alternative pathway in NUAK1 activation that involves PKCα. Finally, we give more insights on the mechanism contributing to the synthetic lethal interaction between NUAK1 and MYC and further explore how NUAK1 sustains cell viability in MYC-overexpressing cells. Some of the results of the presented work have been published in (Monteverde et al., 2017).

3.1 Introduction

NUAK1, also known as ARK5, is a serine/threonine kinase belonging to the AMPK family (Suzuki et al., 2003a). LKB1, in complex with STRAD-MO25, is the major upstream kinase of the family, responsible for the activation of NUAK1 through phosphorylation of the Thr211 in the active T loop (Lizcano et al., 2004b). NUAK1 has been involved in a variety of biological processes: from cell adhesion (Zagorska et al., 2010) to proliferation (Hou et al., 2011) and axon branching (Courchet et al., 2013). Interestingly, Liu et al. identified NUAK1 as being required for survival of tumour cells that overexpress MYC. Particularly, the study revealed that depletion of NUAK1 led to an increase in mTORC1 activity and a collapse in ATP levels, resulting in apoptotic cell death (Liu et al., 2012).

Rapidly growing cells, like cancer cells, require an enhanced production of building blocks, such as amino acids and nucleotides, to sustain cell growth and proliferation. As these processes are energy-demanding, the maintenance of the energetic balance is essential for the survival of cells under metabolic stress. AMP-activated protein kinase is a key regulator of energy homeostasis and its activation to re-establish the energetic balance is crucial for cell survival (Hardie et al., 2012; Shaw et al., 2004b). In fact, it has been shown that cells that overexpress the oncogene c-MYC undergo metabolic stress that triggers the
activation of AMPK. Importantly, NUAK1 was shown to be required for activation of AMPK as downregulation of NUAK1 resulted in an impaired AMPK response to MYC-induced metabolic stress (Liu et al., 2012).

MYC is found to be amplified or, less frequently, mutated in multiple cancers and its role in tumour initiation as well as in tumour maintenance has been well documented (Beroukhim et al., 2010; Nesbit et al., 1999) but the lack of enzymatic activity has limited the application of pharmacological inhibitors as a therapeutic approach. Therefore, the synthetic lethal interaction between NUAK1 and MYC is an attractive strategy for cancer therapy. However, a better understanding of the biological roles of NUAK1 might shed more light on its potential to be used as therapeutic target.

LKB1, the master upstream regulator of NUAK1, is recognised as a critical tumour-suppressor gene responsible for the Peutz-Jeghers syndrome, a hereditary disorder characterized by gastrointestinal hamartomatous polyps and a higher risk of cancer. In addition, LKB1 is frequently mutated in lung cancer and occasionally mutated in other sporadic cancers (Monteverde et al., 2015). Loss of Lkb1 has been shown to accelerate KRas-driven lung cancer as well as enhance the metastatic process (Ji et al., 2007). Although other kinases have been suggested to contribute to NUAK1 activation, such as AKT (Suzuki et al., 2003a), an alternative kinase that could regulate NUAK1 in the absence of LKB1 has not been identified.

Protein Kinase C (PKC) is a family of serine/threonine kinase that consists of numerous isoforms divided in three major groups: conventional PKC (cPKC: PKCα, PKCβI, PKCβII and PKCγ), novel PKC (nPKC: PKCε, PKCδ, PKCη PKCθ) and atypical PKC (aPKC: PKCζ and PKCτ). cPKC isoforms are activated by Ca2+ and phorbol esters or diacylglycerol (DAG), whereas nPKCs require DAG but not Ca2+ for activation and aPKC do not respond to either Ca2+ nor DAG. Remarkably, the PKC family regulates a diverse set of cellular processes including cell proliferation, survival and migration. However, although multiple isoforms share some common functions and substrates, the physiological role of each of them can completely differ depending on the specific cell type. Thus, two isoforms can exert opposite roles in the same setting and the same isoform can behave differently in two distinct cell types (Garg et al., 2014b). For example,
proliferative and anti-proliferative roles have been attributed to PKCα. In particular, PKCα was described to promote cell cycle arrest at the G1 phase in intestinal epithelial cells by induction of the cyclin-dependent kinase inhibitors p21<sup>Cip1</sup> and p27<sup>Kip1</sup> (Frey et al., 1997) and to mediate downregulation of cyclin D1 (Guan et al., 2007). Similarly, activation of PKCα was shown to induce cell cycle arrest through p21<sup>Cip1</sup> in pancreatic cancer cells (Detjen et al., 2000). Conversely, PKCα downregulation was reported to reduce proliferation of human hepatocellular carcinoma cells (Wu et al., 2008) and its overexpression resulted in increased proliferation of glioma and breast cancer cells (Mandil et al., 2001; Ways et al., 1995).

Multiple studies have established a positive role of PKCα in the regulation of cell invasion and metastasis. Specifically, PKCα downregulation was described to impair the migration of several cancer cell lines (Byers et al., 2010; Haughian and Bradford, 2009; Wu et al., 2008) and its activation was shown to promote motility and invasion of breast cancer cells through downregulation of E-cadherin and upregulation of matrix metalloproteinase protein 1 and 9 (MMP-1/9) (Kim et al., 2012a). In addition, through the phosphorylation of the myristoylated alanine-rich C-kinase substrate (MARCKS), which is an actin- and membrane-binding protein, PKCα can further exert a control role on cell motility and morphogenesis (Disatnik et al., 2002; Ott et al., 2013).

A link between PKC and cancer was already identified three decades ago, when cells transformed with KRas or HRas were shown to have higher levels of DAG as well as increased activity of PKC (Wolfman and Macara, 1987). Moreover, cells with increased levels of PKC were found to be more inclined to transformation with KRas (Hsiao et al., 1989). However, the specific contribution to the tumorigenic aspect of each PKC isozymes has been difficult to delineate due to the context-dependent and diversity of their functions. Indeed, until now researchers have been debating on their actual value as therapeutic targets in cancer. In addition, the lack of a clear description of PKCs substrates and the difficulties encountered in the identification of isoform-specific targets has challenged a comprehensive understanding of the biology of PKCs and, consequently, of their role in cancer.
3.2 Results

3.2.1 NUAK1 does not regulate AMPK subunits nor basal activity

To elucidate the molecular mechanism of the role played by NUAK1 in the activation of AMPK (Liu et al., 2012), we first analysed the effect of NUAK1 inhibition and downregulation on the catalytic (α1/α2) and the regulatory subunits (β1/β2, γ1, γ2, γ3) of the AMPK complex. As shown in figure 3.1A, acute treatment up to 4 hours with the selective inhibitor of NUAK1, HTH-01-015, identified by Gray and colleagues (Banerjee et al., 2014a), did not affect the protein levels of the regulatory and catalytic subunits of AMPK. Note that no signal was detected for the γ2, γ3 subunits as probably they are not expressed in U2OS cells (data not shown). NUAK1 downregulation by two independent siRNAs resulted in a modest increase of AMPKβ2 protein levels but only one siRNA caused a slight increase of AMPKα1/α2 and AMPKγ1 protein levels (Fig. 3.1B). Therefore, the overall analysis suggested that NUAK1 does not influence the protein levels of the AMPK subunits.

Figure 3.1 - NUAK1 is not required for the maintenance of AMPK subunits.
A, U2OS cells were treated for the indicated time points with HTH-01-015 (10 μM) and lysates immunoblotted with the indicated antibodies. B, U2OS cells were transfected with 10 nM of two siRNAs targeting NUAK1 or control siRNA (nt). After 48 hours, cells were harvested in lysis buffer and lysates immunoblotted with the indicated antibodies. All images are representative of at least 3 independent experiments.
Alternatively, we asked if acute NUAK1 inhibition could have a more prominent effect on the activation of AMPK rather than the subunit protein levels. As shown in figure 3.2, treatment of U2OS cells with HTH-01-015 for 1 hour was sufficient to efficiently reduce levels of MYPT1 phosphorylation at Ser445, a known and validated NUAK1 substrate (Zagorska et al., 2010), in a dose-dependent manner. In contrast, the basal levels of AMPK activation were not affected upon inhibition of NUAK1, as revealed by the unchanged phosphorylation of Acetyl-CoA Carboxylase (ACC), a well characterized substrate of AMPK (Ha et al., 1994).

![Image](image_url)

**Figure 3.2 - NUAK1 is not required for the maintenance of AMPK basal activity.**
U2OS cells were treated with the indicated concentrations of HTH-01-015 for 1 hour and whole cell extracts were immunoblotted with the indicated antibodies. The antibody against ACC may cross react with ACC2. Images are representative of at least 3 independent experiments.

### 3.2.2 NUAK1 is specifically required for Ca²⁺-mediated activation of AMPK

After excluding a role of NUAK1 on influencing the basal activity of AMPK, we were interested to investigate if NUAK1 regulation of AMPK activation was context-specific rather than a general phenomenon. Therefore, we analysed the AMPK response to multiple activators that mimic the different activation pathways in the presence of NUAK1 inhibition. Particularly, we employed phenformin, an inhibitor of the mitochondrial complex I that activates AMPK through the generation of an energetic imbalance; A769662, a synthetic compound that can directly interact with the AMPK complex causing its allosteric activation; finally, we used the calcium ionophore A23187 to increase the
intracellular levels of Ca\(^{2+}\) and study the aspect of Ca\(^{2+}\)-mediated activation of AMPK. As expected, the different activators could induce the activation of AMPK, as shown by the increased phosphorylation of ACC. Interestingly, NUAK1 inhibition did not affect the response to A769662 whereas the efficiency of ACC phosphorylation in response to A23187 and phenformin was impaired (Fig. 3.3).

![Figure 3.3 - AMPK response to increase in intracellular Ca\(^{2+}\) is impaired by NUAK1 inhibition.](image)

U2OS cells were pre-treated with HTH-01-015 (10 \(\mu\)M) for 1 hour and then stimulated with phenformin (10 mM), A769662 (100 \(\mu\)M) for 1 hour and with A23187 (3 \(\mu\)M) for 10 min. Whole cell protein extracts were immunoblotted for the detection of phospho-ACC\(^{579}\) and total ACC. Densitometric analysis shown in the bar graph. All images are representative of at least 3 independent experiments.

LKB1 is known to be the major upstream kinase for NUAK1 (Lizcano et al., 2004b). However, the contribution of NUAK1 to Ca\(^{2+}\)-dependent activation of AMPK suggested an LKB1-independent regulation of the kinase. Therefore, we repeated the analysis of NUAK1 contribution to AMPK activation in HeLa cells, which do not express LKB1 (Fig. 3.4A). As already documented by others (Fogarty et al., 2010), stimulation of HeLa cells with phenformin did not induce a significant phosphorylation of ACC, and only a moderate increase was observed following A769662 treatment. Nevertheless, in both instances the levels of ACC phosphorylation were not affected by NUAK1 inhibition. In contrast, A23187 was more effective in inducing ACC phosphorylation, which was reduced by NUAK1 inhibition (Fig. 3.4B). Overall, the analysis carried out in U2OS and HeLa cells,
Chapter 3

strongly pointed towards a role of NUAK1 in Ca\(^{2+}\) signalling and independent of LKB1.

Figure 3.4 - NUAK1 is still required for AMPK response to increase in intracellular Ca\(^{2+}\) in the absence of LKB1.
A, Western blot showing LKB1 protein expression in U2OS and HeLa cells. Images are from the same gel & immunoblot, but rearranged to omit extraneous data. B, HeLa cells were pre-treated with HTH-01-015 (10 \(\mu\)M) for 1 hour and then stimulated with phenformin (10 mM), A769662 (100 \(\mu\)M) for 1 hour and with A23187 (3 \(\mu\)M) for 10 min. Whole cell protein extracts were immunoblotted for the detection of phospho-ACC\(^{579}\) and total ACC. Densitometric analysis shown in the bar graph. All images are representative of at least 3 independent experiments.

3.2.3 NUAK1 is activated by Ca\(^{2+}\) signalling by an LKB1-independent pathway

To further elucidate the activity of NUAK1 in the absence of LKB1, we assessed the phosphorylation levels of its substrate, MYPT1, following NUAK1 inhibition. As shown in figure 3.5A, treatment of HeLa cells with HTH-01-015 resulted in a dose-dependent decrease of MYPT1 phosphorylation at Ser445. In addition, MYPT1 phosphorylation was also affected by NUAK1 downregulation in the same cells by two independent siRNAs, confirming that NUAK1 is indeed active in LKB1-null cells (Fig.3.5B).
Figure 3.5 - NUAK1 is active and can be modulated in LKB1-null cells.

A, HeLa cells were treated with the indicated concentrations of HTH-01-015 for 1 hour and whole cell protein extracts were immunoblotted for phospho-MYPT1\textsuperscript{5445} and total MYPT1. Densitometric analysis shown in the bar graph. B, HeLa cells were transfected with 10 nM of two siRNAs targeting NUAK1 or control siRNA (nt). After 48 hours, cells were harvested in lysis buffer and lysates immunoblotted with the indicated antibodies. Densitometric analysis shown in the bar graph. All images are representative of at least 3 independent experiments.

3.2.4 CaMKKβ does not mediate Ca\textsuperscript{2+}-induced activation of NUAK1

Having established the activity of NUAK1 in the absence of the upstream kinase LKB1, we asked which alternative pathway could be engaged to regulate the kinase activity.

It is known that AMPK can be activated by CaMKKβ in response to increase in intracellular Ca\textsuperscript{2+} levels (Woods et al., 2005). Given the observed role of NUAK1-mediated activation of AMPK during Ca\textsuperscript{2+} signalling, we asked if CaMKKβ could be an alternative upstream kinase for NUAK1 as it is for AMPK. To test the hypothesis, we treated HeLa cells with the CaMKKβ inhibitor Sto-609. Inhibition of CaMKKβ efficiently reduced the phosphorylation of AMPK and its target ACC, but no effect was observed on the basal levels of MYPT1\textsuperscript{5445} phosphorylation (Fig 3.6). Moreover, stimulation of cells with the Ca\textsuperscript{2+} ionophore A23187 induced a striking increase in phospho-MYPT1\textsuperscript{5445} that was not affected by Sto-609 treatment.
CaMKKβ is not an upstream kinase for NUAK1.

HeLa cells were pre-treated with Sto-609 (5 μg/mL) for 1 hour and then stimulated with A23187 (3 μM) for 10 min. Whole cell protein extracts were immunoblotted with the indicated antibodies. Image representative of at least 3 independent experiments.

In agreement with the observed Ca²⁺-mediated activation of NUAK1, treatment of HeLa cells with two different Ca²⁺ ionophores, ionomycin and A23187, induced an increase in MYPT1<sup>S445</sup> phosphorylation that was attenuated by NUAK1 inhibition with HTH-01-015 (Fig. 3.7A). Conversely, chelation of the intracellular Ca²⁺ by treatment with BAPTA-AM resulted in the decrease of phospho-MYPT1<sup>S445</sup> (Fig. 3.7B). Taken together, these results revealed that Ca²⁺ signalling could modulate NUAK1 activation, but not through CaMKKβ.
3.2.5 Both NUAK1 and NUAK2 phosphorylate MYPT1\textsuperscript{S445} in response to increased intracellular Ca\textsuperscript{2+}

The observation that NUAK1 inhibition could not completely abrogate MYPT1\textsuperscript{S445} phosphorylation in response to increase in intracellular Ca\textsuperscript{2+} levels suggested that other kinases might be involved in the same pathway. Particularly, NUAK2 has been previously shown to phosphorylate MYPT1 at Ser445 (Zagorska et al., 2010). Therefore, we asked if the remaining phosphorylation of MYPT1 after NUAK1 inhibition could be attributed to NUAK2 activation. As shown in figure 3.8A, downregulation of NUAK2 by siRNA resulted in a partial decrease of phospho-MYPT1\textsuperscript{S445}. However, the combination of NUAK2 downregulation with inhibition of NUAK1 by HTH-01-015 resulted in a striking decrease of phospho-MYPT1\textsuperscript{S445}, confirming that the two kinases share the same target. In addition, the phosphorylation of MYPT1\textsuperscript{S445} in response to A23187 could be more efficiently prevented when both NUAK1 and NUAK2 were inhibited and downregulated, respectively (Fig. 3.8A). Similarly, the simultaneous inhibition of NUAK1 and
NUAK2 using WZ4003, an inhibitor previously shown to have high selectivity for both kinases (Banerjee et al., 2014a), led to the abrogation of phosphorylation of MYPT1$_{S445}$ in response to increased Ca$^{2+}$ signalling compared to the partial effect obtained with NUAK1 inhibition alone using HTH-01-015 (Fig. 3.8B). Therefore, NUAK1 and NUAK2 are both induced by Ca$^{2+}$ and mediate the increase in phospho-MYPT1$_{S445}$ in response to stimulation with A23187.

Figure 3. 8 - Simultaneous depletion of NUAK1 and NUAK2 abrogates modulation of phospho-MYPT1$_{S445}$ in response to calcium.
A, HeLa cells were transfected with siRNA targeting NUAK2 (20 nM) and pre-treated with HTH-01-015 (10 μM) for 1 hour and then stimulated with A23187 (3 μM) for 10 min. N=3. Densitometric analysis shown in the bar graph. B, HeLa cells were pre-treated with HTH-01-015 (10 μM) or WZ4003 for 1 hour and then stimulated with A23187 (3 μM) for 10 min. Whole cell protein extracts were immunoblotted for phospho-MYPT1$_{S445}$ and total MYPT1. N=2.
3.2.6 MYC modulates activation of PKC

Calcium ions are extremely important second messengers in eukaryotic cells and they can activate a number of kinases that mediate the signal transduction to modulate various cellular processes that range from gene transcription to muscle contraction (Clapham, 2007). Multiple studies have suggested an interconnection between MYC and Calcium signalling. It has been reported that MYC expression can induce an increase in intracellular Ca\(^{2+}\) in B cells (Habib et al., 2007) but also that Ca\(^{2+}\) can drive MYC gene expression in various settings (Quesada et al., 2002) (Todorova et al., 2009). Considering the link between Ca\(^{2+}\) and MYC and also the previously described synthetic lethal interaction between NUAK1 and MYC, we wondered if MYC could regulate the expression of a kinase, which is part of the Ca\(^{2+}\) signalling pathways, that could also be involved in NUAK1 activation. To test that, we compared the transcriptome of wild type and MYC-overexpressing Mouse Embryonic Fibroblasts (MEFs). Interestingly, the transcriptome analysis (data not shown) revealed that components of the Ca\(^{2+}\) signalling pathway, such as Pkcc\(_{\alpha}\), Itpr\(_1\) and CaMKK\(_{\beta}\), were upregulated and the same results were confirmed by qPCR analysis (Fig. 3.9A). Enhancement of Ca\(^{2+}\) signalling in MYC-overexpressing cells was further reflected by the increased phosphorylation levels of ACC, downstream of AMPK, upon A23187 stimulation (Fig. 3.9B). In addition, MYC overexpression resulted in a Ca\(^{2+}\)-dependent increase in PKC activity, as shown by the higher phosphorylation levels of its downstream target MARCKS (Aderem, 1992), which were sensitive to Ca\(^{2+}\) chelation and PKC inhibition with BAPTA and Gö6976, respectively (Fig. 3.9C). Moreover, MARCKS phosphorylation levels were diminished upon downregulation of MYC by three independent siRNAs in HeLa cells, indicating that MYC-dependent activation of PKC is conserved across species (Fig. 3.9D).
Figure 3. 9 - Overexpression of MYC induces upregulation of components of the Ca\(^{2+}\) signalling pathway.

**A**, R26- Isl-MYC or wild type MEFs were infected with 300 MOI of Adenovirus-Cre and 24 hours later analysed for mRNA expression levels of Pkc\(\alpha\), Itpr1 and CaMKK\(\beta\). Bar graph representing the Mean and SD from biological triplicates. * p<0.05 and *** p<0.001 determined by two-tailed unpaired T-tests. **B**, Adenovirus-Cre infected R26\(^{sls}\)-MYC or wild type MEFs were stimulated with A23187 (6 \(\mu\)M) for 10 min and whole cell protein extracts were immunoblotted with the indicated antibodies. **C**, Adenovirus-Cre infected R26\(^{sls}\)-MYC or wild type MEFs were treated with BAPTA (10 \(\mu\)M) or Gö6976 (1 \(\mu\)M) for 3 hours prior to lysis. Whole cell protein extracts were immunoblotted with the indicated antibodies. **D**, HeLa cells were transfected with three independent siRNAs (20 nM) targeting MYC and whole cell protein extracts immunoblotted with the indicated antibodies. All images are representative of at least 3 independent experiments, except (D) where n=2.

### 3.2.7 PKC\(\alpha\) mediates NUAK1 activation by Ca\(^{2+}\) signalling

The conventional class of PKC (cPKC) is a subgroup of the PKC family known for being activated by Ca\(^{2+}\) and includes four isozymes: PKC\(\alpha\), PKC\(\beta_i\), PKC\(\beta_{ii}\) and PKC\(\gamma\). Therefore, cPKC represented a good candidate for the upstream calcium-mediated regulation of NUAK1. To test if that was the case, HeLa cells were treated acutely with Gö6976, a potent PKC\(\alpha\) and PKC\(\beta_i\) inhibitor, which induced a dose-dependent decrease of phospho-MYPT1\(^{5445}\) (Fig. 3.10A). Phospho-(Ser) PKC substrate antibody was used as readout of PKC activity in response of Gö6976.
treatment. Notably, whereas HTH-01-015 could sustain MYPT1\textsuperscript{S445} inhibition over a treatment period of 16 hours, phosphorylation levels of MYPT1\textsuperscript{S445} and Phospho-(Ser) PKC substrates recovered after treatment with Gö6976 for the same time frame, suggesting a transient effect of the PKC inhibitor (Fig. 3.10B).

Additionally, acute inhibition of PKC resulted in an attenuation of Ca\textsuperscript{2+}-induced MYPT1\textsuperscript{S445} phosphorylation (Fig.3.10C), indicating its contribution to the pathway that leads to MYPT1 phosphorylation.

![Figure 3.10](image)

Figure 3.10 - Inhibition of PKC impairs MYPT1\textsuperscript{S445} phosphorylation.

A, HeLa cells were treated with the indicated concentrations of Gö6976 for 1 hour and whole cell protein extracts were immunoblotted with the indicated antibodies. B, HeLa cells were treated with HTH-01-015 (10 \(\mu\)M) or Gö6976 (0.5 \(\mu\)M) for 1 hour and 16 hours and whole cell protein extracts were immunoblotted with the indicated antibodies. C, HeLa cells were pre-treated with Gö6976 (0.5 \(\mu\)M) for 1 hour and then stimulated with A23187 (3 \(\mu\)M) for 10 min. Lysates were immunoblotted for phospho-MYPT1\textsuperscript{S445} and total MYPT1. All images are representative of at least 3 independent experiments.

Given that Gö6976 can inhibit two of the four conventional PKC isoforms, PKC\(\alpha\) and PKC\(\beta\)\(_I\), we sought to determine whether one or both isoforms were mediating the observed effect of Ca\textsuperscript{2+}-induced phosphorylation of MYPT1\textsuperscript{S445}. 
Downregulation of PKCα by two different siRNAs (Fig. 3.11A) resulted in a decrease of MYPT1\(^{S455}\) phosphorylation, which was not further reduced by simultaneous depletion of PKCβ\(_i\) (Fig. 3.11B). Note that downregulation of PKCβ\(_i\) could not be confirmed, as no protein or mRNA expression could be detected in HeLa cells, probably indicating that this isoform is not expressed in this cell line (data not shown).

**Figure 3. 11 - PKCα and not PKCβ\(_i\) regulates downstream phosphorylation of MYPT1\(^{S445}\).**

HeLa cells were transfected with 20 nM of two siRNAs targeting PKCα and control siRNA (nt) (A) or with a combination of siRNAs targeting PKCα (20 nM) and PKCβ (20nM) (B). After 48 hours, cells were harvested in lysis buffer and lysates immunoblotted for phospho-MYPT1\(^{S445}\), total MYPT1 and PKCα. Densitometric analysis shown in the bar graph (A). All images are representative of at least 3 independent experiments.

Phosphorylation of MYTP1\(^{S455}\) has proved to be mediated by both NUAK1 and NUAK2, therefore, we sought to obtain a more direct indication of the effect of PKC inhibition on NUAK1 phosphorylation at Thr211 in the activation loop. Thus, to study phospho-NUAK1\(^{T211}\) we made use of an antibody against phospho-AMPK\(^{T172}\) that was previously shown to detect phosphorylation at Thr211 of overexpressed NUAK1 (Fisher et al., 2005). A23187 treatment induced an increase in the phosphorylation of the immunoprecipitated FLAG-tagged NUAK1 that was prevented by treatment with Gö6976, whereas no signal was detected for the T211A mutant, confirming the specificity of the antibody (Fig. 3.12A). The same results could be reproduced with a newly developed polyclonal
antibody raised against Thr211 of human NUAK1 (Fig. 3.12B). Overall, we obtained strong evidence for PKCa regulation of NUAK1 activity and its ability to phosphorylate the downstream target MYPT1 in response to Ca\textsuperscript{2+} signalling.

**Figure 3.12 - Phosphorylation of NUAK1 is decreased by PKC inhibition.**

A-B, HeLa cells were transfected with expression plasmids encoding either wild type or mutant (T211A) FLAG-NUAK1. Forty-eight hours post-transfection, FLAG-NUAK1 wild type cells were pre-treated with Gö6976 (0.5 \( \mu \)M) for 1 hour and then stimulated with A23187 (3 \( \mu \)M) for 10 min. Cells were then lysed and FLAG-tagged proteins were immunoprecipitated and immunoblotted with the indicated antibodies. Detection of phospho-NUAK1\textsuperscript{T211} was performed by cross-reaction of the phospho-AMPK\textsuperscript{T172} antibody (n=3) (A) or by a newly developed antibody raised against phospho-NUAK1\textsuperscript{T211} (n=2) (B). Cells transfected with Empty Vector were used as negative control.

### 3.2.8 PKCa regulates NUAK1 protein levels

Upon depletion of PKCa by two independent siRNAs we observed a marked reduction of NUAK1 protein levels, suggesting that PKCa regulates NUAK1 protein stability. Indeed, as shown in Figure 3.13A-B, the decrease in NUAK1 protein levels upon PKCa downregulation was rescued by proteasome inhibition using MG132. In addition, NUAK1 mRNA expression levels were not significantly
affected by PKCα depletion, confirming a regulation at protein levels as opposed to a transcriptional modulation (Fig. 3.13C).

**Figure 3. 13 - PKCα depletion induces NUAK1 degradation.**

A, HeLa cells were transfected with 20 nM of two siRNAs targeting PKCα or control siRNA (nt) and treated with MG132 (20 μM) for 5 hours prior to lysis. Whole cell protein extracts were then immunoblotted with the indicated antibodies. N=2. B, Bar graph indicating the Mean and SD fold decrease in NUAK1 protein expression in HeLa cells depleted for PKCα and treated with MG132 (20 μM) or DMSO control. N=3. ns= not significant. P value calculated with one-way ANOVA, Tukey’s multiple comparison. C, Hela cells were transfected with two independent siRNAs targeting PKCα (20 nM) or control siRNA (nt) and NUAK1 mRNA levels analysed by qPCR. Bar graph indicating the Mean and SD fold change of NUAK1 mRNA expression relative to control (nt). ns= not significant. P value calculated with one-way ANOVA, Tukey’s multiple comparison.
3.2.9 NUAK1 and NUAK2 reside in two distinct pathways for the regulation of MYPT1\textsuperscript{S445} phosphorylation in response to Ca\textsuperscript{2+} signalling

Notably, PKC\textsubscript{\alpha} downregulation only induced a partial reduction of MYPT1\textsuperscript{S445} phosphorylation (Fig. 3.11A) and treatment with the PKC inhibitor Gö6976 did not completely abrogate phospho-MYPT1\textsuperscript{S445} levels in response to A23187 stimulation (Fig. 3.10C). In light of our data showing a contribution of NUAK2 to Ca\textsuperscript{2+}-induced phosphorylation of MYPT1\textsuperscript{S445} (Fig. 3.8A-B), we asked if the incomplete inhibition of phospho-MYPT1\textsuperscript{S445} upon PKC\textsubscript{\alpha} depletion and inhibition could be attributed to NUAK2. Co-depletion of NUAK1 and PKC\textsubscript{\alpha} in HeLa cells minimally affected phospho-MYPT1\textsuperscript{S445} levels in comparison to NUAK1 depletion alone, consistent with the two kinases residing in the same pathway. Conversely, phospho-MYPT1\textsuperscript{S445} levels were further reduced upon co-depletion of NUAK2 and PKC\textsubscript{\alpha} in comparison to their individual downregulation, indicating that NUAK2 and PKC\textsubscript{\alpha} mediate Ca\textsuperscript{2+}-dependent phosphorylation of MYPT1 from two different signal axes (Fig. 3.14).

![Figure 3.14](image)

Figure 3.14 – PKC\textsubscript{\alpha} and NUAK2 co-depletion further decreases phospho-MYPT1\textsuperscript{S445} levels.

HeLa cells were transfected with siRNA targeting PKC\textsubscript{\alpha} (20 nM) and/or NUAK1 (10 nM) or NUAK2 (20 nM). Whole cell protein extracts were then immunoblotted with the indicated antibodies. N=2. The arrow indicates the correct band for NUAK2. Densitometric analysis shown in the bar graph.
3.2.10 The PKCα-NUAK1 pathway supports viability of MYC overexpressing cells

A previous synthetic lethality screening carried out by Liu et al., identified NUAK1 as being required to support survival of MYC-overexpressing cells (Liu et al., 2012). In agreement with that, inhibition of NUAK1 by HTH-01-015 treatment in HeLa cells, which express high levels of MYC (Shen et al., 2017), induced a significant increase in apoptotic cell death compared to control cells. Interestingly, cell death was observed only at 10 μM of HTH-01-015, whereas partial inhibition of NUAK1 with a lower concentration of the inhibitor did not affect cell survival (Fig. 3.15A). Similarly, in the same cells, downregulation of NUAK1 with two different siRNAs resulted in a significant increase in cell death only when NUAK1 expression was more strongly suppressed (Fig. 3.15B).

Figure 3.15 - NUAK1 inhibition and depletion is lethal in HeLa cells. A, HeLa cells were treated with the indicated concentrations of HTH-01-015. Forty-eight hours later, induction of apoptosis was analysed by Annexin V/Propidium iodide FACS (top) and whole cell protein extracts were immunoblotted with the indicated antibodies (bottom). Error bars represent the SD of the mean of three independent experiments. ***p<0.001 calculated with one-way ANOVA, Tukey’s multiple comparison. B, HeLa cells were transfected with 10 nM of two siRNAs targeting NUAK1 or control siRNA. At day 3 post-transfection, induction of apoptosis was analysed by Annexin V/PI staining (top) and whole cell protein extracts were immunoblotted with the indicated antibodies (bottom). Error bars represent the SD of the mean of three independent experiments. ***p<0.001 calculated with one-way ANOVA, Tukey’s multiple comparison.
Thus, our results suggested that NUAK1 expression at low levels was still able to support cell survival, establishing a threshold of NUAK1 expression below which cells are no longer able to sustain viability. Next, we asked if the synthetic lethal interaction of NUAK1 and MYC was indeed responsible for the observed cell death upon NUAK1 inhibition in HeLa cells. MYC reduction by two independent shRNAs (Fig. 3.16B) significantly decreased the levels of cell death caused by NUAK1 inhibition, consistent with a synthetic lethal interaction (Fig. 3.16A).

**Figure 3.16 - Cell death induced by NUAK1 inhibition is rescued by MYC downregulation.**

HeLa cells were transfected with two shRNA-encoding plasmids targeting MYC or a non-targeting control (shRen). After puromycin selection, cells were treated with HTH-01-015 (10 µM) and 48 hours after treatment analysed by Annexin V/PI staining for apoptosis induction (A). Error bars reflect the standard deviation of biological triplicate samples from one experiment and statistical analysis was performed on a total of five independent experiments. **p<0.01, *p<0.05 calculated with one-way ANOVA, Tukey’s multiple comparison. Whole cell protein extracts were immunoblotted with the indicated antibodies (B).
Furthermore, PKCα downregulation by two independent siRNAs also induced a significant increase in cell death in HeLa cells (Fig. 3.17A), and PKC inhibition with Gö6976 more efficiently induced death in cell treated with a low dose of HTH-01-015 (Fig. 3.17B-C), corroborating a role of PKCα upstream of NUAK1.

Figure 3. 17 - PKCα depletion and inhibition is lethal in HeLa cells.
A, HeLa cells were transfected with 20 nM of two siRNAs targeting PKCα or control siRNA (nt). At day 3 post-transfection, induction of apoptosis was analysed by Annexin V/PI staining (top) and whole cell protein extracts were immunoblotted with the indicated antibodies (bottom). Error bars represent the SD of the mean of three independent experiments. ***p<0.001, **p<0.01 calculated with one-way ANOVA, Tukey’s multiple comparison. B, HeLa cells were treated with Gö6976 (1 μM) and HTH-01-015 (5 μM) and, 48 hours post treatment, induction of apoptosis was analysed by Annexin V/PI staining. Error bars represent the SD of the mean of three independent experiments. Ns= not significant, **p<0.01 calculated with one-way ANOVA, Tukey’s multiple comparison. C, Whole cell protein extracts from HeLa cells stimulated as per B, were isolated after 1 hour of treatment and immunoblotted with the indicated antibodies. Densitometric analysis shown in the bar graph.
Chapter 3

3.2.11 The PKCα-NUAK1 pathway regulates activation of mTORC1 via Raptor

Cell that express higher levels of MYC are characterized by increased protein synthesis, which is required to sustain the increase in proliferation (van Riggelen et al., 2010). Therefore, cells in those conditions are high metabolically demanding and the activation of metabolic checkpoints becomes crucial to cope with energetic stress. Restraining mTOR activity is a mechanism that protects cells form metabolic stress and AMPK is well known to control mTORC1 activation for the maintenance of energetic balance. Particularly, it has been shown that AMPK can inhibit Raptor through phosphorylation of Ser792 (Gwinn et al., 2008). Indeed, as shown in figure 3.18, stimulation of HeLa cells with A23187 induced activation of AMPK and phosphorylation of Raptor$^{5792}$, which resulted in a dynamic response of mTORC1. In particular, whereas phospho-Raptor$^{5792}$ levels increased steadily over time, phosphorylation levels of S6K and 4EBP1, mTORC1 substrates, decreased after an initial increase, in agreement with a dual effect of Ca$^{2+}$ in activating mTORC1 (Li et al., 2016; Zhou et al., 2015) as well as inhibiting Raptor through activation of AMPK.

![Figure 3.18 – Dynamic Ca$^{2+}$-dependent modulation of mTORC1.](image)

HeLa cells were treated for the indicated time points with A23187 (3 μM) and whole cell protein extracts immunoblotted with the indicated antibodies.
Surprisingly, downregulation of PKCa and NUAK1 in HeLa cells resulted in an impaired inhibition of Raptor at basal levels as well as in response to A23187 treatment, as observed by the decreased phosphorylation at Ser792 (Fig. 3.19A). Furthermore, NUAK1-mediated regulation of RaptorS792 phosphorylation was similarly observed in U2OS cells, which retain LKB1 function. Particularly, as shown in Figure 3.19B-C, acute inhibition of NUAK1 with HTH-01-015 or downregulation by two independent siRNAs significantly impaired the inhibitory phosphorylation of Raptor in response to multiple AMPK activators, such as phenformin, Salicylate and A23187, suggesting a higher mTORC1 basal activity but also the inability of AMPK to efficiently control Raptor in the absence of NUAK1.
Figure 3.19 - PKCα and NUAK1 depletion impairs Raptor inhibition at basal levels and in response to AMPK stimulation.

A, HeLa cells were transfected with siRNA targeting PKCα (20 nM), NUAK1 (10 nM) or control siRNA. At day 1 post-transfection, cells were stimulated with A23187 6 μM for 10 minutes and whole cell protein extracts were immunoblotted with the indicated antibodies. B, U2OS cells were pre-treated with HTH-01-015 (10 µM) for 1 hour and then stimulated with phenformin (10 mM), Salicylate (10 mM) for 1 hour and with A23187 (3 µM) for 10 min. Whole cell protein extracts were immunoblotted with the indicated antibodies. Images are from the same gel & immunoblot, but rearranged to omit extraneous data. C, U2OS cells were transfected with 10 nM of two independent siRNAs targeting NUAK1 (10 nM) or control siRNA. At day 2 post-transfection, cells were stimulated with phenformin (10 mM), Salicylate (10 mM) for 1 hour and with A23187 and Ionomycin (3 µM) for 10 min. Whole cell protein extracts were immunoblotted with the indicated antibodies. The star in B and C indicates a cross-reacting band.
Consistent with a role of NUAK1 in regulating mTORC1 activity, its downregulation in HeLa and U2OS cells resulted in a significant increase in protein synthesis, as underlined by an increase in $^{35}$S-Methionine incorporation in comparisons to control cells (Fig. 3.20). In addition, depletion of PKC$\alpha$ in HeLa cells also caused a significant increase in protein synthesis, corroborating its involvement in NUAK1 signalling pathway.

Figure 3.20 - NUAK1 downregulation increases protein translation.
HeLa were transfected with siRNA targeting PKC$\alpha$ (20 nM), NUAK1 (10 nM) or a nontargeting control (nt); U2OS cells were transfected with siRNA targeting NUAK1 (10 nM) or control siRNA (nt). At day 2 post-transfection, both cell lines were analysed for $^{35}$S-Methionine incorporation. Bar graph represents Mean and SD from 3 independent experiments. *$p<0.05$ and **$p<0.01$ calculated with one-tailed unpaired T-test. Data generated in collaboration with Dr John Knight from the Beatson Institute.

In agreement with a role of the PKC$\alpha$/NUAK1 axis to support cell viability by restraining mTORC1 activity through inhibition of Raptor, treatment of HeLa cells with the mTORC1 inhibitor Rapamycin could significantly rescue the cell death induced by either NUAK1 or PKC$\alpha$ downregulation (Fig. 3.21).
Figure 3. 21 - mTORC1 inhibition rescues cell death induced by PKCα or NUAK1 depletion.

HeLa cells were transfected with siRNA targeting PKCα (20 nM) and NUAK1 (10 nM) and treated with Rapamycin (100 nM) at day 1 post-transfection. 48 hours after treatment cells were analysed by Annexin V/PI staining for apoptosis induction. Error bars represent the SD of the mean of three independent experiments. ***p<0.001, **p<0.01 calculated with 2-way ANOVA, Sidak’s multiple comparison test.

Among the family members only AMPK has previously been described to inhibit Raptor by phosphorylation at Ser792 (Gwinn et al., 2008). Therefore, we asked if NUAK1 was mediating AMPK phosphorylation of Raptor or if it could regulate Raptor independently of AMPK. Thus, we studied the effect of NUAK1 inhibition on RAPTOR$_{S792}^{\text{phosphorylation}}$ in Mouse Embryonic Fibroblast depleted of both α1 and α2 catalytic subunits of AMPK. As shown in figure 3.22, AMPK depletion moderately reduced phosphorylation of RAPTOR$_{S792}^{\text{phosphorylation}}$. However, inhibition of NUAK1 by HTH-01-015 decreased phospho-RAPTOR$_{S792}^{\text{levels}}$ both in wild type and AMPK depleted cells, suggesting an AMPK-independent regulation of Raptor by NUAK1.
NUAK1 was identified as a member of the AMPK family based on its 47% and 45% sequence homology to AMPK\(\alpha\)1 and \(\alpha\)2, respectively. Since its discovery, few research groups have worked on understanding its biological functions, and NUAK1 role in migration and invasion together with cell proliferation and metabolic homeostasis has suggested an application of its targeting in cancer therapy. However, not many of the suggested targets or upstream kinases of NUAK1 have been further validated and a more comprehensive understanding of its function and regulation is needed to effectively and fully exploit its therapeutic potential.

The discovery of a synthetic lethal interaction between NUAK1 and MYC opened the door to a novel approach of targeting NUAK1 in MYC-driven cancers. Results reported in this chapter have further investigated the mechanism through which NUAK1 contributes to survival of MYC-overexpressing cells, uncovering a novel Calcium-mediated activation of NUAK1 through PKC\(\alpha\).

Cells overexpressing the oncogene MYC were shown to upregulate AMPK activity, possibly as a mechanism of protection from the energetic stress resulting from
MYC induction (Liu et al., 2012). In addition, the same study suggested that AMPK increased activity was dependent on NUAK1, as its depletion was reported to prevent AMPK phosphorylation at Thr172 and also to decrease the protein levels of the regulatory subunit AMPKβ1. However, we have shown that inhibition or downregulation of NUAK1 in U2OS cells did not affect the protein levels of either the regulatory or catalytic subunits of AMPK (Fig. 3.1A-B). Therefore, data obtained in our study exclude the modulation of the AMPK subunits as part of the mechanism of NUAK1-mediated regulation of AMPK.

However, the analysis performed by Liu and colleagues employed a type of U2OS cells in which a modified form of MYC (MYC-ER) is constitutively overexpressed but can only translocate to the nucleus, thus being activated, upon treatment with 4-Hydroxytamoxifen (4-OHT). Therefore, the discrepancy between our results and data from Liu and colleagues might reside in a basal induction of MYC activity in the absence of 4-OHT treatment, due to a leakiness of the system, that could change the dynamic of the effect of NUAK1 depletion on the AMPK complex, a hypothesis that will require further analysis.

Notably, the requirement of NUAK1 for a complete response of AMPK to increased intracellular Ca\(^{2+}\) levels was preserved in LKB1-null cells (HeLa, Fig. 3.4A-B). Moreover, the observations that NUAK1 activity could be efficiently modulated in HeLa cells (Fig. 3.5A-B) and that it was responsive to Ca\(^{2+}\) modulation (Fig. 3.7A-B) strengthen the theory of a novel Ca\(^{2+}\)-dependent and LKB1-independent regulation of NUAK1. In particular, upon treatment with two Ca\(^{2+}\) ionophores, A23187 and Ionomycin, we observed an increase in phospho-MYPT1\(^{545}\) (Fig. 3.7A), which is a downstream target shared by both NUAK1 and NUAK2 (Zagorska et al., 2010). Indeed, our data indicate that both kinases can
be activated by Ca\(^{2+}\) and mediate the increase in phospho-MYPT1\(^{S445}\) (Fig. 3.8A-B).

In our search for an upstream kinase mediating NUAK1 activation by Ca\(^{2+}\) signalling we could firstly exclude the involvement of CaMKK\(\beta\) (Fig. 3.6), which is known to mediate the Ca\(^{2+}\)-dependent phosphorylation of AMPK (Woods et al., 2005). A role of Ca\(^{2+}\) and CaMKK\(\beta\) in the activation of other AMPK-related kinases (ARKs) has been previously investigated and excluded based on the inability of the ARKs to phosphorylate the AMARA peptide in response to A23187 treatment or expression of CaMKK\(\beta\) (Fogarty et al., 2010). Our data partially agree with the experimental evidence provided by Fogarty and colleagues, as we have excluded a role for CaMKK\(\beta\) in mediating the Ca\(^{2+}\)-dependent activation of NUAK1 and NUAK2, assessed by the unchanged phosphorylation of their downstream target MYPT1 upon CaMKK\(\beta\) inhibition (Fig.3.6). However, our observations support an effect of Ca\(^{2+}\) in NUAK1 and NUAK2 activation as an optimal phosphorylation of MYPT1 in response to A23187 was impaired when both kinases were inhibited (Fig. 3.8A-B), which was rejected by Fogarty et al. with regards to NUAK2, whereas NUAK1 was not included in their biochemical analysis. This inconsistency might be attributed to the use of the AMARA peptide, which was initially considered as a common substrate for all the ARKs but that has been since revisited as a preferential substrate for SIK and AMPK.

Interestingly, multiple experimental evidence suggested a reciprocal regulation between Ca\(^{2+}\) and MYC. The calcium ionophore A23187 was shown to induce MYC expression in Human promyelocytic leukemia cells (HL-60) (Salehi and Niedel, 1990). More recently, calcium was shown to affect MYC activity in addition to its expression, as Ca\(^{2+}\)-loaded Calmodulin was described to interact with MYC and enhance its transcription activity (Raffeiner et al., 2017). On the other hand, MYC was shown to amplify calcium signalling through the downregulation of the Ca\(^{2+}\) efflux pump PMCA4b (Habib et al., 2007) and to bind the promoter of components of the Ca\(^{2+}\)-signalling pathway, such as CaMKK\(\beta\), ITPR1 and PKC\(\alpha\) (Walz et al., 2014). In agreement with Walz et al., upon MYC overexpression we observed an increase in mRNA levels of CaMKK\(\beta\), Itprr1 and Pkca (Fig. 3.9A), a higher sensitivity of AMPK to calcium modulation, as shown by the increased levels of ACC phosphorylation upon A23187 treatment (Fig. 3.9B) and, most importantly, an increased Ca\(^{2+}\)-dependent activity of PKC, as revealed by the
increased phosphorylation levels of the downstream target MARCKS (Fig. 3.9C). Taken together these results agree with the previously reported role of MYC in the amplification of Ca\(^{2+}\) signalling and established a new important link between MYC and NUAK1 through PKC\(\alpha\) (Fig. 3.23).

We identified PKC\(\alpha\) as a novel regulator of NUAK1 activity and protein levels. Specifically, downregulation or inhibition of PKC resulted in decreased phosphorylation levels of MYPT1\(^{5445}\) (Fig. 3.10A & 3.11A). In addition, PKC inhibition could prevent phosphorylation of NUAK1 at Thr211 in response to A23187 (Fig. 3.12 A-B) and PKC\(\alpha\) downregulation induced proteasome-dependent degradation of NUAK1 (Fig. 3.13 A-B). Overall, our data strongly indicate that PKC\(\alpha\) is the upstream kinase regulating NUAK1 basal activity and in response to Calcium, while we additionally report that NUAK2, although it is responsive to Ca\(^{2+}\), is not similarly regulated by PKC\(\alpha\) (Fig. 3.14).

Notably, phospho-NUAK1\(^{T211}\) levels were not completely abolished by inhibition of PKC using G\(\ddot{o}\)6976, but nevertheless they did not increase upon combination of G\(\ddot{o}\)6976 and A23187 (Fig. 3.12 A-B). Taken together, this evidence suggests that PKC is the only kinase mediating NUAK1 phosphorylation in response to A23187 but also that NUAK1 maintains a basal level of phosphorylation at the Thr211 site. This residual phosphorylation might be explained by the presence of an additional upstream kinase or by an auto-phosphorylation activity of NUAK1, thus further biochemical investigations are needed to confirm any of the hypothesis. Interestingly, AMPK has been shown to undergo auto-phosphorylation in response to oxidation induced by peroxide (Zmijewski et al., 2010) and unpublished data from our laboratory suggest a similar mechanism of activation of NUAK1 by oxidative stress, opening to the possibility of an auto-phosphorylation reaction for NUAK1.

The Thr211 in the activation loop of NUAK1 (QDKFLQtFCGSPLY) does not conform to the canonical phospho-PKC Substrate Motif (K/RXpSXK/R). However, other sites appear to be a more suitable match for PKC, such as Ser367 (VMLERQRsLKKSKKE) on human NUAK1, which opens to the possibility of PKC\(\alpha\) phosphorylating an alternative site that could influence phosphorylation of Thr211 and support protein stability due to regulatory mechanisms that are not yet understood.
The regulation of NUAK1 activity by an alternative phosphorylation would not be surprising, as AKT has been previously suggested to modulate NUAK1 activity by phosphorylation at Ser600 (Suzuki et al., 2003a). Furthermore, phosphorylation of additional sites to the threonine residue in the T loop for the modulation of the activity of other ARKs has been reported by multiple experimental evidence (Henriksson et al., 2012; Timm et al., 2008). In any case, further investigations will be required to identify phosphorylation sites on NUAK1 upon Ca\textsuperscript{2+} stimulation and understand which of them might be regulated by PKC\textalpha, contemplating also the possibility of a second kinase, downstream of PKC\textalpha, mediating the observed effects.

Inhibition or downregulation of NUAK1 resulted in a significant increase in death of HeLa cells (Fig. 3.15A-B), which express high levels of MYC due to the upstream genomic integration of the Human papilloma virus 18 (HPV-18) (Adey et al., 2013; Shen et al., 2017). Similarly, downregulation of PKC\textalpha caused a significant increase in cell death (Fig. 3.17A), consistent with a role of PKC\textalpha upstream of NUAK1. In agreement with the synthetic lethality interaction between NUAK1 and MYC, downregulation of MYC in HeLa cells decreased the cell death induced by NUAK1 inhibition (Fig. 3.16A-B). The synthetic lethal interaction between MYC and NUAK1 appears to be independent of LKB1 status, as it was firstly identified in U2OS cells that are proficient for LKB1 (Liu et al., 2012) and confirmed in this thesis in HeLa cells, which are LKB1-deficient. Therefore, given the observed requirement of PKC\textalpha for survival of HeLa cells, additional investigations could be carried out to elucidate if PKC\textalpha depletion might be synthetic lethal with MYC overexpression in the presence of LKB1.

Depletion of NUAK1 was described to be lethal in combination with MYC overexpression and the mechanism for the synthetic lethality interaction involved an unrestrained mTORC1 activity, attributed to the impaired activation of AMPK in the absence of NUAK1 (Liu et al., 2012). However, our data indicated that NUAK1 itself can regulate mTORC1 activity, as downregulation of the PKC\textalpha/NUAK1 axis resulted in increased protein synthesis (Fig. 3.20). In addition, our data suggested that NUAK1 regulation of mTORC1 involved the inhibition of Raptor, a positive regulator of the mTORC1 complex, although this mechanism has been previously attributed to AMPK (Gwinn et al., 2008). Specifically,
inhibition or downregulation of NUAK1 resulted in a decreased phosphorylation of Raptor at Ser792, a function that was conserved among cell lines and not dependent on LKB1 status (Fig. 3.19). Importantly, Raptor\textsuperscript{5792} phosphorylation in AMPK\(\alpha1/\alpha2\)-depleted MEFs was still sensitive to NUAK1 inhibition (Fig. 3.22), indicating that NUAK1 exerts a direct and prominent role in the mechanism rather than simply assisting AMPK-mediated regulation of mTORC1.

Activation of metabolic checkpoints that restrain mTORC1, particularly under energy stress conditions, has been shown to be required for cell survival, as failure in mTORC1 inhibition ultimately leads to apoptotic cell death (Gwinn et al., 2008). Thus, taken together, our data indicate an active role of NUAK1 in the inhibition of Raptor to modulate a metabolic checkpoint that favours survival of MYC-overexpressing cells. As the regulation of Raptor by NUAK1 is independent of LKB1 status, it would be interesting to explore the contribution of PKC\(\alpha\) to the regulation of NUAK1 in the presence of LKB1. Previously published data have highlighted how deletion of Lkb1 strikingly reduced the levels of MYPT1\textsuperscript{5445} phosphorylation, indicating a major control exerted by LKB1 (Zagorska et al., 2010). However, the analysis of a single substrate might not be representative of the kinase activity as the specificity towards substrates might differ according to the type of stimulus or conditions. In addition, the physiological relevance of Ca\(^{2+}\)-mediated activation of NUAK1 should be explored in other conditions, as activation of receptors such as the Epidermal growth factor receptor (EGFR) by the binding of growth factors is known to generate an acute increase in intracellular Ca\(^{2+}\) levels that contributes to the downstream signal propagation. Therefore, further biochemical investigations are needed to explore additional physiological roles of the PKC\(\alpha\)/NUAK1 axis and understand its contribution to various cellular process also in the presence of LKB1.
Figure 3.23 – Proposed model for the MYC-PKCα-NUAK1 signalling pathway. MYC amplification of Ca²⁺ signalling results in activation of downstream pathways that include the Ca²⁺-sensitive kinases CaMKKβ and PKCα. The former leads to activation of AMPK, whereas the latter modulates NUAK1 activity. Activation of NUAK1 and AMPK, in part mediated by NUAK1, contributes to restrain mTORC1 activity through the inhibition of Raptor. In addition, Ca²⁺ signalling mediates the phosphorylation of MYPT1 through the induction of the PKCα/NUAK1 axis and NUAK2, for which the upstream kinase has not been identified.
Chapter 4 - Investigation of NUAK1 role in lung tumorigenesis

4.1 Introduction

Lung cancer is currently the leading cause of cancer-related deaths worldwide, with about 46,000 new cases being diagnosed in the United Kingdom every year. It can be classified in two major groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), the latter representing the 80% of all lung cancer cases. Adenocarcinoma is the predominant histological subtype of non-small cell lung cancer and it shows a high rate of somatic mutations and genomic rearrangements, making it a very complex disease. Particularly, mutations in KRAS, found in approximately 30% of patients with lung adenocarcinoma, can drive the tumorigenic process and are associated with poor prognosis and a high risk of cancer recurrence (Meng et al., 2013). Among frequently mutated genes in lung adenocarcinoma, LKB1, also known as STK11, has the third highest mutation rate after TP53 and KRAS (Ding et al., 2008). Specifically, it is altered in about 20-30% of cases of NSCLC, with a tendency towards co-occurrence with KRAS mutations (The Cancer Genome Atlas Research, 2014). In addition, preclinical models have established the important function of LKB1 as tumour suppressor in lung cancer (Ji et al., 2007; Sanchez-Cespedes et al., 2002).

The AMPK family is a key downstream effector of LKB1, which can positively modulate the AMPK-related kinases (ARKs) (Lizcano et al., 2004b). Through the activation of multiple ARKs, LKB1 can regulate a wide range of biological processes: from cell polarity and metabolism to angiogenesis and chromosome segregation (Bonaccorsi et al., 2007; Kottakis et al., 2016; Londoñorough et al., 2008). Despite the tumour suppressor role of LKB1, multiples members of the AMPK family have been associated with a tumour-promoting role. For example, expression of NUAK1 has been linked to poor prognosis in various cancer types, such as ovarian and colorectal cancer and hepatocellular carcinoma (Cui et al., 2013; Kusakai et al., 2004; Phippen et al., 2016). In addition, the role of NUAK1 in cell adhesion and migration has been shown to contribute to tumour invasion and metastasis (Chen et al., 2017). Shi and colleagues have shown a tumour-promoting role of NUAK1 in lung cancer, as it was found to promote migration.
and invasion of NSCLC cells (Shi et al., 2014). Therefore, NUAK1 represents a promising target for cancer therapy.

Although a tumour-promoting role of NUAK1 has been suggested in various cancer settings, with particular emphasis to its contribution to migration and invasion, the role of NUAK1 in the early phases of the lung tumorigenic process has not been elucidated yet. Therefore, in this chapter we investigate the role of NUAK1 in KRas-driven non-small cell lung cancer and try to understand if NUAK1 exerts some of the tumour suppressor function attributed to its upstream kinase LKB1. In addition, given that MYC is dysregulated in lung cancer as result of KRAS hyperactivation (Sears et al., 2000), and also found to be amplified in a fraction of lung adenocarcinomas (Iwakawa et al., 2011), we sought to determine if the synthetic lethal interaction of NUAK1 and MYC could be beneficial from a therapeutic perspective in a mouse model of NSCLC characterized by MYC overexpression.

4.1.1 Mouse models

To study the mechanism of progression of lung adenocarcinoma and investigate the contribution of NUAK1 to the tumorigenic process, we made use of a mouse model in which lung tumorigenesis is driven by KRas mutation. In particular, we used a conditional strain characterized by a G12D point mutation in the exon 1 of the endogenous KRas gene. Expression of mutant KRas is prevented by a lox-stop-lox (lsl) cassette inserted in the first intron of the gene, which generates a loss of function of endogenous KRas (Jackson et al., 2001). Since homozygosity for loss of KRas is embryonically lethal, only heterozygous animals with KRas G12D mutation were obtained for the experiments. KRas<sup>G12D</sup> was then bred to a conditional knockout of Nuak1 (<i>Nuak1<sup>F/F</sup></i>), in which the exon 3 of endogenous Nuak1 is flanked by loxP sites (Inazuka et al., 2012), to generate lsl-KRas<sup>G12D</sup>/<i>Nuak1<sup>F/F</sup></i> mice (Fig. 4.1). KRas<sup>G12D</sup>/Lkb1<sup>F/F</sup> mice, in which the exon 4 of endogenous Lkb1 and a cDNA construct encoding the remainder of the LKB1 sequence, inserted in replacement of exons 5-7, are flanked by loxP sites (Sakamoto et al., 2005), were additionally used for phenotypic comparison of Lkb1 loss with Nuak1 loss.
Adenovirus-Cre, delivered intranasally, mediates the recombination of the loxP sites causing the excision of either the stop cassette preceding mutant KRas or the floxed exon of Nuak1 or Lkb1, resulting in the induction of KRas\(^{G12D}\) and deletion of Nuak1 or Lkb1 specifically in the lungs and in a time-controlled manner.

Figure 4. 1 – Schematic representation of conditional Isl-KRas\(^{G12D}\) and Isl-KRas\(^{G12D};\)Nuak1\(^{F/F}\) mouse model.

4.2 Results

4.2.1 KRas-mutant lung tumours develop as adenocarcinoma even in the absence of Nuak1

Squamous cell carcinoma (SCC) and Adenocarcinoma (ADC) are the two major histological types of non-small cell lung cancer. Previous studies have indicated that KRas\(^{G12D}\) and KRas\(^{G12D}/p53^{F/F}\) mice develop only adenocarcinoma (Jackson et al., 2005; Jackson et al., 2001; Rekhtman et al., 2012) whereas loss of function of the tumour suppressor LKB1, the major upstream kinase of NUAK1, has been observed in both lung adenocarcinoma and squamous cell carcinoma (Ji et al., 2007; Sanchez-Cespedes et al., 2002). In addition, it has been shown that Lkb1 deletion resulted in trans-differentiation of adenocarcinoma into squamous cell
carcinoma in a mouse model of non-small cell lung cancer driven by \( K\text{Ras}^{G12D} \) mutation, giving rise to a more complex phenotype (Li et al., 2015a). Therefore, we asked if Nuak1 deletion could phenotypically resemble Lkb1 deletion and contribute to tumour heterogeneity. \( K\text{Ras}^{G12D} \) only, \( K\text{Ras}^{G12D}/Lkb1^{F/F} \) and \( K\text{Ras}^{G12D}/Nuak1^{F/F} \) mice were induced with the same dose of Adenovirus-Cre and lungs were harvested at 16 weeks post Adeno-Cre infection. As expected, histological examination of lung lesions from \( K\text{Ras}^{G12D}/Lkb1^{F/F} \) revealed a heterogeneity of tumours, some characterized by solid or papillary growth, typical of the adenocarcinoma subtype (Fig. 4.2, panel A), and others characterized by keratin pearls and cell nests forming round nodules, typical of squamous cell carcinoma (Fig. 4.2, panel B). Contrariwise, \( K\text{Ras}^{G12D} \) only and \( K\text{Ras}^{G12D}/Nuak1^{F/F} \) tumours displayed characteristics of the ADC subtype (Fig. 4.2, panel C and D, respectively). The histological subtypes were then confirmed by immunohistochemical staining for SCC and ADC markers: p63 and the surfactant apoprotein-C (SP-C), respectively. Indeed, \( K\text{Ras}^{G12D}/Lkb1^{F/F} \) tumours with SCC features were positive for p63 staining while ADC stained positively for SP-C; all \( K\text{Ras}^{G12D} \) only and \( K\text{Ras}^{G12D}/Nuak1^{F/F} \) tumours were negative for p63 but positive for SP-C (Fig. 4.2). Therefore, Nuak1 deletion did not contribute to the trans-differentiation from ADC to SCC driven by Lkb1 loss, as ADC was the only histological subtype observed in \( K\text{Ras}^{G12D}/Nuak1^{F/F} \) lung tumours.
Figure 4.2 – KRas\textsuperscript{G12D}/Nuak\textsuperscript{1/F/F} mice develop only lung adenocarcinoma. Representative images of Isl-KRas\textsuperscript{G12D};Lkb1\textsuperscript{F/F}, Isl-KRas\textsuperscript{G12D};Nuak\textsuperscript{1/F/F} and Isl-KRas\textsuperscript{G12D} lung tumour sections stained with Hematoxylin & Eosin, SP-C and p63. Scale bars = 200 µm.
4.2.2 Deletion of Nuak1 does not affect the cell of origin of KRas-mutant lung adenocarcinoma

Although multiple studies have tried to identify the cell of origin of lung adenocarcinoma, there is still some controversy on its histogenesis. Alveolar type 2 cells (AT2) and Clara cells are the two cell types that have been debated for being the initiating cells in KRas-mutant lung adenocarcinoma, as tumours stain positively for AT2 and Clara cells markers such as SP-C and CC10, respectively (Jackson et al., 2001; Sutherland et al., 2014). To investigate if Nuak1 deletion could influence the cell of origin of KRas-driven lung adenocarcinoma, tissue sections of KRas\textsuperscript{G12D}/Nuak1\textsuperscript{F/F} and KRas\textsuperscript{G12D} tumours were stained for SP-C and CC10 markers. As already shown in figure 4.2, KRas\textsuperscript{G12D} and KRas\textsuperscript{G12D}/Nuak1\textsuperscript{F/F} adenomas stained positive for SP-C, whereas epithelial hyperplasia of the bronchioles (EH) showed positivity for the CC10 marker (Fig. 4.3A). In addition, as previously revealed by Jackson and colleagues (Jackson et al., 2001), regions of epithelial hyperplasia that were continuous with atypical adenomatous hyperplasia (AAH) in KRas\textsuperscript{G12D}/Nuak1\textsuperscript{F/F} and KRas\textsuperscript{G12D} mice stained positive for both SP-C and CC10 (Fig. 4.3B). Overall, Nuak1 deletion does not appear to influence the histogenesis of KRas\textsuperscript{G12D} tumours.
Figure 4.3 – Nuak1 deletion does not affect the histogenesis of KRas$^{G12D}$ lung adenocarcinoma.

4.2.3 Nuak1 deletion does not affect KRas-driven tumorigenic process

The tumour suppressor LKB1, which is the master upstream kinase of NUAK1, has been previously shown to exert an important tumour suppressor role in lung tumorigenesis, as loss of Lkb1 gave rise to a more aggressive disease in a mouse model of non-small cell lung cancer driven by $KRas^{G12D}$ mutation (Ji et al., 2007). Therefore, we sought to investigate if Nuak1 could also function as tumour suppressor in the same setting. The tumour burden of $KRas^{G12D}/Nuak^{f/f}$ and $KRas^{G12D}$ only mice, infected with the same dose of Adenovirus-Cre, was analysed at 16 weeks post infection. The analysis revealed that Nuak1 deletion did not affect the tumorigenic process driven by $KRas^{G12D}$, as no significant difference in tumour burden was observed in $KRas^{G12D}/Nuak^{f/f}$ mice compared to $KRas^{G12D}$ only (Fig. 4.4).

Figure 4.4 – Nuak1 deletion does not affect $KRas^{G12D}$-driven lung tumorigenesis.
Box plots representing the tumour burden (Mean ± SEM) of $KRas^{G12D}$ (n=4) and lsl-$KRas^{G12D}/Nuak^{f/f}$ (n=4) mice at 16 weeks post Adeno-Cre infection. ns = not significant. P value calculated with two-tailed unpaired T test.
4.2.4 Characterization of Nuak1 deletion in KRas\textsuperscript{G12D}/MYC lung adenocarcinoma

Given the previously described synthetic lethal interaction between MYC and NUAK1 in MYC-overexpressing cells (Liu et al., 2012), we were interested in exploring the effect of Nuak1 deletion in a mouse model driven by KRas G12D mutation with the addition of MYC overexpression. Therefore, KRas\textsuperscript{G12D} mice were bred with a conditional model of MYC overexpression, in which lsl-human MYC is expressed under the control of the Rosa26 (R26) locus. Homozygous animals for the R26-lsl-MYC allele were used in all the experiments.

The lsl-KRas\textsuperscript{G12D}/R26-lsl-MYC NSCLC mouse model (referred to as KM) has been previously characterized by a former colleague, Dr Sarah Neidler, who showed how a moderate overexpression of MYC can drastically accelerate the lung tumorigenic process driven by KRas G12D mutation, as indicated by the significant increase in tumour burden in KM mice compared to KRas\textsuperscript{G12D} only (Fig. 4.5A-B).

![Figure 4.5 - Moderate overexpression of MYC accelerate KRas\textsuperscript{G12D}-driven lung cancer.](image)

A, Mouse Embryonic Fibroblasts of the indicated genotypes were infected with Adenovirus-Cre and whole cell protein extracts immunoblotted for c-MYC and H2B. B, Box plots representing the tumour burden (Mean ± SEM) of lsl-KRas\textsuperscript{G12D} (n=4) and lsl-KRas\textsuperscript{G12D}R26-lsl-MYC (n=4) mice at 6 weeks post Adeno-Cre infection (data generated by Sarah Neidler). **p<0.01 value calculated with two-tailed unpaired T test.
To investigate the role of Nuak1 in lung tumorigenesis in a setting of MYC overexpression, \(K\text{Ras}^{G12D}/\text{MYC}\) and \(K\text{Ras}^{G12D}/\text{MYC}/\text{Nuak}1^{F/F}\) mice (referred to as KMN) were infected with the same dose of Adenovirus-Cre and lungs harvested at 6 weeks post infection.

Histological examination of \(K\text{Ras}^{G12D}/\text{MYC}\) lungs revealed the presence of multiple lesions: from epithelial hyperplasia of the bronchioles (EH) to atypical adenomatous hyperplasia and adenomas (Fig. 4.6, panel A, B, C, respectively). Furthermore, the observed adenomas were characterized by a predominant papillary structure, displaying a fibrovascular core lined by tumour cells with slightly enlarged nuclei and prominent nucleoli. Similarly, lesions observed in \(K\text{Ras}^{G12D}/\text{MYC}/\text{Nuak}1^{F/F}\) mice were also represented by EH, atypical adenomatous hyperplasia and adenomas (Fig. 4.6, panel D, E, F). However, upon Nuak1 deletion adenomas presented an acinar-predominant pattern, in which tumours formed glandular structures and presented cord-like arranged tumour cells (Fig. 4.6, panel F).
Figure 4.6 – Histological examination of KM and KMN tumours.
Representative H&E pictures of epithelial hyperplasia of the bronchioles (EH, A-D), adenomatous hyperplasia (B-E) and adenoma (C-F) of Isl-KRas$^{G_{12D}}$;R26-Isl-MYC;Nuak$^{+/+}$ and Isl-KRas$^{G_{12D}}$;R26-Isl-MYC lung sections at 6 weeks post Adeno-Cre infection. Scale bars = 200 μm.
4.2.5 MYC overexpression is not synthetically lethal with Nuak1 deletion in KRas-driven NSCLC

To further characterize the effect of Nuak1 deletion in KRas\textsuperscript{G12D}/MYC lung tumours, the analysis of the proliferation rate was carried out by examination of the incorporation of Bromodeoxyuridine (BrdU), the synthetic analogue of thymidine, into newly synthetized DNA of cancer cells. KMN tumours did not differ in the levels of BrdU incorporation in comparison to KM tumours, as indicated by the quantification of the immunohistochemistry staining (Fig. 4.7A). In agreement with the comparable levels of proliferation, the tumour burden at 6 weeks post infection was not significantly different in KMN mice compared to KM (Fig. 4.7B).

Figure 4. 7 – Deletion of Nuak1 does not affect growth of KRas/MYC lung tumours. 
A, Bar graphs representing the Mean ± SEM of BrdU positively stained cells from KM (n=3) and KMN (n=3) lung tumours at 6 weeks post Adeno-Cre infection. B, Box plots representing the tumour burden (Mean ± SEM) of KM (n=7) and KMN (n=7) mice at 6 weeks post Adeno-Cre infection. ns = not significant. P value calculated with two-tailed unpaired T test.
4.2.6 Upregulation of the PI3K/AKT pathway in Nuak1 deleted lung tumours

The Raf/MEK/ERK cascade is a major effector downstream of RAS and is a very important contributor to cell survival and proliferation, often dysregulated in cancer. In addition, increased activation of ERK1/2, as indicated by increased phosphorylation levels, has been correlated with more advanced and aggressive tumours in patients with NSCLC (Vicent et al., 2004). Therefore, we sought to assess ERK1/2 activation status in \(KRas^{G12D}/MYC\) lung tumours and we observed a minority of adenomas characterized by areas that were positive for immunohistochemical staining with phospho-ERK (Fig. 4.8A, panel ii). Interestingly, those specific regions also featured a distinctive morphology, indicative of a more aggressive phenotype: a much lower degree of organization and a loss of cell polarity (Fig. 4.8A, panel i). Furthermore, histological examinations of lungs after 4-5 months from Adeno-Cre infection revealed a higher and wider occurrence of phospho-ERK positive regions, suggesting that the distinctive tumour regions identified at 6 weeks are aggressive sub-clones that predominate as tumours progress to a more advanced disease (Fig. 4.8B). In contrast, analysis of phospho-ERK in \(KRas^{G12D}/MYC/Nuak1^{F/F}\) adenomas at 6 weeks post infection showed a significant reduction of the number of phospho-ERK positive tumours (Fig. 4.8C).
Figure 4.8 – Nuak1 deletion decreases signalling through ERK.

A, Representative pictures of KM lung tumours stained for H&E and phospho-ERK at 6 weeks post Adeno-Cre infection, depicting the morphological changes associated with progression (panel i and ii). Scale bars = 50 µm. B, Representative pictures of KM lung tumours stained for phospho-ERK at 6 weeks (panel i and ii) in comparison to 5 months post Adeno-Cre infection (panel iii). Scale bars = 1 mm (i and iii), 200 µm (ii). C, Scatter dot plot representing the number ± SEM of phospho-ERK positive lung tumours per mouse from KM (n=5) and KMN (n=5) mice at 6 weeks post Adeno-Cre infection. * p<0.05 calculated with two-tailed unpaired T test.

A similar phenotype has been previously observed in KRasG12D/Lkb1F/F lung tumours, which showed decreased phospho-ERK levels in comparison to KRasG12D tumours (Chen et al., 2012). In addition, the same study revealed an increased activity of the AKT and SRC pathways, suggesting that Lkb1 deleted tumours rewire their dependency from MEK/ERK to AKT and SRC pathways to sustain their growth. Therefore, given the observed decrease in phospho-ERK levels upon Nuak1 deletion, we were interested in exploring if upregulation of the PI3K/AKT pathway represented an alternative mechanism to sustain tumour growth in KRasG12D/MYC/Nuak1F/F as in KRasG12D/Lkb1F/F mice.
Staining for phospho-AKT<sup>5473</sup> revealed an increased positivity of lung tumours when Nuak1 was deleted compared to wild type controls (Fig. 4.9).

**Figure 4. 9 – Nuak1 deletion results in increased AKT phosphorylation in lung tumours.**
Representative pictures of phospho-AKT (Ser473) staining of KM and KMN lung tumours at 6 weeks post Adeno-Cre infection. Scale bars = 200 µm.

**4.2.7 Deletion of Nuak1 does not sensitize lung tumours to mTORC1 inhibition**

One of the major effectors of the PI3K/AKT signalling cascade is mTORC1, which positively regulates protein synthesis to sustain cell growth. Given the higher AKT phosphorylation observed in Nuak1 deleted lung tumours and considering the regulation of the mTORC1 subunit Raptor by NUAK1, highlighted in our studies (Chapter 3), we decided to investigate the activation of mTORC1 in our tumour model. Thus, we performed immuhistochemical staining for downstream effectors of mTORC1: phospho-4E-BP1 and phospho-S6. As shown in figure 4.10, deletion of Nuak1 resulted in an increase in phospho-4E-BP1 staining compared
to wild type tumours, whereas no significant difference was observed regarding phospho-S6.

**Figure 4.10 – Nuak1 deletion results in increased phosphorylation of 4E-BP1.**
Representative pictures of KM and KMN lung tumour sections at 6 weeks post Adeno-Cre infection stained with H&E, phospho-S6 (Ser235/236) and phospho-4E-BP1 (Thr37/46). Scale bars = 200 μm.

LKB1 has been shown to negatively regulate mTORC1 (Shaw et al., 2004a) and LKB1-deficient NSCLC cells displayed a higher sensitivity to inhibition of the PI3K-mTORC1 signalling pathways (Whang et al., 2016). Thus, in light of the higher mTORC1 activity observed in Nuak1 deleted tumours, we sought to test the effect of mTORC1 inhibition.
KMN and KM mice at 6 weeks post Adeno-Cre infection were treated acutely with the mTORC1 inhibitor Rapamycin. As shown in figure 4.11A, Rapamycin could efficiently inhibit tumour cell proliferation in both KM and KMN lung tumours, as assessed by BrdU incorporation, but no increased sensitivity was observed in correlation to Nuak1 deletion. In addition, apoptotic levels in response to rapamycin treatment were not significantly different between KM and KMN tumours (Fig. 4.11B), suggesting overall that Nuak1 deletion did not confer higher sensitivity to inhibition of mTORC1 activity.

**Figure 4.11 – Nuak1 deletion does not sensitize tumours to mTORC1 inhibition.**
Bar graphs representing the Mean ± SEM of BrdU (A) and TUNEL (B) positively stained lung tumour cells from KM (n=3) and KMN (n=3) mice treated with vehicle or Rapamycin for 3 days at 6 weeks post Adeno-Cre infection. ns= not significant. P value calculated with one-way ANOVA, Tukey’s multiple comparison.
4.2.8 Deletion of Nuak1 confers a survival advantage to \( \text{K Ras}^{G12D}/\text{MYC} \) mice

Although the tumour burden analysed at 6 weeks post infection did not significantly differ between KM and KMN mice, the observation of phospho-ERK positive regions in KM adenomas, which were absent in KMN tumours, suggested that Nuak1 deletion affected the onset of aggressive tumour sub-clones. Interestingly, a negative correlation between high cytoplasmic phospho-ERK levels and survival of patients with NSCLC has been previously described (Vicent et al., 2004). In addition, preliminary data on the immunohistochemical analysis of CD31 staining, marker of endothelial cells, at 6 weeks post infection revealed a significant reduction in the number of blood vessels in KMN tumours in comparison to KM (Fig. 4.12).

![Figure 4.12](image)

**Figure 4.12 – Nuak1 deletion affects tumour blood vessels.**
Bar graphs representing the Mean ± SEM of CD31 positively stained lung tumour blood vessels from KM (n=2) and KMN (n=3) mice at 6 weeks post Adeno-Cre infection. * p<0.05 calculated with two-tailed unpaired T test. Data generated in collaboration with Lisa Neilson and Dr Sara Zanivan from the Beatson Institute.

Thus, we sought to determine if Nuak1 deletion could have an impact on overall survival in our tumour model. Given the asphyxia caused by the large tumour load obtained with the high dose of Adenovirus-Cre used in the previous experiments, which limits an adequate study of long term survival benefits, KM and KMN mice were infected with a lower dose of Adenovirus-Cre and sacrificed at clinical end-point, i.e. when animals showed signs of respiratory distress, deterioration of body conditions and behavioural changes. As shown in figure
4.13, Nuak1 deletion resulted in a significant increase in survival of KM mice, suggesting a long-term benefit of Nuak1 deletion in NSCLC.

![Graph showing survival analysis](image)

**Figure 4.13 – Nuak1 deletion enhances survival of KRas\(^{G12D}\)/MYC lung tumours-bearing mice.**

Kaplan-Meier survival analysis of KM (n=12) and KMN (n=9) mice induced with a low titer of Adenovirus-Cre (3x10^5 pfu). * p<0.05 determined by log-rank (Mantel-Cox) test.

### 4.3 Discussion

The Liver Kinase B1 (LKB1), also known as STK11, has been identified as the third most frequently mutated gene in lung adenocarcinoma. In addition, the tumour suppressor role of LKB1 in lung cancer has been compellingly determined in pre-clinical models of lung cancer. Specifically, deletion of Lkb1 in a mouse model of NSCLC driven by KRas\(^{G12D}\) showed an acceleration of the disease with enhanced metastatic potential (Ji et al., 2007). However, the data described in this chapter suggest that NUAK1, as downstream effector of LKB1, does not reflect the potent tumour suppressor role of its upstream kinase. Our results indicate that Nuak1 deletion in the lungs does not accelerate the tumorigenic process driven by mutant KRas, as simultaneous deletion of Nuak1 and expression of KRas\(^{G12D}\) did not affect the tumour burden in comparison to KRas\(^{G12D}\) only (Fig. 4.4). Also, whereas Lkb1 deletion has been shown to mediate trans-differentiation of lung adenocarcinoma into squamous cell carcinoma (Li et al., 2015a), here we provide evidence that Nuak1 deletion does not recapitulate
a similar phenotype as only the adenocarcinoma subtype was detected in KRas\(^{G12D}/Nuak1^{F/F}\) lungs at 16 weeks post Adeno-Cre infection (Fig. 4.2). Although deletion of Nuak1 did not have an impact on the tumorigenic process driven by mutant KRas in the lungs, other studies have suggested a beneficial effect of NUAK1 inhibition in multiple cancer settings. Particularly, a previous synthetic lethality screening done by Liu and colleagues identified NUAK1 as being required for survival of MYC-overexpressing cells (Liu et al., 2012). Interestingly, the study showed that depletion of NUAK1 impaired the graft of hepatoma cells expressing MYC and resulted in a significant extension in survival of tumour-bearing mice. We characterized the effect of Nuak1 deletion in a genetically engineered mouse model for NSCLC driven by KRas\(^{G12D}\) mutation and accelerated by MYC overexpression (KM model). Remarkably, upon Nuak1 deletion (KMN model) we observed a change of the histological features of lung adenomas, which were characterized by predominant acinar structures in contrast to Nuak1 wild type tumours that presented a papillary predominant growth. Despite these morphological differences, at 6 weeks post infection the levels of tumour cells proliferation did not significantly differ between KM and KMN lung tumours (Fig. 4.7A), in agreement with the observation of the unchanged tumour burden (Fig. 4.7B). Clinical data have suggested that there is not a significant difference in terms of survival between the papillary and acinar types of tumours, whereas the micropapillary subtype has been reported to have the worst survival outcome (Russell et al., 2011). Therefore, currently the biological meaning and clinical implications of the transition from a papillary to an acinar subtype are not yet understood.

The MEK/ERK cascade downstream of Ras is frequently dysregulated in cancer and we identified enhanced ERK activation, suggested by increased phosphorylation levels, as KM tumours progress to more advanced stages. Furthermore, increased phospho-ERK levels were associated with tumour regions featuring morphological hallmarks of progression, such as loss of cell polarity and enlarged nuclei (Fig. 4.8A-B). Although Nuak1 deletion did not affect the tumour burden of KM mice at 6 weeks post Adeno-Cre infection, it resulted in a reduced level of ERK activation while increasing AKT phosphorylation (Fig. 4.8C and 4.9). AKT has been suggested as an alternative kinase for NUAK1 but a reciprocal role of NUAK1 regulating AKT has not been described yet. Further
analyses are needed to uncover the mechanism of the observed upregulation of AKT in the absence of NUAK1. Moreover, analysis of phospho-4E-BP1 and phospho-S6, which are targets of mTORC1, a downstream effector of AKT, revealed higher phosphorylation levels of 4E-BP1 in KMN tumours in comparison to KM tumours (Fig. 4.10).

Raptor has been shown to recruit 4E-BP1 to the mTORC1 complex, facilitating its phosphorylation (Hara et al., 2002). Therefore, as we uncovered that NUAK1 contributes to Raptor inhibition (Fig. 3.15), it is possible that the preferential phosphorylation of 4E-BP1 over S6 is a result of Raptor activation in Nuak1 deleted lung tumours.

The LKB1/AMPK axis is well known for regulating protein synthesis (Shaw et al., 2004a). In particular, AMPK can modulate mTORC1 activity through the negative regulation of Raptor and the positive regulation of TSC2, an inhibitor of mTORC1. In addition, Lkb1 deletion has been shown to increase mTORC1 activation both in vitro and in vivo and our data suggested a similar role for Nuak1 (Fig. 3.10 and Fig. 4.10). Therefore, targeting the increased protein synthesis that is required for highly proliferative cells, such as tumour cells, to sustain their growth appeared as a potential therapeutic strategy. Although Nuak1 deletion resulted in an increase of mTORC1 activity it did not sensitise tumour cells to Rapamycin. However, there is discordant evidence on the efficacy of mTORC1 inhibition in inducing cell death of LKB1-null cancer cells. Particularly, an in vitro study carried out by Whang and colleagues using wild type and LKB1-null human lung cancer cell lines highlighted the higher sensitivity of the latter to mTORC1 inhibition using Rapamycin, as demonstrated by the decreased viability and colony formation of LKB1-null cells as compared to LKB1 wild type cells upon treatment (Whang et al., 2016). Conversely, other studies have disproved the increased sensitivity of LKB1-null cells to mTOR inhibitors, suggesting a feedback activation of the AKT pathway that overcomes mTOR inhibition (Xiao et al., 2015). Similarly, Momcilovic and colleagues have shown the lack of relation between LKB1 status and sensitivity to the mTOR inhibitor MLN0128 (Momcilovic et al., 2015). Moreover, multiple studies have suggested that Rapamycin has a differential effect on 4E-BP1 and S6K, which is the upstream kinase of S6. Treatment with Rapamycin was shown to repress S6K activity in a sustained manner, whereas phosphorylation levels of 4E-BP1 were re-established after an initial inhibition (Choo et al., 2008). Given the increase
of phospho-4E-BP1 but not of phosho-S6 observed in Nuak1 deleted tumour, one possibility is that the inefficiency of Rapamycin to inhibit 4E-PB1 is the cause of the lack of enhanced sensitivity of KMN tumours. We have not established whether phosphorylation of 4E-BP1 occurs independently of mTORC1 activation in our model, as it has been suggested an AKT-dependent modulation of the substrate, in which case inhibition of AKT might represent a better therapeutic approach. However, testing of ATP-competitors for mTORC1 that more efficiently inhibit 4E-BP1 phosphorylation might give more information on the contribution of mTORC1 to proliferation and survival of Nuak1 deleted tumour cells.

An important finding of this study that will be confirmed and further explored is the potential role of NUAK1 in tumour angiogenesis, as the percentage of tumour blood vessels was decreased in Nuak1 deleted lung tumours in comparison to wild type (Fig. 4.12). Interestingly, a role of LKB1 in angiogenesis has been previously highlighted by multiple research groups, although with conflicting findings. In particular, deletion of Lkb1 was reported to cause vascular abnormalities, among others, in the developing embryos, with alterations in sprouting and maturation of blood vessels (Ylikorkala et al., 2001). An additional study carried out in adult mice described a similar role of LKB1 in supporting angiogenesis, since it was observed that formation of new blood vessels following an ischemic insult was impaired in mice bearing Lkb1 deletion in endothelial cells (Ohashi et al., 2010). However, other studies have provided evidence towards an antiangiogenic role of LKB1. For example, it was recently described that tumour implanted in mice with endothelial deletion of Lkb1 displayed increased angiogenesis in comparison to Lkb1 wild type endothelial cells (Zhang et al., 2017). Additional investigations have corroborated an antiangiogenic function of LKB1, proposing multiple mechanisms: from regulation of VEGF to degradation of the angiogenic receptor neuropilin-1 (NRP-1) (Liang et al., 2014; Okon et al., 2014). Overall, LKB1 might play a dual role in angiogenesis, which could differ according to tissues or development stage. We have not established if the angiogenic role of NUAK1 in our tumour model is dependent on the upstream kinase LKB1, which will require additional analysis. However, we also need to consider that the observed involvement of NUAK1 in tumour angiogenesis might not be related to LKB1 because, as highlighted by
data obtained in this chapter, LKB1 does not seem to mediate its tumour suppression functions in lung tumorigenesis through NUAK1. Moreover, some functions exerted by NUAK1 are not shared by LKB1 but actually contradicting with it. For example, whereas LKB1 has been shown to suppress cell invasion and its deletion to increase the metastatic potential, NUAK1 role in promoting invasion and metastasis has been compellingly established in multiple settings. Therefore, it appears that the two kinases may not lie within the same path for all their functions.

Further investigations in our KMN model might clarify NUAK1’s involvement in angiogenesis and elucidate the mechanisms through which its deletion contributed to the observed extension of survival (Fig. 4.13). Deletion of Nuak1 did not affect tumour cells proliferation in the presence of MYC overexpression at 6 weeks post infection. However, previous studies and also unpublished data from our laboratory indicate that NUAK1 expression increases with tumour progression. Therefore, the progression to more advanced stages and the related increase in metabolic stress might impose a more prominent and long-term dependence on NUAK1 for survival of MYC overexpressing cells. Furthermore, Nuak1 deletion might contribute to the inhibition of the metastatic process and together with an impairment in tumour vasculature, which is essential in providing oxygen and nutrients to tumour cells as well as a route for metastatic dissemination, oppose cancer progression, establishing itself as tumour promoter in NSCLC as opposed to LKB1.
Chapter 5 - The role of the ERBB network in supporting KRas mutant lung adenocarcinoma

5.1 Introduction

KRAS is a member of the RAS family of small GTPase together with the H- and N-RAS isoforms. The RAS family of genes is often mutated in cancer, with activating mutations in KRAS frequently found in three of the four most lethal cancers: pancreatic adenocarcinoma, colorectal adenocarcinoma and lung adenocarcinoma (Oikonomou et al., 2014). Most mutations are found at the residue G12 of KRAS and they cause the formation of a persistent GTP-bound form, which represents a constitutively active state. Interestingly, alterations of RAS genes are events that occur in the early phases of tumour initiation but multiple experimental evidence point towards a role of continued expression of mutant RAS in tumour maintenance as well, corroborating its important role in the different stages of cancer progression (Brummelkamp et al., 2002; Singh et al., 2009).

Despite the significant progress made in the understanding of RAS biology since the first detection of its activating mutations in human cancer in 1982 (Parada et al., 1982; Santos et al., 1982), targeted therapies for KRAS mutant cancers are lacking and they still represent a challenge for clinical oncology. Many attempts have been made to inhibit RAS and over time the efforts have been broadened from targeting RAS activity to affecting RAS function by interfering with its localization or by inhibiting RAS effectors. However, whereas patients with EGFR-mutant lung cancer can benefit from therapy with EGFR tyrosine kinase inhibitors (TKI), KRAS mutations have been suggested as negative predictors of response to therapies with EGFR TKI (Linardou et al., 2008; Massarelli et al., 2007).

The study of the role of Nuak1 in the tumorigenic process driven by KRas shed some light on the potential benefit of NUAK1 inhibition. However, it is unlikely that targeting of NUAK1 alone would be therapeutically sufficient in lung cancer. Therefore, we focused on the investigation of the mechanisms associated with
tumour progression of a $K_{Ras}^{G12D}/MYC$ NSCLC mouse model in order to identify new therapeutic targets.

In this chapter, we elucidate the role of the ERBB network in the lung tumorigenic process driven by KRas, challenging the dogma that inhibition of ERBB receptors is not beneficial in patients affected by KRAS mutant NSCLC. Data provided in this chapter are part of a broader study carried out in collaboration with Björn Kruspig and Sarah Neidler.

### 5.1.1 Mouse models

Most of the experiments were performed using a lsl-$K_{Ras}^{G12D}$/R26-lsl-MYC$^{Hom}$ NSCLC mouse model (referred to as KRas$^{G12D}$/MYC or KM), in which the KRas G12D point mutation is preceded by a lox-stop-lox (lsl) sequence, and lsl-human MYC is expressed under the control of the Rosa26 (R26) locus. In addition, to monitor tumour growth in live animals we employed the near-infrared fluorescent protein encoded by the iRFP gene, which was inserted in the endogenous $Hprt$ locus and preceded by a lox-stop-lox cassette to control its expression (Hock et al., 2017). Upon administration of Adenovirus-Cre, the simultaneous induction of mutant KRas, exogenous MYC and iRFP, when present, was achieved (Fig. 5.1).

![Figure 5.1 – Schematic representation of the lsl-$K_{Ras}^{G12D}$/R26-lsl-MYC/Hprt-lsl-iRFP mouse model.](image)
5.2 Results

5.2.1 Upregulation of the ERBB network during progression of KRas mutant lung adenocarcinoma

As mentioned in Chapter 4, histological examination of lungs of \(\text{KRas}^{G12D}/\text{MYC}\) (KM) mice after six weeks from Adeno-Cre infection revealed the presence of more aggressive sub-populations within the tumour, characterized by different morphological features (Fig. 4.8A). In addition, exclusively these tumour areas were positive for immunohistochemical staining with phospho-ERK, a downstream effector of KRAS and a marker associated with tumour progression (Vicent et al., 2004). To identify the underlying molecular events involved in the observed morphological transition to a more advanced phenotype, we compared the transcriptome of isolated phospho-ERK\(^{\text{high}}\) regions to phospho-ERK\(^{\text{low}}\) regions of lung adenomas after 6 weeks from Adeno-Cre infection. GeneGO analysis of the data set obtained from the RNA sequencing analysis revealed that multiple pathways associated with regulation of cell adhesion, cell motility and cytoskeletal remodelling were upregulated in phospho-ERK\(^{\text{high}}\) regions (data not shown). Surprisingly, multiple components of the ERBB signalling network were found to be enriched in the phospho-ERK\(^{\text{high}}\) regions (Table 5.1). In particular, expression of ERBB receptors such as ERBB2 and ERBB3 was increased, together with multiple ERBB ligands such as Epiregulin, Amphiregulin and Tgf\(\alpha\). Upregulation of LamC2, Fabp5 and Keratine 19, all shown to enhance signalling through EGFR/ERBB family RTKs (Garg et al., 2014a; Powell et al., 2015), was also identified. Furthermore, increased expression of the sheddase ADAM9 and ADAM10, proteolytic enzymes responsible for the release of soluble form of receptor ligands, was observed. Overall, the analysis strikingly indicated a potential role of the ERBB network in the progression of \(\text{KRas}^{G12D}/\text{MYC}\) lung adenomas.
<table>
<thead>
<tr>
<th>High phospho-ERK associated gene expression</th>
<th>Δ (fold)</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ERBB family ligands</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epiregulin</td>
<td>24.82</td>
<td>2.78e-13</td>
</tr>
<tr>
<td>Amphiregulin</td>
<td>4.25</td>
<td>4.98e-11</td>
</tr>
<tr>
<td>Transforming Growth Factor alpha</td>
<td>2.69</td>
<td>0.0048</td>
</tr>
<tr>
<td>Heparin-bound EGF</td>
<td>2.31</td>
<td>0.020</td>
</tr>
<tr>
<td><strong>ERBB ligand sheddases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adam9</td>
<td>2.00</td>
<td>0.0001</td>
</tr>
<tr>
<td>Adam10</td>
<td>1.89</td>
<td>0.0016</td>
</tr>
<tr>
<td><strong>ERBB Receptors/Receptor Tyrosine Kinases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erbb2</td>
<td>1.55</td>
<td>0.060</td>
</tr>
<tr>
<td>Erbb3</td>
<td>1.53</td>
<td>0.054</td>
</tr>
<tr>
<td><strong>ERBB Accessory proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IQGAP2</td>
<td>5.30</td>
<td>0.0004</td>
</tr>
<tr>
<td>LamC2</td>
<td>3.48</td>
<td>2.56e-9</td>
</tr>
<tr>
<td>Keratin 19</td>
<td>2.96</td>
<td>2.06e-6</td>
</tr>
<tr>
<td>FABP5</td>
<td>2.79</td>
<td>6.15e-3</td>
</tr>
<tr>
<td><strong>RAS pathway</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raf1</td>
<td>1.86</td>
<td>0.0178</td>
</tr>
<tr>
<td>BRaf</td>
<td>1.52</td>
<td>0.063</td>
</tr>
<tr>
<td>CRaf</td>
<td>1.80</td>
<td>0.0037</td>
</tr>
</tbody>
</table>

Table 5.1- Overexpression of genes belonging to the ERBB network in phospho-ERK\textsuperscript{high} tumour regions.

Phospho-Erk\textsuperscript{high} and phospho-ERK\textsuperscript{low} tumour regions from KM mice (n = 4) were isolated by laser-capture microdissection and gene expression measured by RNA-SEQ. The table represents normalized Ras and ERBB network gene expression in phospho-Erk\textsuperscript{high} relative to phospho-Erk\textsuperscript{low} tumour regions. FDR = false discovery rate. Data generated by Sarah Neidler.

Interestingly, Western blot analysis of protein lysates isolated from multiple lung tumours at 6 weeks post infection showed detectable levels of phospho-EGFR, phospho-ERBB2 and phospho-ERBB3, indicating activity of the ERBB receptors in the developing adenomas (Fig. 5.2).
Figure 5.2 – ERBB receptors are active in KRasG12D/MYC lung adenomas. Protein extracts were isolated from KM lung tumours at 6 weeks post Adeno-Cre infection and were immunoblotted with the indicated antibodies. Each lane represents an individual lung tumour; all the ten tumours were harvested from a single mouse.

5.2.2 KRasG12D/MYC lung tumours are sensitive to ERBB inhibition

The observed upregulation of the ERBB network in developing KRas/MYC lung tumours indicated a potential contribution of the ERBB signalling in sustaining tumour progression. To test the sensitivity of ERBB receptors inhibition in our KRasG12D/MYC NSCLC mouse model, we made use of the clinically approved drug Neratinib, which is an irreversible inhibitor of EGFR and ERBB2 (Subramaniam et al., 2015). As shown in figure 5.3A, acute Neratinib treatment resulted in an efficient inhibition of EGFR and ERBB2, as suggested by their decreased phosphorylation levels in comparisons to vehicle treated controls. Most importantly, Neratinib treatment caused a significant decrease of tumour cell proliferation, as suggested by the reduction of the proliferation marker Ki67, and in a significant increase of apoptosis, as indicated by TUNEL staining, compared to vehicle treated controls (Fig. 5.3B-C).
Figure 5.3 – ERBB inhibition induces growth arrest and cell death in KM lung tumours.

A, KM mice at 6 weeks post Adeno-Cre infection were treated with Neratinib (n=3) or vehicle control (n=3) for three days before harvesting tumour tissue for protein isolation. Whole cell protein extracts were immunoblotted with the indicated antibodies.

B, Representative images of lung tissue sections of KM mice at 6 weeks post Adeno-Cre infection treated for three days with Neratinib or vehicle control immunostained for Ki67 and TUNEL. Scale bars = 100 µm.

C, Bar graphs representing the Mean ± SEM of Ki67 and TUNEL positively stained lung tumour cells from KM mice treated with vehicle (n=3) or Neratinib (n=3) for three days. ***p<0.01 calculated with two-tailed unpaired T test.
5.2.3 Inhibition of the ERBB receptors impairs KRas-driven tumorigenesis

Having established the sensitivity of KM tumours to inhibition of ERBB receptors by Neratinib treatment, we sought to investigate the extent of the contribution of the ERBB signalling to the tumorigenic process driven by mutant KRas. To achieve that, KRas\textsuperscript{G12D}/MYC mice were treated daily with Neratinib for 4 weeks, starting at 2 weeks post infection, a time point when only early lesions such as atypical adenomatous hyperplasia and epithelial hyperplasia of the bronchioles could be detected. Strikingly, continuous Neratinib treatment impaired the tumorigenic process driven by mutant KRas as shown by the significant decrease in tumour burden in KM treated mice compared to control mice. Conversely, prolonged inhibition of EGFR only, by treatment with a daily dose of Erlotinib, did not have a significant impact on tumour burden in comparison to vehicle treatment (Fig. 5.4A-B). Overall, these results suggested that multiple ERBB receptors are required since the early stages of the tumorigenic process of KRas\textsuperscript{G12D}/MYC lung cancer.
Figure 5.4 – Neratinib but not Erlotinib treatment reduces lung tumour burden of KM mice.
A, Box plots indicating the tumour burden (Mean ± SEM) and B, representative H&E images of KM mice treated with either Neratinib (n=3), Erlotinib (n=4) or vehicle control (n=6) for 4 weeks, starting at 2 weeks post Adeno-Cre infection (PI). ns= not significant, *p<0.05 calculated with one-way ANOVA, Tukey’s multiple comparison. Scale bars = 1 mm.

5.2.4 ERBB blockade enhances therapeutic impact of MEK inhibition in KRas mutant lung adenocarcinoma

The observed tumour preventive effect of the ERBB receptors inhibition in KRas<sup>G12D</sup>/MYC lung tumorigenesis prompted us to investigate the therapeutic outcome of Neratinib treatment. However, daily treatment of established KRas<sup>G12D</sup>/MYC lung tumours for 7 days with Neratinib did not have a significant effect on overall survival in comparison to vehicle treatment (Fig. 5.5).
Figure 5.5 – Neratinib treatment does not increase the overall survival of KM mice.
Kaplan-Meier survival analysis of KM mice treated with Neratinib (n=7) or vehicle control (n=9) for 7 days starting at 6 weeks post Adeno-Cre infection, which is indicated as time 0 in the graph. ns= not significant. P value determined by log-rank (Mantel-Cox) test.

Further in vitro studies on KRAS mutant human lung cancer cell lines (H2009, H358, A549) revealed that Neratinib treatment did not induce a significant increase in cell death in two of three cell lines. However, the achievement of a more pronounced inhibition of the MEK/ERK cascade by combination of ERBB and MEK inhibition using Neratinib and Trametinib, respectively, could efficiently and significantly enhance cell death in all the lines tested, as compared to single drugs and vehicle control treatment (Fig. 5.6).
Figure 5.6 – Combination of ERBB and MEK inhibition more efficiently induces cell death in KRas mutant human lung cancer cell lines.

Bar graph representing the Mean ± SEM of cell death induced by the indicated doses of Neratinib and/or Trametinib in human NSCLC cells, measured 48hrs after treatment. Cell death was analysed by Incucyte live-cell imaging system in the presence of Sytox green and corrected for confluence. N=3. Data generated by Björn Kruspiig.

Given the efficacy of the combination of Neratinib with Trametinib in inducing cell death in the human lung cancer cell lines tested in vitro, we sought to determine the therapeutic effect of the combinatorial treatment in our KRas^{G12D}/MYC NSCLC in vivo model.

Following Adenovirus-Cre administration, KRas^{G12D}/MYC/Irfp animals were monitored weekly for detection of iRFP signal using the PEARL system for near-infrared fluorescent imaging (LI-COR), starting at 2 weeks post infection. When the intensity of the iRFP signal, which correlates with tumour burden, reached a threshold of approximately 800 units, daily treatment with Neratinib in combination with Trametinib was carried out for 5 consecutive days.

As shown by quantification in figure 5.7A, we could attest that the tumour growth followed an exponential trend in untreated mice, as suggested by the exponential increase of the iRFP signal intensity over time. On the contrary, treatment with the combination of Neratinib and Trametinib caused a plateau of the iRFP signal, indicating an arrest in the tumour growth during the treatment period. Similarly, representative pictures in figure 5.7B indicated an increase of the iRFP signal intensity over the treatment period in mice that received the vehicle control whereas the iRFP signal was reduced in the presence of the combinatorial therapy.
Chapter 5

Figure 5.7 – iRFP signal detection identified impaired growth of lung tumours treated with Neratinib in combination with Trametinib.

A, iRFP signal in KM mice was monitored using a PEARL imaging system (LI-COR) and intensity curves calculated using the Weibull growth equation. iRFP signal is represented as baseline corrected values. Treatment with Neratinib & Trametinib was started when the signal threshold (800 arbitrary units) was reached and continued for five days. Each dot represents a day of imaging. B, Representative LI-COR PEARL images of lung tumours from KM mice treated with Neratinib & Trametinib or vehicle control.
Furthermore, in agreement with the observed arrest in tumour growth, the combination of Trametinib and Neratinib could significantly further extended overall survival, in comparisons to single treatments and vehicle control (Fig. 5.8).

Figure 5.8 – Combination of Neratinib with Trametinib enhances survival of KM mice.
Kaplan-Meier survival analysis of KM mice treated with vehicle control (n=9), Neratinib (n=7), Trametinib (n=10) or a combination of the two drugs (n=10) for 7 days starting at 6 weeks post Adeno-Cre infection, which is indicated as time 0 in the graph. *p<0.05, **p<0.001 determined by log-rank (Mantel-Cox) test.

Western blot analysis of tumour samples isolated from KM mice treated acutely with Neratinib and/or Trametinib revealed an increase in AKT phosphorylation upon Trametinib treatment, which has been previously documented by Sun and colleagues (Sun et al., 2014). Moreover, Neratinib treatment could reduce the Trametinib-mediated increase in AKT phosphorylation to basal levels and, whereas the levels of phospho-ERK were only modestly reduced by Neratinib, combination with Trametinib efficiently abrogated phosphorylation of ERK (Fig. 5.9). Overall, combination of Neratinib with Trametinib appeared to be more effective than the single treatments in inhibiting two key pathways that sustain tumour cell survival and proliferation downstream of ERBB receptors and KRAS, the mitogen-activated protein kinase (MAPK)- and the PI3K/AKT pathways.
Figure 5.9 – Simultaneous inhibition of the ERBB receptors and MEK impacts on AKT activation.
Protein extracts were isolated from lung tumours of KM mice treated for three days with Neratinib (n=2), Trametinib (n=2), a combination of both drugs (n=2) or vehicle control (n=2) at 6 weeks post Adeno-Cre infection, and immunoblotted with the indicated antibodies.

5.3 Discussion

Activating mutations of the oncogene Ras are among the main drivers of the tumorigenic process in several tissues. In particular, somatic mutations in RAS are detected in 20% of human tumours, of which more than 80% are related to KRAS isoform. Although RAS was the first mutated gene to be identified in human cancer and its biological functions extensively studied over the years, we are still battling with the search of a successful therapeutic strategy that tackles its oncogenic activity. Therefore, the investigations reported in this chapter intended to provide with a better understanding of the molecular mechanisms at the base of KRas-driven tumour progression in the lung to develop novel therapeutic approaches.
Experimental evidence obtained in this study have surprisingly uncovered a functional role of the ERBB signalling in supporting KRas driven tumorigenesis. Specifically, tumour regions with morphological and molecular features of progression were found to be characterized by the upregulation of multiple
components of the ERBB network, such as the ERBB receptors and their ligands (Tab. 5.1). In addition, inhibition of the ERBB receptors with Neratinib significantly reduced tumour cell proliferation and increased apoptotic levels in established tumours (Fig. 5.3), and most strikingly, it impaired tumour initiation when treatment was started at an early stage of tumorigenesis (2 weeks post-Adeno-Cre infection) (Fig. 5.4). Overall, these findings not only support a functional requirement of the ERBB signalling in developing KRas mutant lung tumours but also in the tumour initiation process.

These surprising but important observations challenge the current field on several aspects and are supported by recently published data that change our understanding of Ras biology. Firstly, as the three common KRAS mutations in lung cancer (G12C, G12D, G12V) confer a persistent activation status, it has been inferred that upstream signals, such as modulation by the ERBB receptors, can no longer influence RAS activity. However, a recent study has questioned that concept by providing evidence of a maintained basal GTPase activity of mutant KRasG12C that could be targeted with high affinity by a novel small molecule inhibitor (ARS853), which was able to reduce the levels of GTP-bound RAS and impair the signalling to the downstream effectors Raf and ERK (Lito et al., 2016). Thus, the new finding of mutant KRas still cycling between an on and off state has indicated that its activity can be modulated by upstream signalling.

In addition, the mutual exclusive occurrence of KRAS and EGFR activating mutations has been attributed to their redundant function due to localization in the same or overlapping signalling pathways. Therefore, the mutual exclusivity would further support that hyperactivation of the ERBB receptors would not be required due to their redundancy in a setting of KRAS mutation. However, two recent studies have revealed an alternative and intriguing explanation for the absence of concomitant mutations in KRAS and EGFR. In particular, co-expression of mutant KRAS and EGFR in human lung cancer cell lines induced hyperactivation of the MAPK pathway (ERK, p38 and JNK) and cell death, suggesting a synthetic lethal interaction between the two mutant oncogenes (Unni et al., 2015). Additionally, by using an elegant double-inducible in vivo system of KRasG12V and EGFRL858R, Santamaria’s group has described how induction of mutant EGFR in established KRas-driven lung adenocarcinoma caused an initial increase in tumour cells death that was followed by restoration of tumour progression together with a decreased activity of the MAPK and PI3K
pathways (Ambrogio et al., 2017). Therefore, it is possible that a distinct threshold of the ERBB signalling influences tumour survival and progression outcome. Thus, despite constitutive activation of EGFR, i.e. in case of mutations, might be detrimental to KRas driven tumours due to unsustainable levels of oncogenic signalling, our data suggested that a modest increase of ERBB signalling could support KRas driven tumorigenesis.

Secondly, the sensitivity of KRas mutant lung tumours to ERBB inhibition therapy addresses the reported clinical failure of EGFR inhibition in patients with KRAS mutant NSCLC. In particular, EGFR tyrosine kinases inhibitors (TKI) and anti-EGFR monoclonal antibodies have been successfully used in cancer patients with EGFR mutations, whereas KRAS mutations have been suggested as a negative predictor for the response to both therapies. Data from our KM mouse model reported in this chapter agree with the clinical observation that EGFR-inhibition alone, using Erlotinib, does not affect the tumorigenic process driven by mutant KRas (Fig. 5.4). However, the observed reduction of tumour burden upon inhibition of multiple ERBB receptors using Neratinib, suggests that the clinical outcome could be improved by the inhibition of multiple ERBB receptors.

Continuous treatment of established tumours with Neratinib for seven days did not result in a survival advantage in comparison to vehicle control (Fig. 5.5). Although a more prolonged treatment could improve the therapeutic outcome, the inability of Neratinib to induce a significant increase in cell death in human lung cancer cell lines (Fig. 5.6) suggested that inhibition of ERBB signalling was not sufficient to impair tumour growth.

The increased ERK phosphorylation as tumours progressed to more advanced stages (Chapter 4, Fig. 4.8) indicated the importance of the MAPK cascade in support of this process. Indeed, components of the cascade, such as the three isoforms of Raf, were modestly upregulated in the phospho-ERK_{High} tumour regions together with the ERBB network (Tab. 5.1). Therefore, a more profound inhibition of the MAPK cascade by dual targeting of ERBB signalling and the downstream effector MEK could more efficiently induce cell death in the human cancer cell lines tested (Fig. 5.6) and, most importantly, cause an arrest in tumour growth in vivo (Fig. 5.7) that translated in an increased overall survival of KM mice in comparisons to single treatments (Fig. 5.8).
Although MEK inhibition alone induced a significant increase in cell death in all cell lines tested (Fig. 5.6) and significantly increased KM survival in comparison to vehicle treatment (p<0.05) (Fig. 5.8), clinical studies have obtained discouraging results for lung cancer. For example, Trametinib was shown to induce a similar response rate and progression-free survival as standard chemotherapy with docetaxel in patients with previously treated KRAS mutant NSCLC (Blumenschein et al., 2015). Further studies have tried to address the lack of therapeutic effect of MEK inhibition and combine it with the targeting of additional pathways for an improved outcome. Recent experimental evidence has suggested that inhibition of MEK results in upregulation of the Fibroblast growth factor 1 (FGFR1) as a compensatory response mechanism. Thus, a combinatorial therapy with inhibition of MEK and FGFR1 was proposed to be more effective for treating KRAS-mutant lung cancer (Manchado et al., 2016). An alternative mechanism of resistance to MEK inhibition was suggested to be mediated by the transcriptional induction of ERBB2 and ERBB3. Indeed, ERBB inhibition was shown to have a synergistic effect with MEK inhibition with a more efficient induction of cell death in colon and lung cancer cells (Sun et al., 2014). Therefore, although originating from a different contextualization of the ERBB network function in KRas mutant lung cancer as in our model upregulation of the receptors represents an intrinsic property of KM tumours rather than an induced consequence of MEK inhibition, our data are in agreement with the findings of Sun and colleagues in supporting the use of a combinatorial ERBB and MEK inhibition therapy. In particular, the increase in AKT activity observed due to MEK inhibition using Trametinib was prevented by combination with Neratinib (Fig. 5.9), suggesting that inhibition of the AKT pathway could be part of the synergistic mechanism of Trametinib and Neratinib treatment. However, further studies will be required to delineate the molecular details of the combinatorial therapy, assess the potential emergence of resistance, as it represents a major mechanism of failure of long term treatments, and establish the possible molecular mechanisms of resistance.

MYC gene amplifications are detected in approximately 10% of lung adenocarcinoma (cBioPortal) and we have shown that a moderate overexpression of MYC could significantly contribute to accelerate KRas driven lung tumorigenesis (Chapter 4, Fig. 4.5). Therefore, combination of KRasG12D with
MYC overexpression provided with a good model to study both the initial and later phases of the tumorigenic process. However, we can exclude that the molecular phenotype described in this chapter is an artificial result of the engagement of the ERBB receptors to sustain exogenous MYC overexpression as we have previously reported that expression from the Rosa26 locus is refractory to growth factor signalling (Murphy et al., 2008). In addition, we can also exclude that the tumour regions featuring signs of progression reflect a differential expression efficiency of the exogenous MYC, as RNA-SEQ analysis did not reveal any difference in MYC expression levels between phospho-ERK\textsuperscript{High} and phospho-ERK\textsuperscript{Low} regions (data not shown). Therefore, we can conclude that the phenotype observed is not simply driven by exogenous MYC and that our findings, in support to available data, strongly suggest a renewed potential of targeting the ERBB network in KRAS mutant NSCLC.
Chapter 6 – Final Discussion

Since the relatively recent identification of NUAK1 in 2003 (Suzuki et al., 2003a), multiple studies have revealed its role in a variety of cellular processes that established a connection with cancer. Enhancement of proliferative signalling, resistance to cell death and activation of invasion and metastasis are some of the so called “hallmarks of cancer” in which NUAK1 has been shown to play a role. In addition, NUAK1 expression has been reported to correlate with tumour stage and survival outcome in many cancer types (Cui et al., 2013; Kusakai et al., 2004; Lu et al., 2013), indicating that its targeting could be clinically relevant. However, our knowledge of NUAK1 regulation and function can be considered still limited particularly in comparison to AMPK, which has been the main focus of investigation among all the AMPK related kinases (ARKs). Indeed, currently only a restricted number of NUAK1 substrates and upstream regulators are well characterized, while a more in depth understanding of NUAK1 network is lacking.

Data presented in this thesis describe a novel modality of regulation of NUAK1 that involves modulation by Ca\(^{2+}\) levels. This activation modality was initially considered a peculiarity of AMPK, not shared by other AMPK related kinases (Fogarty et al., 2010). However, recent published data reported a Ca\(^{2+}\)-mediated activation of SIK2 (Miranda et al., 2016) and we propose a similar activation for NUAK1 and NUAK2. Therefore, increase in intracellular Ca\(^{2+}\) levels might represent an activation modality common for the AMPK family or at least shared by multiple ARKs.

The Ca\(^{2+}\)/calmodulin-dependent protein kinase kinase-beta (CaMKKβ) has been established as the upstream kinase regulating AMPK activation in response to Ca\(^{2+}\) (Woods et al., 2005), whereas the kinase mediating the activation of SIK2 has not been identified yet. Our experimental evidence has indicated that Protein Kinase C α (PKCα) is the Ca\(^{2+}\)-responsive kinase that regulates NUAK1 activation, whereas NUAK2 does not appear to be modulated by the same kinase.

The tumour suppressor LKB1 has been described as the master kinase for the AMPK family members and deletion of Lkb1 was shown to abolish NUAK1 activity.
in non-transformed MEFs (Zagorska et al., 2010). However, a dominant regulation of NUAK1 by LKB1 is puzzling to some extent. Some aspects of NUAK1 cellular functions are in agreement with the reported roles of LKB1 and experimental evidence has compellingly demonstrated that NUAK1 mediates some of LKB1 physiological functions. For example, LKB1 was described for its role in axon specification during neuronal polarization (Barnes et al., 2007; Shelly et al., 2007) and subsequent studies have underlined its role in axon branching of cortical neurons through activation of NUAK1 (Courchet et al., 2013). In addition, the LKB1/NUAK1 axis has been involved in the regulation of phosphorylation of Myosin Light chain 2 (MLC2) (Zagorska et al., 2010), which plays an important role in cell adhesion and polarity (Vicente-Manzanares et al., 2009). However, molecular connections between LKB1 and NUAK1 in the control of metastasis have not been recognised. Several studies have established the incontrovertible role of NUAK1 as a positive regulator of cell migration and invasion (Chang et al., 2012; Chen et al., 2017; Chen et al., 2013), whereas most data available indicate an opposite role for LKB1 (Chan et al., 2014; Deguchi et al., 2010; Goodwin et al., 2014). Therefore, it is possible that the function of NUAK1 in migration might be regulated by an alternative kinase.

In particular, our identification of PKCα as a kinase modulating NUAK1 activation in response to Ca^{2+} stimulation opens new frontiers to the understanding of the biology of NUAK1. Notably, PKCα, which has been established as a positive regulator of cell migration and invasion, might regulate NUAK1 in regard to the metastatic process and potentially many others. As new biological roles for NUAK1 continue to emerge, more aspects of its tumour promoter role are being described but also additional degrees of separation from LKB1 are revealed. For example, NUAK1 has been recently involved in the induction of epithelial-to-mesenchymal transition (EMT) (Obayashi et al., 2016; Xu et al., 2016), which has been debated for playing a role in the metastatic process but also implicated in the mechanisms of drug resistance (Fischer et al., 2015; Shibue and Weinberg, 2017). Similarly to NUAK1, PKCα has been shown to promote EMT and mediate drug resistance (Abera and Kazanietz, 2015), whereas LKB1 has been suggested to inhibit EMT (Carretero et al., 2010; Roy et al., 2010). Therefore, evaluation of the PKCα/NUAK1 axis in the induction of EMT might be an additional aspect to consider from a physiological point of view but also as therapeutic approach to chemoresistance.
Intriguingly, we have exposed a new role of PKC\(\alpha\) in its function as a linker between NUAK1 and MYC. Particularly, MYC was found to amplify Ca\(^{2+}\) signalling through the transcriptional upregulation of multiple components such as ITPR1, CaMKK\(\beta\) and PKC\(\alpha\). Importantly, MYC overexpression induced a more prominent effect at the level of activity of PKC rather than at expression levels. In addition, depletion of either NUAK1 or PKC\(\alpha\) was shown to be lethal in HeLa cells, which express high levels of the oncogene MYC, consistent with a role of the PKC\(\alpha\)/NUAK1 axis in supporting the survival of MYC overexpressing cells.

NUAK1 has already been described to promote survival of MYC-overexpressing cells by restraining mTORC1 activity (Liu et al., 2012). In our studies, we were further able to delineate the mechanism underling the involvement of NUAK1 in the regulation of mTORC1. Particularly, our data revealed a direct role of NUAK1 in the inhibition of Raptor, which might represent an important metabolic checkpoint that contributes to the pro-survival mechanism in the setting of MYC oncogene-induced stress.

MYC is an emblematic oncogene in its function as it is known to drive proliferation but also to induce apoptosis. In particular, a threshold level of MYC has been suggested to determine cell fate. Indeed, whereas low expression levels of MYC can sustain aberrant proliferation, elevated levels of MYC trigger a tumour suppressive function with the induction of ARF/p53 and apoptotic pathways (Murphy et al., 2008). PKC\(\alpha\) has been suggested to exert a pro-survival function through phosphorylation of the anti-apoptotic protein BCL-2 (Ruvolo et al., 1998) and enhancement of AKT activity (Li et al., 1999). Therefore, a potential function of PKC\(\alpha\) would be to protect cells from death induced by high levels of MYC, mitigating MYC tumour suppressive role in favour of its oncogenic activity.

Overall, our data strengthen the rationale for the therapeutic targeting of NUAK1 and provide insights for the inhibition of PKC\(\alpha\), which so far has produced mixed and largely negative outcomes in clinical oncology (Marshall et al., 2004; Paz-Ares et al., 2006; Villalona-Calero et al., 2004), as a potential therapeutic strategy in MYC-deregulated cancers.

NUAK1 has been indicated to act as a tumour promoter, since an increased expression has been reported in more advanced tumour stages and has been
associated with poor survival for different cancer types. Our studies conducted in a mouse model of Non-small cell lung cancer (NSCLC) driven by mutant KRas\(^{G12D}\) have demonstrated that NUAK1 does not share the tumour suppressive role of LKB1, whose deletion has been reported to accelerate lung tumorigenesis (Ji et al., 2007). At 16 weeks post infection, deletion of Nuak1 did not affect the tumour burden in the lungs of Kas\(^{G12D}\) mice, although a survival analysis might offer a more exhaustive interpretation of its role. Indeed, Nuak1 deletion increased the survival of mice in which lung tumorigenesis was driven by KRas\(^{G12D}\) and accelerated by MYC overexpression. The synthetic lethal interaction between MYC and Nuak1 might contribute to the observed survival benefit but it is also possible that deletion of Nuak1 results in the loss of its intrinsic tumour supportive mechanisms. For example, preliminary results have suggested a potential role of NUAK1 in tumour angiogenesis, as we observed a decrease in tumour blood vessels formation upon Nuak1 deletion, which might represent a novel biological function of NUAK1, not related to MYC. The pro-angiogenic role of NUAK1 could be partially responsible for the observed increase in survival of Nuak1 deleted mice, as blood vessels are essential in providing nutrients and oxygen to the highly metabolic tumour cells, other than representing the preferential way for tumour dissemination to distant sites. On the other hand, a reduction in tumour blood vessel might represent an obstacle for an efficient systemic delivery of chemotherapeutic agents. However, an analysis of the structure and permeability of the remaining blood vessels together with a pharmacokinetics and tumor uptake study might indicate if the observed reduction in tumour blood vessels could considerably affect drug delivery.

We observed a decrease of phospho-ERK levels in KRas\(^{G12D}/MYC/Nuak1^{F/F}\) tumours, which might delay the development of aggressive sub-clones, responsible for a rapid progression of the disease, and reflect the observed survival benefit. Notably, Nuak1 deletion also resulted in an increase in AKT activation, which might be supported by an enhanced insulin sensitivity as previously described in a Nuak1 knockout mouse model (Inazuka et al., 2012). Therefore, it is possible that Nuak1 deletion triggers a cross-inhibition between AKT and Raf to downregulate ERK phosphorylation, a mechanism previously reported (Moelling et al., 2002). However, further investigations will be required for a more comprehensive understanding of the mechanisms behind the observed
effects of Nuak1 deletion. Firstly, additional studies will be needed to confirm the pro-angiogenic role of NUAK1 and explore the mechanism. In addition, given the established role of NUAK1 in promoting invasion and metastasis, it will be of great interest to investigate the effect of Nuak1 deletion from a metastatic perspective in the \( KRas^{G12D}/MYC \) NSCLC mouse model. Although therapeutic targeting of NUAK1 in NSCLC might not be itself sufficient for a substantial regression of the disease, as we improve our understanding of the signalling network that includes NUAK1 we might discover new aspects of its therapeutic potential. On the other hand, a more in-depth knowledge of the mechanisms that drive the progression of lung cancer might as well have multiple implications from a therapeutic point of view and offer new opportunities for NUAK1 targeting.

With the study of the molecular mechanisms of NSCLC progression, we revealed that the ERBB network is significantly upregulated in KRas mutant lung adenocarcinoma and demonstrated its involvement in the initial phases of the tumorigenic process as well as in the progression of the disease to more advanced stages. Indeed, we have compellingly shown that inhibition of the ERBB network leads to a better therapeutic outcome when combined with MEK inhibition, which as single therapy failed to provide encouraging results in clinical trials (Blumenschein et al., 2015). Therefore, the dependence of KRas mutant lung tumours on the ERBB network might prompt the revisiting of current therapeutic regimes and identify new successful combinatorial therapies. Interestingly, LKB1 deletion was shown to sensitize NSCLC cell lines to EGFR inhibition (Whang et al., 2016). Additionally, a link between PKC\( \alpha \) and ERBB receptors has been suggested by several studies. For example, PKC\( \alpha \) was reported to increase ERBB2 protein levels in breast cancer, establishing a feedback loop in which activation of ERBB2 led to increased PKC\( \alpha \), which in turns contributed to sustain ERBB2 levels (Magnifico et al., 2007). In addition, upregulation of PKC\( \alpha \) was suggested to mediated the resistance to EGFR inhibition in NSCLC cells (Abera and Kazanietz, 2015). As NUAK1 resides downstream of both PKC\( \alpha \) and LKB1, targeting of NUAK1 in combination with inhibition of ERBB receptors might represent a new and more efficient therapeutic strategy to explore in NSCLC.
Collectively, data presented in this thesis have revealed novel mechanisms of regulation of NUAK1, strengthening the molecular basis for its targeting in tumours addicted to MYC oncogene, and uncovered new potential physiological roles of NUAK1. Indeed, the identification of PKCα as an alternative upstream kinase might be the beginning of a more comprehensive understanding of the NUAK1 signalling network. In addition, by improving our knowledge of the mechanisms involved in lung cancer progression, we have provided new targets that could be exploited for therapeutic purposes not only in lung cancer but also in other tumours driven by mutant KRas, such as pancreatic ductal adenocarcinoma, that still represents a major challenge in clinical oncology.
References


upstream kinases. Proceedings of the National Academy of Sciences of the United States of America 100, 8839-8843.


to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell **110**, 163-175.


Vincent, S., Lopez-Picazo, J. M., Toledo, G., Lozano, M. D., Torre, W., Garcia-Corcon, C., Quero, C., Soria, J. C., Martin-Algarra, S., Manzano, R. G., and


degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Molecular cell 49, 1167-1175.


